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Modulators of Cellular and Biochemical PRC2 Activity 
Abstract 
EZH2 is a SET domain-containing methyltransferase and the catalytic 
component of the multimeric Polycomb- group (PcG) protein complex, PRC2. When in 
complex with other PRC2 members (EED, SUZ12, AEBP2, and RBBP4), EZH2 
catalyzes methylation of H3K27, a histone modification associated with transcriptional 
repression and developmental regulation.  As several PRC2 components are 
upregulated or mutated in a variety of human cancers, efforts to discover small-
molecule modulators of PRC2 and understand its regulation may yield therapeutic 
insights. Identification of small-molecule probes with distinct chemotypes, MOAs, and 
selectivity profiles are not only of great value, but necessary in establishing 
comprehensive probe sets capable of illuminating the various roles of EZH2 in 
oncogenesis.  
Here we describe efforts to identify and characterize small-molecule modulators 
of PRC2 and further understand its regulation. Chapter II outlines the expression and 
purification of 5-component PRC2 (EZH2-EED-SUZ12-AEBP2-RBBP4) and the 
establishment of biochemical and cellular HTS assays.  These assays were used to 
screen a diverse set of small molecules (>120,000), identifying biochemical PRC2 
inhibitors and activators (described in Chapter III).  One biochemical PRC2 inhibitor, 
BRD1835, appeared to inhibit PRC2 activity through a novel artifactual mechanism 
involving interaction with peptide substrate, leading to apparent peptide-competitive 
behavior and putative cellular activity (described in Chapter IV). The characterization of  
  iv!
novel biochemical PRC2 activators, BRD3934 and BRD8284, is discussed in Chapter 
V. Chapter VI describes the use of an HCS assay to identify known bioactive 
compounds that alter intracellular levels of H3K27me3 through modulating H3K27me3-
connected regulatory nodes or by targeting PRC2 directly. These efforts led to the 
discovery that an antifungal agent, miconazole, is capable of activating PRC2 activity in 
vitro, while a mucolytic agent, bromhexine, selectively ablates cellular H3K27me3 levels 
through targeting an activity distinct from PRC2. Finally, Chapter VII discusses novel 
PRC2-connected crosstalk mechanisms identified through screening libraries of 
uniquely modified histone peptides for their ability to bind or support methylation by 
PRC2. These studies enhance our understanding of PRC2 regulation by revealing the 
effects of H3R26 and H3K23me1 modifications on enzymatic activity, implicating their 
respective methyltransferases in PRC2 regulation. 
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Chapter I 
 
1  Chromatin, histone methylation, and PRC2 
 
 
 
 
 
 
 
 
 
 
 
   2 
1.1  Chromatin function and regulation 
  In eukaryotes, DNA exists as part of a nucleoprotein complex known as chromatin, 
a structure permitting over a meter of DNA to fit within a nucleus of less than 10 microns 
in diameter (1). The fundamental unit of chromatin, the nucleosome (Figure 1.1), 
consists of ~147 base pairs of DNA wrapped around an octamer of core histone 
proteins—an H3/H4 heterotetramer in complex with two H2A/H2B dimers (2)—enabling 
compaction of DNA into higher-order structures. These structures comprise 
euchromatin domains, marked by low levels of compaction and greater accessibility, 
and highly condensed heterochromatin domains (3) Given that underlying DNA must be 
accessible to various cellular machineries to perform key functions, such as DNA 
damage repair, replication, transcription, and recombination, regulation of chromatin 
structure is essential for basic cellular physiology (4,5). Moreover, beyond simply 
regulating DNA accessibility, nucleosomes act as signaling scaffolds, enabling 
coordination of activities at specific genomic loci through the recognition and binding of 
regulatory proteins to post-translational modifications occurring on DNA or histones (6).  
  To date, over 130 site-specific modifications have been identified on histones, 
present on both the globular domains and, most frequently, the unstructured N-terminal 
tails (7). These modifications, including acetylation, ubiquitination, phosphorylation, and 
methylation, are deposited and removed by distinct chromatin-modifying enzymes 
(CMEs) that are often recruited to specific genomic loci through interactions with 
sequence-specific DNA-binding proteins (e.g. transcription factors) (8). In a similar 
fashion, CME recruitment can be regulated by large intergenic non-coding RNAs 
(lincRNAs) –a mechanism recently attributed to transcriptional regulation by Xist and   3 
HOTAIR, two lincRNAs found to facilitate heterochromatinization of target genes 
through interaction with CME complex PRC2 (9,10). In a sequence-independent 
manner, some CMEs can interact directly with RNA polymerase II and associated 
elongation factors (e.g. Set2 and Set1 in yeast, respectively) (11,12), while others 
recognize and bind pre-existing chromatin modifications enriched at specific genetic loci 
(13). 
  Genome-wide analysis of histone modifications (i.e. ChIP-seq) has revealed 
distinct localization of specific chromatin ‘marks’, connecting them to various regulatory 
activities at promoters, enhancers, and gene bodies (14). Consequently, many CMEs 
act as transcriptional co-activators or co-repressors, regulating transcriptional initiation 
and elongation or facilitating heterochromatin formation at a given gene (15). As 
described in further detail below, the roles of CMEs in controlling gene expression 
programs designate them as central players in organismal development, the 
maintenance of cell state, and disease pathogenesis.   
 
Figure 1.1  Structure of the nucleosome  
147 base pairs of DNA wrapped around an octamer of histone proteins (H2A, H2B, H3, and H4). Each 
histone comprises an alpha-helical globular domain and an unstructured N-terminal tail that extends beyond 
the core particle.(1KX5: DOI:10.2210/pdb1kx5/pdb)  
 
Organic Synthesis Towards a Genomic Medicine    Chem 201: Core Lecture Topic 11 
 
  11-1 
Class title:  “Chromatin and small-molecule modulators” 
 
Key points: 
 
•  Chromatin  refers  to  the  nucleoprotein  complex  comprising  histone  proteins  and  DNA 
(among others) that serves both to compact cellular DNA and to regulate the expression of 
different  genes  in  different  cells.  Small  molecule-probes  resulting  from  target-oriented 
synthesis were used to discover one of the first families of chromatin-modifying enzymes to 
be characterized – the histone deacetylases (HDACs). 
 
•  External  proteins  and  hormones  signal  to  the  nucleus.  The  memory  of  the  signals  is 
recorded by “marks” on chromatin – e.g., methyl and acetyl groups on specific lysines. The 
mechanisms  used  to  achieve  “epigenetic  inheritance”  are  the  same  as  those  used  to 
propagate the original signals. 
 
•  Epigenomics in biology and medicine is an extremely fruitful area. The promise of this area 
in medicine will only be realized if organic synthesis and chemical biology are channeled in 
ways that enable the discovery of small molecules that alter chromatin states – e. g. ,  t o 
reprogram cell states in vivo.  
 
Chromatin  and  gene  regulation. I n  t h e  p r e v i o u s  c l a s s ,  w e  e x p l o r e d  h o w  t a r g e t -oriented 
organic synthesis can yield powerful probes. Whereas the probes discussed in the last class 
played a key role in immunophilin research and shed light on signal transduction, today we will 
examine  a  second  study  of  target-oriented  synthesis  that  yielded  probes  of  chromatin,  a 
complex of DNA and histone proteins that is key to gene regulation.  
 
 
 
Figure 11-1. Structure of a nucleosome, a central element of chromatin comprising an octet of histone 
proteins and ~150 base pairs of DNA.  
 
Chromatin  had  been  known  for  many  decades.  It  was  viewed  as  a  structural  element  that 
enabled the compaction of extremely long DNA molecules (total length per nucleus is on the 
order of one meter) into the tiny nucleus of a cell. One visionary scientist, Vincent Allfrey, noted   4 
1.2  Histone methyltransferases (HMTs) and the roles of methylation 
Methylation of specific histone residues regulates a diverse set of fundamental 
processes orchestrated on chromatin, from transcription to heterochromatin formation to 
DNA repair (14-16). Histone methyltransferases (or more appropriately, protein 
methyltransferases) are a family of enzymes (>60 in humans (17)) comprising three 
classes—arginine methyltransferases (PRMTs), SET domain-containing lysine 
methyltransferases (PKMTs), and non-SET domain-containing lysine 
methyltransferases, each of which binds and uses the cofactor S-adenosylmethionine 
(SAM) to transfer a methyl group to lysine or arginine residues on histone and non-
histone proteins (18) (Figure 1.2). While lysine residues can be mono-, di-, or 
trimethylated, arginine methylation—given the chemical nature of the guanidino group—
is more complex, with monomethylation occurring on either delta- or omega-N
G atoms 
and dimethylation occurring symmetrically (omega-N
G, N
G –dimethylarginine) or 
asymmetrically (omega-N
G-dimethylarginine) (19).  
Histone methylation exhibits its effects primarily through the recruitment of 
effector proteins (termed ‘readers’) whose binding is dependent on the residue modified 
(e.g. H3R2, H3K4, H4K20, H126, etc.), degree of methylation (i.e. mono-, di-, or 
trimethylation), as well as the presence or absence of specific neighboring chromatin 
modifications (13,15,20-22).  Known effector proteins contain one or more ‘reader 
domains’ that selectively bind their target PTMs using—in the case of methyl-lysine 
readers—an aromatic “cage” within their binding pockets (22). Methyl-lysine reader 
domains include PHD fingers, WD40 domains, and the Royal Family proteins, including 
Chromo, Tudor PWWP, and MBT domains (23), all of which have been found in several    5 
 
 
Figure 1.2 Histone methyltransferase mechanism and products 
(A) Currently accepted mechanism for processive lysine methylation (18). SAH is released after each cycle of 
methylation. (B) Crystal structure of EHMT1 in complex with H3K9me1 and SAH (DOI:10.2210/pdb3HNA/pdb).  
(C) Structures of methylarginine residues.  
 
hundred diverse human proteins to date (24). While a majority of reader proteins 
regulate transcriptional events, others are involved in maintaining higher-order 
chromatin structure (e.g. HP1 and L3MBTL1) (25-27), recruiting DNA damage response 
factors (e.g. MSH-6 and 53BP1) (28,29), or facilitating replication (e.g. LRWD1) (28).  
  As the roles of histone methylation in transcriptional regulation have been 
extensively studied, several methyl ‘marks’ have been broadly linked to activating or 
repressive transcriptional activities. For instance, H3K4, H3K36, and H3K79 methylation 
at a given genetic loci typically associates with transcriptional activation, while H3K9, 
H3K27, and H4K20 methylation often suggests transcriptional repression (15). 
However, a given mark can mediate several outcomes depending on its context. For 
example, H3K4me3 was recently found to recruit both transcriptional repressors 
(Sin3/HDAC corepressor complex via GATAD1) and activators (SAGA and NuRF   6 
complexes), suggesting multiple transcriptional outputs (28,30,31). Similarly, 
H3K36me3, a mark typically associated with transcriptional activation and RNAP II 
elongation (32,33), mediates transcriptional silencing through PRC2 recruitment (via 
PHF19 binding) during ESC differentiation (34,35).  
The localization of specific methyl marks corresponds to their overall function—
those enriched at transcriptional start sites (TSSs) or distal enhancers typically regulate 
transcription initiation events, while those occurring on gene bodies often facilitate  
transcriptional elongation or regulate the general accessibility of various machineries to 
DNA (32,36-40). For instance, H3K4me3, present at the TSS of several actively 
transcribed genes, increases the rate of pre-initiation complex (PIC) formation through 
the recruitment of basal transcription factor TFIID via binding of TAF3—a PHD finger-
containing protein (41,42). H379me2, localized throughout gene bodies, is thought to 
regulate elongation, as the only known H3K79 methyltransferase, hDOT1L, is found in 
complex with core elongation factors Paf1 (11) and p-TEFb (43). Enhancer chromatin is 
characteristically enriched in H3K4me1 and H3K27ac, providing a robust signature for 
genome-wide identification of enhancers across cell types (44). While the specific 
functional consequences of these marks are still under active investigation, it is 
speculated that H3K4me1 recruits TIP60/p400 complex (via its H3K4me1 reader 
domain) to facilitate H2A.Z incorporation at enhancer regions, thus promoting an open 
chromatin state that enables transcription factor binding (45,46).  
As many important and diverse processes are mediated by histone methylation, 
HMTs—as well as all associated readers and erasers (histone demethlyases)— play 
central roles in their regulation. For this reason, it is not surprising that aberrant   7 
expression, localization, or activity of HMTs has been linked to a variety of disease 
states, from neurodevelopmental disorders (47-50) to a large number of cancers (51-
55). With this biological liability, however, comes opportunity, as small-molecule 
modulators of readers, writers, and erasers of these modifications provide a potential 
route for manipulating cellular states for therapeutic benefit in regenerative medicine 
(e.g. transdifferentiation, induced pluripotency, etc.) and targeted cancer treatment.    
1.3  Polycomb repressive complex 2 (PRC2) and EZH2  
EZH2 is a SET domain-containing methyltransferase and the catalytic 
component of the multimeric Polycomb- group (PcG) protein complex, PRC2 (Figure 
1.3). When in complex with other PRC2 members (EED, SUZ12, AEBP2, and RBBP4), 
EZH2 catalyzes mono- and dimethylation of H3K27, requiring only EED and SUZ12 for 
basal enzymatic activity (56). To achieve efficient H3K27 trimethylation, PRC2 requires 
an additional component, PHF1/PCL1, which enables loci specific regulation of 
H3K27me3 deposition (57,58). Other PCL proteins (MTF2/PCL2 and PHF19/PCL3), as 
well as JARID2, have been shown to interact with PRC2, facilitating recruitment to 
target genes and further stimulating activity (35,59-63). 
Beyond varying the composition of PRC2, EZH2 activity can be governed by 
direct phosphorylation (66-69), glycosylation (70), or allosterically regulated through its 
partner proteins. For example, as a consequence of binding H3K4me3 or histone H3 
(within residues 35-42), SUZ12 adopts conformations that inhibit or activate EZH2, 
respectively (64,71), while WD40 domain-containing protein, EED, can activate PRC2 
when bound to known repressive marks— H3K27me3 and, to a lesser degree, 
H3K9me3 (65,72). These regulatory mechanisms are thought to assist in the spreading   8 
of H3K27me3 and initiation of heterochromatin formation, leading to transcriptional 
repression of target genes (56). Phosphorylation of EZH2 at T350 by CDK1 promotes 
PRC2 binding to lincRNAs , Xist and HOTAIR, facilitating recruitment to target loci (66). 
Conversely, phosphorylation of EZH2 at S21 (AKT) and T487 (CDK1) has been shown 
to disrupt the PRC2 complex and inhibit H3K27 methyltransferase activity (69,73). 
   
 
Figure 1.3 Composition of PRC2  
PRC2 is a multimeric complex comprising three core components (EZH2, EED, and SUZ12) and two 
accessory components (AEBP2 and RBBP4) that further stimulate activity (56). JARID2 and PCL proteins 
are thought to enhance PRC2 activity in vivo and endow trimethylation activity, respectively (57,60). Core 
components, EED and SUZ12, have been found to regulate PRC2 activity through allosteric regulation 
involving interactions with chromatin and specific modifications thereof (64,65) 
 
In mammals, there is an EZH2 paralog, EZH1, which harbors a nearly identical 
SET domain (96% identity) and shares 76% identity with EZH2 overall.  EZH1 can form 
PRC2-type complexes in place of EZH2 (PRC2-EZH1), endowing the complex with 
H3K27 methyltransferase activity (albeit weaker) (74,75). In fact, PRC2-EZH1 targets a 
large subset of EZH2-regulated genes (75) and is able to maintain embryonic stem cell 
pluripotency in EZH2(-/-) ESCs (76), suggesting that EZH1 plays a redundant role. 
However, EZH1 is reciprocally expressed during development, with some tissues   9 
expressing high levels of EZH2 (low EZH1) and others (e.g. skeletal, kidney, and brain) 
expressing high levels of EZH1 (low EZH2) (75,77-80). Moreover, PRC2-EZH1 co-
localizes with H3K4me3 at transcriptionally active genes in differentiating myocytes, 
interacting with RNA Pol II complex to promote elongation (81). As these studies 
revealed distinct genomic localization, EZH1 and EZH2 paralogs may have specific 
functions depending on the cellular context.  
Like many HMTs, PRC2 plays an essential role in several biological processes. 
Through methylation of promoter histones, PRC2 supports development by silencing 
lineage-specification genes and key developmental regulators (e.g. the HOX gene 
cluster) (36). H3K27me3 is found at enhancer regions upstream of early developmental 
genes, further implicating PRC2 in developmental regulation (82). Moreover, EZH2 is 
required for IgH rearrangement in pre-B cells, a key step in B-cell maturation (80).  
Since many PcG-regulated genes must be stably repressed through cell division, PRC2 
is also thought to contribute to the transmission of repressive marks during cell division, 
maintaining cell fate (83). Thus, while some methyl marks (e.g. H3K79me2) are lost 
through cell division—primarily those that regulate housekeeping functions occurring on 
the level of chromatin—H3K27me3 appears to be truly ‘epigenetic’ in nature, setting 
EZH2 apart from most methyltransferases.   
1.4  The emerging role of PRC2 in cancer 
Several PRC2 components are upregulated or mutated in a variety of human 
cancers. Overexpression of EZH2 has been observed in cancers of the lung, skin, 
colon, and bladder and thought to contribute to their progression (84). In breast and 
prostate cancer, EZH2 has emerged as a biomarker for tumor aggressiveness, with   10 
high expression levels correlating with increased proliferation rates and invasiveness 
(85,86). In follicular lymphoma (FL) and germinal center B-cell-like diffuse large B-cell 
lymphoma (GCB DLBCL), EZH2 activating mutations, involving substitution of Y641 in 
the SET domain, have been found in 7% and 22% of cases, respectively (87). These 
EZH2 mutants, while essentially incapable of methylating unmodified H3K27, are 
hyperactive on mono- and dimethylated H3K27 compared with the wild-type enzyme, 
suggesting an oncogenic role (88,89), at least in certain contexts (see below). This 
notion is further supported by the occurrence of cancer-associated inactivating 
mutations in UTX (an H3K27me3 demethylase) (90). 
Whether EZH2 acts as an oncogenic or a tumor suppressor appears to be 
context dependent, as several inactivating mutations have been identified in both 
myeloid disorders (i.e. MDS/MPN; ref. 55) and T-cell acute lymphoblastic leukemia (T-
ALL) (91). These mutations are not only limited to EZH2, but can span other PRC2 
components, such as SUZ12 and EED, and known positive regulators, such as JARID2 
(91,92). Moreover, it has recently been reported that in T-ALL, H3K27 demethylases 
can function as a tumor suppressor  (UTX) or oncogene (JMJD3) in the same disease 
context (93). This dichotomy of EZH2 (and opposing demethylases) in supporting 
oncogenesis raises concerns about the potential effects of prolonged use of EZH2 
inhibitor therapies; however, it is unknown whether loss of EZH2 HMTase activity is 
sufficient to support tumorigenesis.  
1.5  Small-molecule probes for EZH2 and other HMTs. 
In contrast to the large number of distinct histone deacetylases inhibitors, reports 
of small-molecule modulators of HMTs have only recently emerged (94). G9a and   11 
Su(var)3-9 inhibitors, BIX-01294 (95) and chaetocin (96), were among the first probes to 
be identified, followed by DZNep, an indirect pan-methyltransferase inhibitor that lowers 
global histone methylation through the reduction of available SAM levels (97).  
As evidence for the roles of HMTs in disease accumulated, so did their potential 
as promising drug targets, prompting several pharmaceutical companies to initiate 
probe development efforts (Figure 1.4). Inhibitors of DOT1L, developed by Epizyme, 
were the first in a wave of highly potent SAM-competitive HMT inhibitors recently 
reported (98). Shortly following, Epizyme, GSK, and others disclosed small-molecule 
probes for EZH2 (74,99-102).  While immensely useful, these compounds are 
structurally similar, share the same mechanism of action (competition with the SAM 
cofactor), and inhibit both the WT and hyperactive mutant forms of EZH2. To date, no 
direct substrate-competitive or mutant-selective inhibitors of EZH2 have been reported 
or small-molecule probes of other PRC2 components. However, Orkin and colleagues 
recently described a stabilized alpha-helical peptide (SAH) capable of inhibiting PRC2 
through disruption of EZH2-EED interaction (103). 
 
Figure 1.4 Structures of newly discovered HMT inhibitors 
GSK (GSK343, GSK126), Epizyme (EPZ005687), Constellation (Cpd 3), Novartis (EI1), and SGC 
(UNC1999) inhibitors for EZH2 are structurally similar, with the exception of Constellation compound 3. 
Epizyme’s hDOT1L inhibitor (EPZ004777) is also shown above.  
   12 
The emergence of first-in-class EZH2 inhibitors has enabled evaluation of the 
target in DLBCL (104), MLL-AF9 leukemia (103), and aggressive rhabdoid sarcomas 
(105), revealing high therapeutic potential in animals studies. Clinical studies are 
currently underway, but early observations suggest anti-lymphoma activity of Epizyme’s 
clinical candidate, E7438, in NHL patients (106). Whether this currently dominating 
EZH2i chemotype presents specific pharmacodynamic (PD) or pharmacokinetic (PK) 
liabilities, is yet to be determined.  
Further studies are needed to gauge the effectiveness of EZH2 inhibitors in 
cancers dependent on Polycomb-independent EZH2 activity (69,73,107) and to 
determine whether these compounds increase the likelihood of myeloid disorders (55)—
or have other unforeseen side-effects via disruption of cytosolic EZH2 function (108). 
More importantly, additional studies are needed to investigate the impact of EZH2i in 
other cancer contexts, given the aforementioned dichotomy of EZH2 and UTX in 
supporting tumorigenesis (51,93). Furthermore, dependencies on PRC2 functions 
beyond its methyltransferase activity may require probes that disrupt localization in 
addition to enzymatic activity (75,81).  
1.6  Concluding remarks 
Identification of small-molecule probes with distinct chemotypes, MOAs, and 
selectivity profiles are not only of great value, but necessary in establishing 
comprehensive probe sets capable of illuminating the various roles of EZH2 in 
oncogenesis. Towards this aim, we sought to recombinantly express and purify 5-
component PRC2 (EZH2-EED-SUZ12-AEBP2-RBBP4), establish biochemical and 
cellular HTS assays (Chapter II), and screen a diverse set of compounds to discover   13 
modulators of PRC2 activity (Chapter III). My doctoral thesis describes these efforts as 
well as the characterization of inhibitors (BRD1835; Chapter IV) and activators 
(BRD3934 and BRD8284; Chapter V) of PRC2 biochemical activity identified in our 
primary HTS campaign.  Chapter VI describes the use of an HCS assay to identify 
known bioactive compounds that alter intracellular levels of H3K27me3 through 
modulating H3K27me3-connected regulatory nodes or by targeting PRC2 directly. This 
screen ultimately led to the discovery of an antifungal agent, miconazole, capable of 
activating PRC2 activity in vitro, as well as a mucolytic agent, bromhexine, that 
selectively ablates cellular H3K27me3 levels through targeting an activity distinct from 
PRC2. Lastly, Chapter VII discusses novel PRC2-connected crosstalk mechanisms 
identified through screening libraries of uniquely modified histone peptides for their 
ability to bind or support methylation by PRC2.  
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2.1  Introduction 
2.1.1  Biochemical approaches to measuring HMTase activity 
While there is no widely accepted standard for measuring HMT activity, 
numerous methods have been developed. Some assays measure SAH production, in 
coupled-enzyme (1-3) and competitive fluorescence polarization (4) formats, while 
others measure levels of methylated substrate, by way of radiometric detection (5-8), 
immunodetection (9-11), mass spectrometry (9), or capillary electrophoresis (12). 
Depending on the HMT of interest and application (i.e. kinetic studies, HTS, etc.), each 
approach has its advantages and limitations.   
Most coupled-enzyme assays detect methyltransferase activity by enzymatically 
converting the byproduct of methylation, SAH, into homocysteine which can then be 
quantified using ThioGlo (2) or Ellman’s reagent (1)—both thiol-reactive fluorescent 
probes. While these assays have proven useful for kinetic characterization and small-
molecule discovery for some HMTs (13-15), the requirement of additional enzymes to 
produce signal complicates optimization of key assay parameters (e.g. buffer 
conditions) and can increase the false positive rate when screening for inhibitors; 
moreover, the use of thiol-reactive probes can alter HMT activity and negatively impact 
the signal-to-background ratio when surface cysteines are present.   
  Radiometric HMT assays quantify 
3H or 
14C incorporation into target substrate 
(by scintillation counting or autoradiography) following incubation with labeled cofactor, 
S-[methyl-
3H]- or S-[methyl-
14C]-adenosyl-methionine. Radiolabeled product is typically 
purified via small-scale chromatography (e.g. ZipTip®) (16), SDS-PAGE (17), or filter-
binding methods (7,18) to remove excess labeled cofactor; however, the development   27 
of scintillation proximity assays (SPA) has obviated this step, provided that the product 
can be immobilized (usually by means of biotin) (8). While these methods afford high 
sensitivity and are generally less prone to artifacts (19), safety concerns and the 
practical considerations of handling radiological waste limit their use in high-throughput 
screening.  
  In contrast to radiometric assays, immunodetection of specific methylated 
products has proven to be a valuable approach in the realm of high-throughput assay 
development. In 2007, Kubicek et al. reported the discovery of BIX-01294, a substrate-
competitive G9a inhibitor found in a screen of 125,000 compounds using a dissociation-
enhanced lanthanide fluoroimmunoassay (DELFIA). In DELFIA, biotinylated product is 
captured on a streptavidin-coated surface, incubated with a methylation-specific 
antibody bound to a europium-conjugated secondary antibody, and then detected via 
time-resolved fluorescence (9,20). Chemiluminecence-based detection has also been 
reported, using an HRP-linked secondary antibody in place of lanthanide-conjugates 
(10). HMT profiling services provided by BPS Bioscience has demonstrated the utility of 
this approach, as >20 distinct, validated HMT assays are commercially available for 
small-molecule characterization.    
Due to the requirement of several wash steps and extensive liquid handling in 
DELFIA, several HMT-adapted homogenous immunoassays have also been developed. 
These include AlphaLISA (11) and LANCE (21), both of which require use of 
biotinylated substrates and selective antibodies to generate a FRET-like (AlphaLISA) or 
FRET-based (LANCE) signal upon ternary complex formation. While these assays 
remove the need for wash steps, the cost of reagents can be prohibitive to scale-up,   28 
limiting the scope of high-throughput screening campaigns. Furthermore, compared with 
DELFIA, assay artifacts are more prominent, as compounds that disrupt singlet oxygen 
transfer (in the case of AlphaLISA) or display autofluorescence (LANCE) will emerge as 
low-signal outliers. 
While versatile and amenable to HTS, antibody-based HMT assays are limited by 
the quality, consistency, and availability of selective antibodies. Fortunately, in response 
to the growing activity in chromatin research, many companies, such as AbCam and 
Cell Signaling Technology, have developed several products with proven selectivity and 
low lot-to-lot variability, meeting the increased need for reliable antibodies against 
histone marks. As a result, these products have enabled antibody-based assay 
development for a number of histone methyltransferases (11,21).  
2.1.2  Assay development for small-molecule screening  
  Small-molecule screening has become a major source for starting points in the 
development of chemical probes and drugs. At the heart of a successful screening 
campaign, lies a robust and well validated, high-throughput assay. Development of such 
assays requires careful optimization of several key parameters to ensure reproducibility 
and statistically-significant signal over background (22,23). As screens of >100,000 
compounds are often required to cover sufficient chemical space, cost and automation 
compatibility must also be considered. Failure to establish a proper workflow and assay 
prior to a high-throughput screening campaign can lead to unmanageable false-positive 
and false-negative rates, hindering identification of worthy lead compounds.  
Most HTS assays fall into two major categories – biochemical assays, using 
purified target protein to measure direct binding (NMR, small-molecule microarray, etc)   29 
or activity modulation by small molecules, and phenotypic assays, measuring the effect 
of compounds on cellular features (ATP levels, reporter gene activity, morphology, etc.). 
Each approach has its unique set of considerations in terms of proper assay 
development. For biochemical assays measuring enzymatic activity, it is important to 
obtain quality protein preparations and have an understanding of target biochemistry; 
for example, enzyme kinetic parameters (KM, VMAX) under established buffer conditions. 
Defining appropriate buffer conditions is also a key step, requiring evaluation of enzyme 
activity in the presence of different additives (salts, reducing agents, etc.) and buffers at 
varying pH. Optimal enzyme, substrate, and cofactor concentrations are often 
determined based on measured KM and VMAX values, but can be influenced by their cost 
and stability. Product detection systems must be adaptable to miniaturization (96-, 384-
,or 1536-well formats) and automation, allowing sensitive and reproducible 
measurement of activity. Lastly, to prevent high false-negative rates, reaction time and 
detection is optimized to ensure measurement in the linear range (24). 
   If imaged-based phenotypic screening (HCA/HCS) is employed, other factors are 
taken into account, with proper selection of representative, validated cellular 
phenotypes—robustly detected by automated microscopy—being the most critical. Use 
of consistent cell lines and growth/treatment conditions is required to ensure detection 
of the given phenotype with low variability between assay plates and wells. Parameters 
such as compound incubation time, cell number/density, growth media, and any 
necessary staining procedures must be carefully optimized prior to screening. 
Furthermore, establishment of appropriate imaging and image analysis protocols should 
also be considered (25).    30 
In order to screen for and validate small–molecule modulators of PRC2, we 
developed both biochemical (primary; DELFIA) and cell-based (secondary; H3K27me3 
HCA) assays suitable for HTS. Described in detail below, these efforts required 
expression and purification of active PRC2 (EZH2-EED-SUZ12-RBBP4-AEBP2 
complex), identification of a suitable substrate, determination of kinetic parameters, and 
optimization of an HTS-ready DELFIA.  As a secondary assay, we developed an 
immunofluorescence-based HCA protocol to detect changes in cellular H3K27me3 
levels, which we validated using siRNA against EZH2 and EED.  
2.2  Results and discussion 
2.2.1  Expression and purification of recombinant PRC2  
Expression and purification of recombinant five-component PRC2 (EZH2, EED, 
SUZ12, AEBP2, and RBBP4; 5C-PRC2) was first developed by Cao and Zhang in an 
effort to dissect the function of individual subunits found in isolated PRC2 complexes 
(26). Due to the difficulty in expressing full-length EZH2 in E.coli (26,27), Cao employed 
a baculovirus expression strategy to ensure proper folding and enable co-expression of 
PRC2 components, generating an active complex (26). In order to produce large 
quantities of highly active PRC2 for high-throughput screening and subsequent follow-
up studies, we applied a similar strategy with minor modifications.  
After cloning each component cDNA into Gateway-compatible bacmid-transfer 
vectors containing an N-terminal 6XHIS tag (for RBBP4, AEBP2, and SUZ12) or no tag 
(EED and 1xFLAG-EZH2), we generated bacmid constructs through amplification of 
transformed DH10BAC E. coli harboring recombined transgenes, purifying large bacmid 
DNA via anion-exchange chromatography.  Bacmids were then transfected into   31 
Spodoptera frugiperda (Sf9) cells to generate baculovirus stocks (denoted P1) that were 
amplified through infection of large-scale Sf9 suspension cultures to yield high-titer viral 
stocks (P2) suitable for subsequent amplification or immediate protein expression.  
To optimize expression of each PRC2 component, we infected log-phase Sf9 
cells with each component baculovirus individually at multiple MOIs and allowed 
expression to proceed for 48, 72, or 96 hrs. After infected cells were harvested and 
lysed, the levels of transgene expression under these varying conditions were 
determined for each component by western blot. For all components, expression was 
greatest at 96hrs, while the MOI required to achieve maximum expression varied for 
each component (Figure 2.1). 
 
Figure 2.1 Expression optimization for PRC2 components 
Log-phase Sf9 cells were infected with varying dilutions of PRC2 component baculoviruses for 48, 72, or 96 
hours.  Total protein was resolved via SDS-PAGE and recombinant protein was detected via western blot to 
estimate relative expression levels.  
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  We expressed 5C-PRC2 by infecting Sf9 cells with each component baculovirus 
simultaneously (at their respective, optimal MOIs), allowing co-expression to proceed 
for 96 hours. To isolate recombinant complex, we harvested cells post-infection and 
lysed via sonication. Lysates were cleared by centrifugation and incubated with anti-
FLAG M2 agarose beads, capturing all 1XEZH2-containing complexes—including 5C-
PRC2. These complexes were then eluted with 3XFLAG peptide and the resulting 
eluate was separated through a gel filtration column (Superdex 200) to isolate 5C-PRC2 
based on its predicted molecular weight (~325 kDa).  
 
Figure 2.2 Characterization of recombinant 5C-PRC2  
(A) Superdex 200 16/600 SEC separation of PRC2 elutions. Peaks eluting around 40 mL (“Early PRC2 
Peak”; ~660 kDa) and 55 mL (“Late PRC2 Peak; ~300 ka) were collected
*. (B) SDS-PAGE of “Early” and 
“Late” PRC2 peaks. (C) Western blots for each PRC2 component within PRC2 fractions. (D) Native PAGE 
of PRC2 elutions and EZH2 western blot. 
2.2.2  Characterization of recombinant PRC2  
After purification, we confirmed incorporation of each component into PRC2 by 
western blot and verified homogeneity of the five-component complex by native PAGE   33 
(Figure 2.2). Native PAGE revealed two prominent bands, one in the 480 kDa range 
and another around 780 kDa (as estimated by molecular weight standards). Anti-EZH2 
western blots confirmed that these bands contained EZH2 and were likely monomeric 
(~325 kDa) and dimeric (~650 kDa) forms of the PRC2 complex. The existence of 
distinct complexes had been previously speculated, but they have only recently been 
characterized and reported (28). While these forms have not been shown to differ in 
enzymatic activity, dimeric and monomeric PRC2 bind lincRNA (e.g. HOTAIR) with 
varying affinities in vitro (28).  
 
Figure 2.3 Confirmation of recombinant 5C-PRC2 activity 
(A) Workflow of radiometric PRC2 assays. (B) Activity of recombinant PRC2 on histone octamer (1 ug) and 
peptide (1 uM) substrates as measured by LSC. Data represent the mean and standard error of triplicate 
measurements. (C) MALDI-TOF spectra of H3[21-44]-GK-biotin peptide isolated from PRC2 reaction at time 
0 min (left) and 180 min (right). 
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We initially measured activity of recombinant PRC2 using a radiometric assay 
(16), incubating purified enzyme with histone octamer or an H3-derived peptide (H3[21-
44]) in the presence of 
3H-SAM for 2 hrs at RT. In comparison to the “no enzyme” 
controls, our recombinant PRC2 displayed activity on both substrates (with higher 
activity on octamer) (Figure 2.3B). To further confirm this activity and determine the 
degree of substrate methylation (i.e. mono-, di-, or trimethylation), we repeated our 
reaction in the presence of peptide and cold SAM, measuring peptide mass via MALDI-
TOF mass spectrometry. These experiments revealed significant levels of 
monomethylation, modest levels of dimethylation, and no detectable trimethylation 
(Figure 2.3C)—results consistent with the finding that 5C-PRC2 is deficient in its ability 
to methylate H3K27me2-modified substrates in vitro (18).   
 
Figure 2.4 Kinetic characterization of recombinant 5C-PRC2 
(A) Workflow for plate-based LSC assay. (B,C) Michaelis- Menten plots for SAM and H3[21-44]-GK-biotin 
peptide, respectively. Mean and SEM for initial velocities were generated from linear regression fits (PRISM 
6.0) of triplicate measurements over six time points (0,15, 30, 45, 60, and 75 min). KM and VMAX values were 
determined using the Michaelis-Menten analysis module in PRISM 6.0. 
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  For the purpose of downstream assay development, we next aimed to kinetically 
characterize our recombinant PRC2, measuring its kinetic parameters (KM and VMAX) for 
SAM and H3[21-44] peptide. Using an LSC protocol adapted for higher throughput 
(Figure 2.4A), we performed time-course measurements of PRC2 activity under varying 
concentrations of cofactor (Figure 2.4B) and substrate (Figure 2.4C).  Our recombinant 
PRC2 was found to have KM values for SAM in the 2 uM range, while the KM for H3[21-
44] was around 150 nM.  As IC50 values (as opposed to Ki) are typically measured when 
assessing compound activity, it is important to establish assay conditions (namely, 
cofactor and peptide concentration) that take kinetic parameters into consideration. 
Depending on the mechanism of action, strong deviations between a compound’s Ki 
(true potency) and IC50 (apparent potency) occur when cofactor or substrate 
concentrations exceed their respective KM values (29,30). 
2.2.3  Development of DELFIA for PRC2 HTS 
With an established source of validated PRC2, we next aimed to develop a 
biochemical assay suitable for high-throughput screening. DELFIA (Figure 2.5A) was 
chosen as our primary assay detection method due to its versatility, relatively low cost, 
and reported success in similar HTS campaigns (9). As we had previously confirmed 
PRC2 activity on a biotinylated H3-derived peptide, our first challenge was to identify an 
antibody capable of detecting the methylated product (H3K27me1/2) selectively over 
the unmodified substrate. Using our former conditions, we set-up 40 uL reactions in 
384-well DELFIA plates (streptavidin-coated) and screened a panel of H3K27me-
selective antibodies (Figure 2.5B). While most of the antibodies failed to generate 
significant signal over background (no-enzyme control), three showed promising S/B   36 
(>20) at a wide range of dilutions. Ultimately, an H3K27me2-selective antibody, 
CS#9728, was selected for its ability to deliver high signal at a reasonable dilution; 
moreover, this lot was available from Cell Signaling Technology in quantities that met 
our estimated needs for high-throughput screening.  
Next, we optimized SAM, H3[21-44] peptide, and enzyme concentrations to 
minimize material requirements, yet maintain high signal (Figure 2.6). Using our 
H3K27me2-selective antibody for detection, we first titrated peptide (from 50- 800 nM) 
and then SAM (2.5 – 20 uM), selecting final concentrations based on KM values and 
overall signal. For our assay, we aimed to maximize signal, yet prevent significant Ki 
versus IC50 discrepancies by using final concentrations at 2X KM for peptide (300 nM) 
and 2.5X KM for SAM (5 uM). Once optimal substrate and cofactor concentrations were 
determined, we titrated enzyme to find the minimum concentration that would produce 
high signal and behave linearly over the reaction course (Figure 2.6C,D). Under our 
optimized SAM and peptide conditions, 30 ng PRC2 (2.3 nM) was sufficient for 
detection (>20 S/B) and subsequent time course experiments confirmed linearity. 
 
Figure 2.5 Antibody selection for PRC2 DELFIA  
(A) Overview of DELFIA.  (B) Signal-to-background measured for 10 methylation-specific antibodies at various 
dilutions in PRC2 DELFIA. Data represent the mean of four replicate wells.  
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Figure 2.6 Optimization of substrate, SAM, and PRC2 concentrations 
Resulting DELFIA signal (RFU) from titration of (A) H3[21-44] peptide, (B) SAM, and (C) PRC2. Reaction 
time was optimized by time course experiment (D), verifying linear progression over 60 minutes. Data points 
represent mean and SEM of four replicate wells.   
 
2.2.4  Development of a Cellular H3K27me HCS assay  
In anticipation of compound triaging, we next aimed to develop an assay capable 
of assessing the cellular activity of putative PRC2 modulators. As the number of initial 
screening hits (or lead analogs) could be large, we limited ourselves to assays that 
could be adapted to high throughput. Since many PRC2 target genes are known (and 
repressed by H3K27 methyltransferase activity), we considered HTS-compatible gene-
expression assays (GE-HTS) using TurboCapture (31) or Cells-to-CT™(32) methods for 
RT-qPCR readout; however, the cost of reagents and variability associated with these 
measurements persuaded us to consider other approaches.  
Since disruption of PRC2 alters global H3K27me levels (33,34), we reasoned 
that measuring this mark may be an appropriate gauge of intracellular PRC2 activity.   38 
Western blotting and mass spec approaches are effective (9,35), but lack the necessary 
throughput;  ELISAs can be adapted to high-throughput, but require histone purification 
prior to readout. For these reasons, we pursued development of a high-content assay 
(HCA) using high-throughput microscopy to detect intracellular H3K27me2/3 via 
immunofluorescence (IF).  
Using HeLa cells, we first screened a panel of H3K27me2/3-specific antibodies for 
their ability to generate a nuclear signal. While several antibodies nonspecifically 
stained the cytoplasm, we found three that selectively stained the nucleus with high 
intensity (Figure 2.7). Selectively of these antibodies towards H3K27 methylation was 
then determined through use of MODified™ Histone Peptide Arrays, a miniaturized 
panel of 384 uniquely-modified histone peptides immobilized on cellulose spots affixed 
to a glass slide. Of the three antibodies tested, two demonstrated absolute selectivity to 
H3K27 methylation (CS#9728 and CS#9733), while the other bound a wide range of 
modified H3 peptides (CS#9755). Interestingly, both CS#9728 and CS#9733 were  
 
Figure 2.7  Profiling selectivity of H3K27me antibodies 
(Top) Binding of H3K27me2/3 antibodies to MODified Histone Peptide Array containing 384 uniquely modified histone 
peptides. With the exception of those phosphorylated at S28, CS# 9728 binds H3K27me1 and H3K27me2-modified 
peptides, while CS# 9733 binds only H3K27me3-modified peptides. CS#9755 binds non-selectively to several 
methylated H3 peptides. (Bottom) IF staining demonstrates nuclear localization of antibodies in HeLa cells.   
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unable to bind H3K27me peptides harboring H3S28 phosphorylation (H3S28ph). Since 
H3S28ph is not a suitable substrate for PRC2 (36, Chapter VII), this phenomenon was 
deemed unlikely to severely impact estimation of global H3K27me levels.     
 
Figure 2.8 H3K27me HCS Assay Development 
(A) Western blot confirming knockdown of EED (top) and EZH2 (bottom) in HeLa cells after 72 hrs (using 3 distinct 
siRNAs) compared to negative control (NC). (B) Average nuclear intensity of cells stained with H3K27me2 
antibody (CS#9728) post-knockdown. Data represent mean and SEM of eight replicate wells (C) Western blot 
confirming knockdown of EZH2 prior to histone extraction and (D) H3K27me3 ELISA. Data represent mean and 
SEM of six replicate wells.    
 
To assess whether this staining was dependent on H3K27me2/3 levels, we used 
siRNA to knockdown EZH2 and EED, measuring average nuclear fluorescence after 
staining with our H3K27me-selective antibodies (Figure 2.8A,B). Perturbation of both 
EZH2 and EED significantly lowered nuclear signal after 72 hrs, suggesting that 
intracellular H3K27me2/3 levels could be measured reliably by immunofluorescence. To 
further confirm that 72 hr knockdown of EZH2 resulted in lowered H3K27me levels, we 
extracted histones and performed an H3K27me3 ELISA (Figure 2.8C,D). Consistent   40 
with IF data, knockdown of EZH2 resulted in a significant reduction (>40%) of 
H3K27me3. 
2.2.5  Discussion and Conclusion  
To date, all known selective HMT probes have originated from molecules identified 
in high-throughput screening campaigns, highlighting screening as a major source of 
chemical starting points for selective small-molecule probes (9,22). As we aimed to 
identify small-molecule probes with chemotypes and MOAs distinct from the current set 
of EZH2 inhibitors, we developed both biochemical (primary; DELFIA) and cell-based 
(secondary; H3K27me3 HCA) assays suitable for HTS. In order to establish a protein 
source for screening, we established a platform to express and purify 5-component 
PRC2 (EZH2-EED-SUZ12-AEBP2-RBBP4), verifying its composition (by western blot 
and native PAGE) and enzymatic activity by radiometric assay and MALDI-TOF. We 
then developed a PRC2 DELFIA, following substrate selection, kinetic characterization 
of PRC2, and identification of a reliable detection antibody. As proper assay 
development is key to HTS success, we optimized assay parameters through titration of 
each assay component, confirming assay reproducibility and linearity in the process.  
Development and siRNA-based validation of an HCA for cellular H3K27me3 levels then 
followed. These assays were used to screen and triage over 120,000 compounds 
assayed over two rounds (>60,000 compounds each), identifying several putative PRC2 
inhibitors and activators (as described in Chapter III).  
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2.3  Experimental Methods 
Cloning PRC2 components and bacmid purification.  PRC2 component cDNAs 
were obtained from Harvard DF/HCC DNA resource core, with the exception of SUZ12 
(Origene) and 1XFLAG-EZH2 (kind gift from Bradley Bernstein). Briefly, 1XFLAG-EZH2 
(NM_004456), and EED (NM_003797) were sub-cloned into pDEST8, while SUZ12 
(NM_015355), AEBP2 (NM_153207), and RbAp48 (NM_005610) were sub-cloned into 
pDEST10 using the Gateway® LIC (Life Technologies). These constructs were 
transformed into MAX Efficiency DH10Bac competent cells (Life Technologies) and 
bacmid DNA was purified using Qiagen’s Large-Construct Kit.  
PRC2 expression and purification.  Sf9 cells cultured in Sf-900 SFM  III (Life 
Technologies) were transfected with bacmid DNA to obtain a viral stock which was 
subsequently amplified as described in the Bac-to-Bac Baculovirus Expression System 
Manual (MAN0000414; Life Technologies). Sf9 cells were co-infected with PRC2 
component baculoviruses and harvested 96 hrs post-infection. Cells were then lysed via 
sonication in lysis buffer (20 mM Tris pH 8, 500 mM NaCl, 4 mM MgCl2, 0.4 mM EDTA, 
2 mM DTT, 20% glycerol, 0.1% IGEPAL CA-630). Lysates were incubated for 3 hrs with 
anti-FLAG M2 agarose (Sigma, A2220) at 4°C. After incubation, beads were washed 
three times with wash buffer (20 mM Tris pH 8, 150 mM NaCl, 2 mM MgCl2, 0.2 mM 
EDTA, 1 mM DTT, 15% glycerol, 0.01% IGEPAL CA-630) and bound PRC2 was eluted 
with 3X FLAG peptide (Sigma, F4799) diluted to 200 ug/mL in wash buffer. Eluate was 
then concentrated and loaded onto a Hi-Load 16/60 Superdex 200 pg column (GE 
Heathcare). Fractions containing full complex were pooled, concentrated, and stored at 
-80°C until further use.    42 
Cell lysis, western blotting, nativePAGE, and antibodies. Total protein was isolated 
from cells via M-PER Extraction Reagent (Pierce) or, for Sf9 expression optimization, 
1X-LDS Sample Buffer (Life Technologies).  For detection of PRC2 components and 
confirmation of EED and EZH2 knockdown, purified protein or cell lysate was diluted in 
1X LDS Sample Buffer containing 1X Reducing Agent (Life Technologies) and 
separated on 4-12% Bis-Tris NuPAGE gels (Life Technologies) prior to 1 hr transfer 
(30V at RT) onto Immobilon PVDF membranes (Bio-Rad). For NativePAGE, purified 
protein was separated on 4-16% NativePAGE gels (Life Technologies), in the absence 
of loading buffer or additives, following manufacturer’s protocol for separation and 
western blotting of detergent-containing samples. Anti-EZH2 (CST; #3147), anti-EED 
(Abcam: ab4469), anti-SUZ12 (Abcam; ab12073), anti-AEBP2 (Abcam; ab107892), 
anti-RBBP4 (Abcam; ab117746), anti-FLAG M2 (Sigma; F1804), and anti-6XHIS 
(Abcam; ab18184) antibodies were diluted in 5% non-fat milk or 5% BSA in TBST to 
manufacturer’s specification for overnight primary antibody incubations. Anti-mouse IgG 
or anti-rabbit IgG HRP conjugates (GE) diluted 1:2500 in primary antibody diluent 
(incubated at RT for 1hr) was used for chemiluminescence detection with SuperSignal 
West Pico Chemiluminescent Substrate (Pierce) following TBST washes.    
PRC2 radiometric assays.  PRC2 was diluted to final concentration in 2X enzyme 
buffer (50mM Tris HCl pH 8.5, 10 mM DTT). Reactions were initiated with an equal 
volume of an SAM solution (NEB) containing 
3H-SAM (at 25% total SAM concentration; 
NET155001MC; PerkinElmer) and H3[21-44]-GK-biotin (AnaSpec) or histone octamer 
(BPS Biosciences) and incubated at room temperature. For initial validation studies, 
reactions were quenched with 7.5 M guanidium HCl and processed via C4 (histone   43 
octamer) or C18 (peptide) ZipTip® for LSC as described in (16). For kinetic analysis, 
100 uL aliquots were quenched in an equal volume of 3.2 mM SAM at various time 
points in a 96-well plate. After all time points were collected, quenched reactions were 
transferred to a streptavidin-coated 96-well DELFIA plates (PerkinElmer) and incubated 
at RT for 1 hr. Unreacted 
3H-SAM was removed by washing plates three times with 200 
uL of wash buffer (50mM Tris pH 7.4, 150 mM NaCl, 0.05% Tween 20, 0.2% BSA) per 
well. Modified peptide was then eluted by a 1 hr RT incubation with 100 uL/ well elution 
buffer (70% ACN, 5% formic acid, 1 mM biotin) and 
3H incorporation was measured by 
LSC (TriCarb 2910; PerkinElmer). 
PRC2 MALDI-TOF.  PRC2 was diluted to 40 nM in 2X enzyme buffer (50mM Tris HCl 
pH 8.5, 10 mM DTT). Reactions were initiated with an equal volume of an SAM solution 
(NEB) containing
 2 uM H3[21-44]-GK-biotin (AnaSpec) and incubated at room 
temperature. Reactions were quenched at various time points with 7.5 M guanidium HCl 
and processed via C18 (peptide) ZipTip® as described in ref(16). Eluate was dried by 
GeneVac evaporation and resuspended in 10 uL of 70% ACN with 0.1% TFA. 0.5 uL of 
resulting solution was combined with an equal volume of 20 mg/mL CHCA matrix 
(Thermo) and spotted on a Waters 96-sample target plate. After drying, samples were 
analyzed using MALDI MicroMX mass spectrometer (Waters). 
PRC2 DELFIA.  PRC2 activity was measured using DELFIA performed on 384-well, 
white, streptavidin-coated plates (PerkinElmer). Briefly, PRC2 was diluted in 20 uL 2X 
Enzyme Buffer (50mM Tris HCl pH 8.5, 10 mM DTT) and reactions were initiated with 
20 uL of a SAM (NEB) solution containing H3[21-44]-GK-biotin (Anaspec). Plates were 
incubated at room temperature for 1 hr and then washed three times with 100 uL of   44 
wash buffer (50mM Tris pH 7.4, 150 mM NaCl, 0.05% Tween 20, 0.2% BSA). 
Fluoroimmunoassay (FI) Buffer (50 mM Tris HCl pH 7.8, 150 mM NaCl, 0.05% Tween 
40, 25 µM DTPA, 0.2% BSA, 0.05% BGG) containing a anti-H3K27me2 rabbit IgG (Cell 
Signaling, #9728) with 691 ng/mL Eu-N1-anti-rabbit IgG (PerkinElmer) was added at 50 
uL per well. Following 1 hr incubation at room temperature, the plates were washed 
three times with wash buffer and 50 uL of Enhancement Solution (PerkinElmer) was 
added to each well. Plates were incubated for 30 min at room temperature and time-
resolved fluorescence (TRF) was measured on Wallac Envision 2104 Multilabel Reader 
(400 us window, 400 us delay, 320 excitation, 615 emission). 
Immunofluorescence.  HeLa cells (ATCC) were cultured in DMEM supplemented 
10%(v/v) FBS, 1 mM sodium pyruvate, and 100 U mL-1 penicillin-streptomycin. Cells 
were diluted in culture medium at 5e4 cells/mL and plated in black clear-bottom 96-well 
plates (Corning, 3904) at 100 uL/well. After 24 hr incubation at 37°C/5% CO2, 100 nL of 
compound or DMSO vehicle was pinned into each well and cells were incubated for an 
additional 48 hrs. Treated cells were fixed with 4% paraformaldhyde for 10 min, 
permeabilized with 0.3% Triton X-100 in PBS for 20 min, and blocked with 3% BSA in 
PBST for 1 hr at room temperature. Cells were then incubated with primary antibody 
(anti-H3K27me3 or anti-H3K27me2 antibody; Cell Signaling, #9733 and #9728, 
respectively) diluted in blocking buffer overnight at 4°C. A mixture of 1 nM Hoechst 
33342 (Life Technologies) and 2 ug/mL Alexa Fluor 488 goat anti-rabbit IgG (Life 
Technologies, A11008) in blocking buffer was then added. Following 1 hr incubation at 
RT, cells were then imaged on an ImageXpress Micro automated microscope 
(Molecular Devices) using a 10X objective with laser-based focusing. Image analysis   45 
was performed using the Cell Scoring module in the MetaXpress software (Molecular 
Devices) to determine average nuclear fluorescence per well.  
MODified™ Histone Peptide Array.  Histone peptide arrays (ActiveMotif) were blocked 
with %5 non-fat milk in TBST for 1 hr at RT prior to antibody incubation. Anti-H3K27me2 
(CST; #9755), anti-H3K27me2 (CST; #9728), and anti-H3K27me3 (CST; #9733) 
antibodies were diluted 1:500, 1:2000, and 1:2000, respectively, in blocking buffer and 
incubated on individual arrays for 1 hr at RT. Arrays were washed with TBST and 
incubated with anti-rabbit IgG-HRP (GE) diluted 1:2500 in blocking buffer for 1 hr at RT 
and washed in TBST prior to chemiluminescence detection with SuperSignal West Pico 
Chemiluminescent Substrate (Pierce). 
EZH2 and EED knockdown.  HeLa cells (ATCC) were cultured as described above. 
Cells were plated at 2e5 cells/well in 6-well dishes and transfected with Silencer® 
Select siRNA (Ambion) for EZH2 (EZH2-1 siRNA, s61343; EZH2-2 siRNA, s61426; 
EZH2-3 siRNA, s157425) and EED (EED-1 siRNA, s76035; EED-2 siRNA, s159465; 
EED-3 siRNA, s159467) using X-tremeGENE siRNA transfection reagent according to 
manufacturer’s protocol. 
Histone extraction and ELISA.  Cells were rinsed with PBS, scraped into ice-cold 
PBS, and collected via centrifugation at 200 x g for 10 minutes. Pellets were 
resuspended in 0.2 volumes of 0.4 N HCl and incubated for at least 30 minutes on ice to 
extract histones. Cellular debris was then cleared by centrifugation at 10,000 x g for 10 
minutes. Supernatant containing extracted histones was then neutralized with 0.4 
volumes of 1 M sodium phosphate (pH 12.5) and concentration was determined via 
Bradford assay. H3K27me3 ELISA was performed using Histone H3 trimethyl Lys27   46 
ELISA and, for normalization, Total Histone H3 ELISA kits from ActiveMotif, following 
manufacturer’s protocols.  
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3.1  Introduction  
As small-molecule screening has become a major source for starting points in the 
development of chemical probes and drugs, we aimed to use a suite of HTS-compatible 
PRC2 assays to screen a diverse set of small molecules, aspiring to identify novel 
PRC2 inhibitors that could be developed into impactful chemical tools. Toward this goal, 
we established a critical path for hit selection and compound triaging prior to screening 
(Figure 3.1), taking into account several aspects that would be desirable for bona fide 
chemical probes, including sufficient in vitro potency, selectivity over related HMTs, and 
cellular activity that associates well with its biochemical profile (1,2). Final selection of 
lead compounds would also depend on chemical tractability (for medicinal chemistry 
optimization), structural novelty, and mechanism of action– with priority given to hit 
compounds inhibiting in a substrate-competitive or allosteric manner. Given the large 
number of SAM-dependent enzymes encoded by the human genome (~0.9% of all 
genes) (3), we speculated that SAM-competitive probes would be more likely to induce 
off-target cellular effects, depending on the potency and in-class selectivity of the 
compound.  
One significant challenge associated with screening large collections of diverse 
molecules is distinguishing true modulators (those exhibiting classical target 
engagement) from those exhibiting artifacts specific to the assay. As a high incidence 
(>90% in some cases) (4) of these false-positive hits are typically identified through 
HTS, we included several assays designed to eliminate compounds inhibiting through 
various nonspecific mechanisms. Compounds that inhibit by such means are known as 
pan-assay interference compounds or PAINS, as they often arise as frequent hitters in a   54 
large number of primary HTS campaigns against diverse targets (5). Although many 
PAINS interfere with assay readout by modulation of fluorescence signal (6), or 
inhibition of signal-generating reporter enzymes (7), a majority of these compounds can 
directly disrupt the target enzyme through irreversible modification (8), redox effects (9), 
or, most commonly, sequestration by compound aggregation (10-12).  
Nonspecific aggregate-forming compounds are highly sensitive to assay buffer 
conditions and are often disrupted in the presence of small amounts of detergent (such 
as Tween 20 or Triton X-100) providing a basis for high-throughput detection (13). As 
part of our workflow to identify artifacts, we included a detergent-based assay, removing 
compounds that lost significant activity (>10-fold reduction in IC50) in the presence of 
Tween 20 (0.1% v/v). To rule out other mechanisms, primary hits were assayed in 
counterscreens against related HMTs (G9a and NSD2), as many nonspecific 
compounds are promiscuous in their inhibitory activity.  In addition, we implemented a 
secondary filter, using alternative substrates (full-length histone H3) and an orthogonal 
detection method (
3H-radiolabeling and liquid scintillation counting), to remove false-
positives dependent on use of peptide substrates and DELFIA.  
This chapter describes the implementation of a PRC2 DELFIA to identify small-
molecule modulators within a collection of over 120,000 compounds. After two rounds of 
screening, 294 confirmed hits were identified and subsequently profiled against G9a 
and NSD2 to assess selectivity and included in assay interference screens to identify 
potential false-positives as mentioned above. As PRC2 disruption alters global 
H3K27me3 levels (14,15), cellular activity was assessed using an H3K27me3 HCS 
assay to prioritize compounds with putative on-target engagement in cells. In the end,   55 
one apparent PRC2 inhibitor (BRD-K97550475) and one putative activator (BRD-
K51079083) were selected for resynthesis and extensive follow-up studies.   
 
Figure 3.1  Critical path to PRC2 probe discovery 
 
3.2  Results and discussion 
3.2.1  Initial screening of 65,333 compounds and hit retest in PRC2 DELFIA 
Using PRC2 DELFIA, we conducted an initial screen of over 65,000 compounds. 
These compounds included ~47,000 compounds derived from diversity-oriented 
synthesis (DOS) and ~18,000 compounds from standard GPCR, kinase, bioactive, 
natural product, and other commercial screening decks. To limit reagent costs, we 
conducted our 384-well primary assay in singlicate, as we would later confirm hits in 
dose. To measure assay performance and quality for each assay plate, we used a Z-
factor statistic (16), assessing the degree of separation between DELFIA signal 
distributions of negative control (DMSO) and positive control (PosCon) wells. Since no 
potent small-molecule inhibitors for PRC2 were known at the time of the screen, options   56 
for positive controls were limited to SAH and sinefungin, two non-selective SAM-
competitive compounds that exhibited prohibitively weak activity in our assay. 
Furthermore, the inclusion of wells lacking a key reagent (such as enzyme or SAM) was 
technically challenging given available automation. To address this problem, we used 3 
uM biotin as a control, as it would compete with biotinylated-product immobilization on 
streptavidin-coated DELFIA plates and effectively lower signal. While limited in its utility, 
this positive control allowed us to account for high-background generating events 
occurring with detection. Lastly, to correct for systematic variations in signal within our 
assay plates (due to temperature, evaporation, or instrumentation), we included ‘base 
plates’ in which only DMSO (no compound) was added to assay wells. Throughout the 
screen, two ‘base plates’ were added to each batch of assay plates (typically ~30)—one 
plate at the beginning and end of each run.   
For a majority of assay plates, we were able to maintain high S/B with strong 
separation between PosCon and DMSO wells (average Z’ Factor >0.5; Figure 3.2A,C). 
Using a normalized activity cutoff of <50%, 327 compounds showing apparent inhibition 
of PRC2 were called, yielding a 0.5% hit rate (Figure 3.2B). While enriched in 
compounds originating from the natural products library (~30%), hit compounds from 
each major screening deck were identified— including Bioactives (14%), DOS (8%), 
HDAC-biased (5%), GPCR (16%), Kinase (15%), Structurally Diverse (5%), and 
Commercial (10%) collections.  
Of the identified hits, we were able to obtain 305 compounds for retest in 8-point 
dose, as several were unavailable from our compound management service. After two 
rounds of retest assays, 270 hits were confirmed (89% retest rate), showing does-  57 
responsive inhibition with varying potencies in the high nM to high uM range. The 
statistical screening and retest summary is included in Table 3-1 below. 
 
Figure 3.2 First round of primary screening using DELFIA 
(A) Scatter plot showing distribution of normalized DELFIA signal from DMSO wells (yellow) and positive control 
(PosCon) wells (3 uM biotin; blue) across all assay plates. (B) Distribution of normalized DELFIA signal from 
compound wells across all assay plates. Compounds lowering signal by >50% were called hits (shown in teal)  
(C) Z’ factor (comparing PosCon wells to DMSO) for each assay plate across batches.  
 
Table 3-1 Summary statistics for first round of HTS 
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3.2.2  Artifact elimination and counterscreening against G9a and NSD2 
We next aimed to triage our hits by eliminating artifact compounds and assessing 
compound selectivity for PRC2 over two related HMTs, G9a and NSD2. As discussed 
earlier, many false positives arise as a result of direct interference with assay signal 
(e.g. fluorescence, luminescence, etc.). To identify compounds lowering signal through 
disruption DELFIA detection, we performed a PRC2 DELFIA, pinning hit compounds 
into assay plates after reaction and proceeding immediately to antibody incubation and 
detection. In an alternative version of this assay, compounds were pinned in the 
absence of enzyme, but in the presence of biotinylated product peptide (H3[21-44], 
K27me2). No compounds were found to lower signal in either control assay, suggesting 
that all hit compounds lowered signal, specifically or nonspecifically, through disruption 
of PRC2 activity. 
Since G9a DELFIA had been previously reported (17) and an HTS–ready NSD2 
DELFIA was developed in our lab (18), we aimed to prioritize hits based on selectivity 
for PRC2 over these two methyltransferases. Using these DELFIAs, we 
counterscreened all 270 confirmed hits in 8-point dose, identifying 14 compounds that 
inhibited both G9a and NSD2, 54 compounds that inhibited only NSD2, 56 compounds 
that inhibited only G9a, and 146 compounds that showed no detectable activity on 
either HMT at the highest concentrations tested (Figure 3.3). We chose 92 compounds 
that had at least 5-fold selectivity over G9a and/or NSD2 and an IC50 of less than 10 uM 
against PRC2 for further study. The potency (IC50) and PRC2 selectivity values (ratio of 
PRC2 IC50 over G9a or NSD IC50) for compounds inhibiting G9a and NSD2 are 
summarized Table S3-1  and Table S3-2, respectively.    59 
 
Figure 3.3 Summary of HMT counterscreen 
All 270 of the confirmed PRC2 hits were screened against NSD2 and G9a using established DELFIAs. The diagram 
above illustrates the selectivity of PRC2 hits, showing that nearly half of compounds inhibit other HMTs to varying 
degrees. Compounds exhibiting >50% activity at the highest tested dose were deemed hits.  
 
3.2.3  Detergent-based assay for identification of aggregator compounds 
As mentioned previously, artifactual inhibition can occur through a variety of 
mechanisms, but one most challenging to predict based on structure alone, is 
aggregation (10). Depending on the buffer conditions, some molecules can form large 
colloidal aggregates in solution, leading to nonspecific inhibition through sequestration 
of target enzyme (10). One such method to identify these compounds is to evaluate 
their sensitivity to detergent, as many aggregators will lose activity in the presence of 
small concentrations of Tween 20 or Triton-X100—presumably through colloidal 
disruption (13).  
As our assay buffer lacked detergent, we assayed the 92 prioritized compounds 
in the presence and absence of 0.01% Tween 20, noting any significant changes in 
activity against PRC2 (IC50). Of the compounds tested, several exhibited significant 
attenuation of activity (>0.5 logIC50 shift) in the presence of detergent, with many losing 
activity entirely. As they were likely inhibiting through aggregation-based mechanism,   60 
these compounds were de-prioritized and not considered for further study. A total of 51 
compounds were deemed insensitive to detergent addition, showing little (<0.5 logIC50 
shift) or no loss of activity, and further evaluated in downstream assays (e.g. H3K27me3 
HCA). Examples of putative inhibitors exhibiting differential detergent sensitivity are 
illustrated in Figure 3.4 below; the results of this assay are summarized in their entirety 
in Table S3-3. 
 
Figure 3.4 Examples of detergent-sensitive and -insensitive compounds 
(A) BRD-A56964404 (top) potency shifts slightly in the presence of detergent (bottom), while (B) BRD-K99293846 
(top) loses complete activity in the presence of detergent (bottom).  Data points represent the mean and standard 
error of triplicate measurements. 
 
3.2.4  Assessing cell-based activity with an H3K27me3 HCS assay 
To further triage our list of prioritized compounds, we evaluated the top 51 
inhibitors in an H3K27me3 HCA, treating HeLa cells with DMSO vehicle or various 
concentrations of compound. Following 48 hr incubation, cells were stained for   61 
H3K27me3 and imaged by automated microscope (IX Micro), using an optimized 
immunofluorescence protocol (described in the previous chapter).  Average nuclear  
 
Figure 3.5 Compounds scoring in the H3K27me3 HCA 
Structures of compounds lowering average nuclear fluorescence with a Z-score < -1.0  in an H3K27me3 HCS assay. 
Over-represented in this list are 8-membered ring sultams. See Experimental Methods for details on Z score 
calculation. 
 
fluorescence and total cell number were determined for each treatment condition by 
image analysis –using the Multi Wavelength Cell Scoring in MetaXpress. Since 
background fluorescence (attributed to nonspecific antibody interactions, 
autofluorescence, etc) could not be assessed, we used a Z-score metric (see 
Experimental Methods) to identify compounds that, compared to the signal distribution 
of DMSO wells, significantly lowered average nuclear fluorescence signal. Of the 51 
compounds evaluate, only 10 were found to lower H3K27me3 signal by at least one 
standard deviation. Over-represented in this list was a cluster of four 8-membered ring 
sultams—members of the SNAr SO2 DOS library (Figure 3.5). BRD-K97550475, the top 
hit in this assay and a member of the SNAr library, appeared to lower average nuclear   62 
fluorescence, while not significantly affecting cell number (Figure 3.6). Given its 
apparent activity in both cellular and biochemical assays (and the number of related 
compounds exhibiting presumed cellular activity), BRD-K97220475 was selected for 
resynthesis and further study. These efforts are described in detail in Chapter IV.    
 
Figure 3.6 BRD-K97550475 activity in PRC2 DELFIA and H3K27me3 HCA  
(A) Structure of BRD-K97550475. (B) Activity in PRC2 DELFIA. Data points represent the mean and standard error of 
triplicate measurements. (C) Raw image of H3K27me3 staining in the presence of 10 uM BRD-K97550475 (top) 
versus DMSO (bottom) suggests cell-based activity.  
 
3.2.5  Screening of an additional 58,917 DOS compounds in PRC2 DELFIA 
In hopes of uncovering more potent PRC2 modulators and additional starting 
points for probe development, we used a modified PRC2 DELFIA to screen an 
additional 58,917 DOS compounds. As the available compound libraries had been 
reorganized with the addition of new DOS compounds, we screened a total of 66,203 
DOS compounds, assaying 7,286 DOS compounds included in the previous screen. 
Represented in the set of non-overlapping DOS molecules were novel scaffolds—
including members of Pyridone, THQ, Oxazocane, and Tricyclic glycal libraries—as well 
as new analogs of previously explored scaffolds (e.g. RCM, Azetidine, and SO2 SnAR).    63 
 Aiming to lower the number of potential aggregator hits and further bias for 
identification peptide-competitive modulators, we included 0.01% Tween 20 in the assay 
buffer and lowered peptide concentration from 300 nM to 62.5 nM H3[21-44] (or 0.5X 
KM). Substrate methylation appeared linear over the course of an hour, so previous 
reaction time and SAM concentration (2X KM) were maintained. Given the reduced 
signal (~10 S/B) resulting from the new substrate concentration, we performed our 
assay in duplicate to compensate for potential increases in plate-to-plate variation. As 
before, 3 uM biotin was used as a positive control for Z’ Factor calculations and DMSO 
base plates were employed to correct for variations within each assay plate. 
Comparable to the initial PRC2 DELFIA screen, we noted good separation between 
signal distributions for biotin and DMSO wells within assay plates, maintaining an 
average Z’ Factor of 0.55 (Figure 3.7).  
 
Figure 3.7 Second round of primary screening using PRC2 DELFIA 
(Left) Scatter plot showing the distribution of normalized DELFIA signal across replicates for DMSO (shown 
in grey) and poscon (3 uM biotin; showing in red) wells across assay plates. (Right)  Scatter plot showing the 
distribution of normalized DELFIA signal across replicate test wells (shown in blue) overlaying DMSO and 
poscon distributions.  
 
A total of 191 primary hits were called, each of which lowered PRC2 DELFIA 
signal by >50% in a single replicate and/or >30% in both replicates. Interestingly, a 
large number of high signal outliers (potential PRC2 activators) were identified among   64 
this collection of DOS molecules. Compounds that increased DELFIA signal by >50% 
relative to DMSO were deemed hits (274 total compounds) and ordered for retest.  All 
primary hits (both activators and inhibitors) were retested in 8-point dose. Of the 
putative inhibitors, we identified 60 compounds that lowered signal by >30% at the 
screening dose (25 uM), but only 24 compounds exhibited reproducible dose-
responsive inhibition with IC50 values <20 uM.  Notably, over half (13/24) of these 
compounds were structurally related to the previously identified 8-membered ring 
sultams (e.g. BRD-K97550475), while the remainder clustered into various other 
structural categories (e.g. Pyridone, RCM, THQ/Povarov). Of the potential activators, 
235 of the 274 hits retested (>50% increase in signal) at the screening dose; however, 
only 23 compounds could increase DELFIA signal in a dose-responsive manner. These 
putative activators clustered into five major structural categories, all with AC50 values 
(assuming maximum activation of 10-fold) in the 3-25 uM range. Screening statistics 
and retest summary are included in Table 3-2 below, while example structures for all 
clustered inhibitors and activators, along with measured activity (IC50 values), are 
included in Figure 3.8.  
Table 3-2 Summary statistics for second round of screening 
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Figure 3.8  Potency (IC50 or AC50) and representative structures of clustered activators and inhibitors 
identified in the second iteration of PRC2 HTS.   
Along with complete lists of potency values (IC50 or AC50), representative structures for each cluster of identified (A) 
inhibitors and (B) activators are shown above. For AC50 determination, S0 was set to 100% activity and Sinf to 500% 
activity for all activators.  See Experimental methods for details on AC50 and IC50 calculations and compound 
clustering. 
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We next aimed to determine whether these additional hit compounds displayed 
apparent PRC2 modulation through assay disruption or aggregation-based 
mechanisms. Given the small number of activators and inhibitors identified, we used 
low-throughput dynamic light scattering (DLS) to determine if our compounds 
aggregated near IC50 concentrations in PRC2 assay buffer. Even up to 100 uM, no 
particle formation was detected for any compounds tested, suggesting that they were 
inhibiting or activating by mechanisms distinct from aggregation. Furthermore, 
detection-interference counterscreens also confirmed that our selected inhibitors and 
activators were not artifacts of DELFIA readout. Encouraged by these results, we 
selected the top three novel and most potent clusters of inhibitors—representing RCM 
(Cluster #3), Pyridone (Cluster #10), and Povarov (Cluster #12) chemical series—for 
further study. As mechanistic studies on BRD1835, an 8-membered ring sultam, were 
underway at the time of their identification, newly identified SNAr SO2 members were 
not explored further. Characterization of the largest cluster of activators (Cluster #0; 
Figure 3.8B) is described in detail in Chapter V.  
3.2.6  Initial characterization of RCM, Pyridone, and Povarov series inhibitors  
Strong stereochemical preferences in regard to compound activity are typically 
suggestive of true target engagement, as small-molecule binding occurs in the context 
of a chiral protein environment.  The DOS compound libraries available at the Broad 
Institute are designed to enable rapid identification of stereochemical structure-activity 
relationships (SSAR) (19), containing a large number of stereoisomers (if not all) for any 
given DOS molecule. In order to establish preliminary SSAR for the RCM, Pyridone, 
and Povarov series compounds, we obtained and assayed (in 8-point dose) all available   67 
stereoisomers of the most potent compounds represented in each of the top three 
inhibitor clusters identified. Overall, we evaluated the activity 14 stereoisomers of BRD-
K55066668 (RCM) as well as the corresponding enantiomers of BRD-K66064682 
(Pyridone) and BRD-K41008034 (Povarov).  
For all chemical series tested, no striking SSAR (i.e. absolute stereoselectivity) 
could be established. Pyridone enantiomers exhibited similar activity against PRC2, with 
BRD-K66064682 and its enantiomer, BRD-K57393707, inhibiting at 7 and 3.2 uM, 
respectively (Figure S3.1). Both Povarov compounds tested were found to have 
significant issues with purity—a phenomenon later confirmed to be a common issue 
with members of this library. Only the enantiomer of the initial hit compound was active 
against PRC2 (BRD-K34245999; 4.7 uM IC50 at 33% purity) due to the remarkably low 
purity (2%) of BRD-K41008034 (Figure S3.2). Lastly, while stereoisomers of the hit 
RCM compound (BRD-K55066668) were found to inhibit PRC2 over a wider range of 
potencies (1-30uM), no clear SSAR patterns emerged (Figure S3.3).  
While efforts to establish SSAR failed to deliver evidence supporting clear PRC2 
engagement, we continued to characterize these compounds on the basis of HMT 
selectivity and MOA. For these studies, we focused on the most potent compounds 
resulting from SSAR studies (RCM- BRD-K55066668, Pyridone- BRD-K57393707, and 
Povarov-BRD-K34245999). Using a G9a DELFIA, we found that all compounds 
inihibited PRC2 with absolute selectivity over this HMT, as they had no activity on G9a 
at concentrations up to 100 uM (Figure 3.9B). To determine whether PRC2 inhibition 
was competitive for peptide or cofactor, we tested the activity of each compound in 
PRC2 DELFIA, measuring IC50 under varying SAM and peptide concentrations. While   68 
the Ki (true potency) for competitive inhibitors should be invariant under differing 
substrate and cofactor conditions, the IC50 is known to change in a manner proportional 
to the ratio of substrate or cofactor concentration to its respective KM (20). While all 
compounds  
 
Figure 3.9 G9a DELFIA and initial MOA studies of representative members of top PRC2 inhibitor clusters 
identified in second iteration of screening. 
(A) Structures of BRD-K55066668 (RCM), BRD-K57393707 (Pyridone), and BRD-K34245999 (Povarov) and their 
associated activities in (B) G9a DELFIA. (C) Initial MOA studies measuring the activity of each compound in PRC2 
DELFIA under different substrate (H3[21-44]) concentrations.  Data points represent the mean and standard error of 
triplicate measurements in all assays.  
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retained similar potency in the presence of up to 50 uM SAM (25X KM), each one of our 
top hits appeared to be highly sensitive to the addition of peptide, losing activity 
completely in the presence of 250 nM (~1.5X KM) peptide (Figure 3.9C). These results 
suggested that all compounds identified might inhibit through a peptide-competitive 
mechanism. 
We next explored whether these compounds could lower H3K27me3 levels in 
HeLa cells using the previously described HCA assay, testing compounds in 12-point 
dose. Results for two of the hit compounds are shown in Figure 3.10. While global 
H3K27me3 levels appeared to decrease in the case of BRD-K55066668 and increase in 
the case of BRD-K55066668, cell number appeared to drop at all active concentrations 
of compound, suggesting that these alterations in average nuclear fluorescent signal 
were mere artifacts of immunostaining and imaging dead or dying cells.  
Given their lack of cellular activity, flat SSAR, and remarkable sensitivity to the 
addition of peptide, we next explored whether these compounds could be behaving 
through peptide-binding or peptide–sequestration mechanisms. Detailed studies into 
BRD1835 found that some compounds able to inhibit PRC2 exhibit this behavior, 
endowing them with apparent substrate-competitive activity. Using a fluorescently 
labeled version of the peptide substrate, we explored whether high concentrations of 
each of these compounds could generate a detectable FP signal. As suspected, each of 
these compounds, to varying degrees, could increase FP signal over DMSO (Figure 
3.11), suggesting the formation of peptide-compound complexes (of presumably high 
molecular weight). While these compounds could be engaging PRC2, the current data   70 
support a novel, potentially artifactual mechanism undesirable of a chemical probe. This 
mechanism is further discussed in Chapter IV. 
 
Figure 3.10 Activity of top Pyridone and RCM inhibitor analogs in H3K27me3 HCA  
(A) Structures of top Pyridone (BRD-K57393707) and RCM (BRD-K55066668) compounds arising from SSAR 
studies of selected PRC2 inhibitor candidates. (B) Effect of various concentrations of BRD-K57393707 and BRD-
K55066668 on DMSO-normalized average nuclear fluorescence (%Average DMSO H3K27me3) and (C) cell number 
in H3K27me3 HCA. Data points represent the mean and standard error of triplicate measurements in all assays.  
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Figure 3.11  HiLyte™ Fluor 488-H3[21-44] FP assay on top RCM, Pyridone, and Povarov PRC2 inhibitors. 
Activity of RCM (BRD-K55066668), Pyridone (BRD-K57393707), and Povarov (BRD-K342455999) PRC2 inhibitor 
candidates (100 uM) in peptide-binding FP assay using 31.25 nM HiLyte™ Fluor 488-H3[21-44]. Compared with 
DMSO, all compounds substantially increased mP signal, suggesting an interaction with peptide. Data points 
represent the mean and standard error of four replicate measurements. 
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3.3  Experimental methods  
PRC2 HTS DELFIA.  PRC2 activity was measured using DELFIA performed on 384-
well, white, streptavidin-coated plates (PerkinElmer). In short, PRC2 was diluted in 20 
uL 2X Enzyme Buffer (50mM Tris HCl pH 8.5, 10 mM DTT) with (second HTS) or 
without (first HTS) 0.02% Tween 20, 100 nL compound was pinned, and reactions were 
initiated with 20 uL of a SAM (NEB) solution containing (600 nM for initial HTS and 125 
nM for second HTS) H3[21-44]-GK-biotin (Anaspec). Plates were incubated at room 
temperature for 1 hr and then washed three times with 100 uL of wash buffer (50mM 
Tris pH 7.4, 150 mM NaCl, 0.05% Tween 20, 0.2% BSA). Fluoroimmunoassay (FI) 
Buffer (50 mM Tris HCl pH 7.8, 150 mM NaCl, 0.05% Tween 40, 25 µM DTPA, 0.2% 
BSA, 0.05% BGG) containing a anti-H3K27me2 rabbit IgG (Cell Signaling, #9728) with 
691 ng/mL Eu-N1-anti-rabbit IgG (PerkinElmer) was added at 50 uL per well. Following 
1 hr incubation at room temperature, the plates were washed three times with wash 
buffer and 50 uL of Enhancement Solution (PerkinElmer) was added to each well. 
Plates were incubated for 30 min at room temperature and time-resolved fluorescence 
(TRF) was measured on Wallac Envision 2104 Multilabel Reader (400 us window, 400 
us delay, 320 excitation, 615 emission). 
G9a and NSD2 purification and DELFIAs. GST-G9a (amino acids 685-1000) and 
NSD2-SET were prepared as previously described—(17) and (21), respectively. 
Biochemical activity of G9a was measured as described in (17). NSD2 activity was 
measured by DELFIA using the PRC2 protocol described above with few modifications. 
NSD2-SET was diluted to 3 ng per well in 2X Enzyme Buffer (50mM Tris HCl pH 8.5, 5 
mM DTT) and reactions were initiated with 20 uL of a 10 uM SAM (NEB) solution   73 
containing 600 nM biotin-H3[21-40] following compound addition. For product detection, 
FI buffer containing a 1:24,000 dilution of anti-H3K36me1 rabbit IgG (Abcam, Ab9048) 
with 22ng/mL Eu-N1-anti-rabbit IgG was used.  
Detergent and DELFIA-interference assays DELFIA assays were conducted as 
above with the following modifications. Detergent screening was performed using assay 
buffer with and without 0.01% Tween 20. For DELFIA-disruption assays, compounds 
were either pinned 1 hr post-reaction initiation and washed after 10 min or pinned into 
2X Enzyme Buffer without enzyme, substituting H3K27me2-modified H3[21-44]-GK-
biotin (AnaSpec) for unmodified H3[21-44]-GK-biotin 
Fluorescence polarization. Compound or DMSO was diluted to 2X final concentration 
in 1X Enzyme Buffer and added at 20 uL per well in black 384-well plates. H3[21-44] -
HiLyte488 peptide was then diluted to 62.5 nM in 1X Enyzme Buffer and added at 20 uL 
per well. Following 10 min incubation, fluorescence polarization (mP) was measured 
using Wallac Envision 2104 Multilabel Reader (FP FITC dual optical module; Excitation: 
480 nm, Emission: 535 nm for both S- and P-channels).  
Immunofluorescence.  HeLa cells (ATCC) were cultured in DMEM supplemented 
10%(v/v) FBS, 1 mM sodium pyruvate, and 100 U mL-1 penicillin-streptomycin. Cells 
were diluted in culture medium at 5e4 cells/mL and plated in black clear-bottom 96-well 
plates (Corning, 3904) at 100 uL/well. After 24 hr incubation at 37°C/5% CO2, 100 nL of 
compound or DMSO vehicle was pinned into each well and cells were incubated for an 
additional 48 hrs. Treated cells were fixed with 4% paraformaldhyde for 10 min, 
permeabilized with 0.3% Triton X-100 in PBS for 20 min, and blocked with 3% BSA in 
PBST for 1 hr at room temperature. Cells were then incubated with primary antibody   74 
(anti-H3K27me3; Cell Signaling, #9733) diluted in blocking buffer overnight at 4°C. A 
mixture of 1 nM Hoechst 33342 (Life Technologies) and  2 ug/mL Alexa Fluor 488 goat 
anti-rabbit IgG (Life Technologies, A11008) in blocking buffer was then added. 
Following a 1 hr incubation at RT, cells were then imaged on an ImageXpress Micro 
automated microscope (Molecular Devices) using a 10X objective with laser-based 
focusing. Image analysis was performed using the Multi Wavelength Cell Scoring 
module in MetaXpress (Molecular Devices) to determine average nuclear fluorescence 
and nuclei counts per well. Z-scores were calculated as indicated below. Mean and 
standard deviation (STDEV) were calculated for all DMSO wells within each assay 
plate.   
€ 
Z − score =
Average Nuclear FluorescenceCompound − MEAN(Average Nuclear FluorescenceDMSO Wells)
STDEV(Average Nuclear FluorescenceDMSO Wells)
 
 
Data analysis and curve fitting (IC50, AC50).  For IC50 and AC50 determination, DMSO-
normalized, background-subtracted activity values (see equation below) for each 
compound at varying concentration were fit using Condoseo GeneData Screener 
(Smart Fit Strategy using default settings with no restrictions and no requirement for 
convergence).  
€ 
%Activity =100 ×
SignalCompound − MEAN(SignalPosCon wells)
MEAN(SignalDMSO wells) − MEAN(SignalPosCon wells)
 
 
Compound clustering. All compound clustering was performed using ChemMine- 
Binning Clustering (0.6 Tanimoto Coefficient) online tool (22)   75 
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4.1  Introduction  
In the previous chapter, we described the identification of BRD-K97550475 
(BRD0475), an 8-membered ring sultam from SO2 DOS library and confirmed hit 
emerging from an HTS campaign for PRC2 modulators. This compound exhibited low 
uM range potency against PRC2, high selectivity (over NSD2 and G9a), and putative 
cellular activity in an HCS assay—lowering global H3K27me3 levels in HeLa cells.  
Given these findings, we nominated BRD0475 for further investigation, resynthesizing 
all 8 associated stereoisomers for initial SSAR studies. While no absolute 
stereochemical preference was observed, one stereoisomer, BRD1835, demonstrated 
consistently higher potency over BRD04750 and other stereoisomers tested. BRD1835 
exhibited apparent cellular activity on global H3K37me3 levels and initial mechanistic 
studies revealed that it inhibited PRC2 in a peptide-competitive manner. As no peptide-
competitive probes had been disclosed, we pursued further development and 
characterization of BRD1835, exploring the molecular basis of its inhibition of PRC2 
activity. This chapter describes these efforts to determine the mechanism of action 
(MOA) of BRD1835 and evaluate its cellular activity.   
4.2  Results and discussion  
4.2.1  BRD0475 SSAR studies and the Identification of BRD1835 
The skeletal and stereochemical diversity yielded by DOS enables construction 
of compound libraries designed to facilitate establishment of not only structure-activity 
relationships (SAR), but also sterochemical structure-activity relationships (SSAR) (1,2). 
As we aimed to understand these relationships for future compound optimization, we   80 
obtained each BRD0475 stereoisomer, measuring activity against PRC2 in DELFIA 
(Figure 4.1A). All stereoisomers inhibited PRC2 activity, with IC50 values between 6- 30 
uM, suggesting no strong stereochemical preference (i.e. ‘flat’ SSAR). We rationalized 
that the variation in 8-membered ring conformation between stereoisomers was likely 
small (an assumption later verified by crystallography), leading to similar spatial 
arrangements in key bonding functionalities. Inhibiting PRC2 with ~7 uM IC50, BRD1835 
was found to be the most potent stereoisomer (2-fold more potent than BRD0475). To 
verify that BRD1835 maintained PRC2 selectivity, we tested its activity on NSD2 and 
G9a as before, measuring little activity of this compound against either of these distinct 
HMTs (Figure 4.1B).  
 
Figure 4.1  BRD0475 SSAR studies identify BRD1835 
 (A) Structure of BRD1835 and PRC2 DELFIA IC50 values for stereoisomers. (B) Activity of BRD1835 in PRC2, G9a, 
and NSD2 assays. IC50 values were determined by fitting methods described in Experimental Methods. Data points 
represent the mean and standard error of duplicate measurements in each assay.  
 
As differing stereochemical configurations could alter aggregation properties, we 
measured BRD1835 activity in the presence of detergent (0.01% Tween 20) and used 
dynamic light scattering (DLS) to detect any potential particle formation under our buffer 
conditions (Figure S4.1A). DLS has been used in several studies and is the gold   81 
standard for identifying small-molecule aggregators (3-5). To avoid errors in particle size 
estimations by incorrect model selection, we examined DLS autocorrelation functions, 
comparing those of DMSO, BRD1835, and a known aggregator—Nile red (Figure 
S4.1B,C). While Nile red exhibited stronger intensity autocorrelation over longer decay 
times—a hallmark of large particles, BRD1835 (up to 250 uM) and DMSO shared 
similar low intensity autocorrelation with rapid decay. Furthermore, BRD1835 retained 
potency (<10uM) in the presence of 0.01% Tween 20 and exhibited similar activity 
under high and low enzyme concentrations (Figure 4.2), suggesting that this compound 
was unlikely inhibiting PRC2 through an aggregation–based mechanism. 
 
Figure 4.2 BRD1835 detergent sensitivity assay and enzyme titration 
(A) Activity of BRD1835 on PRC2 in the presence of 0.01% Tween 20. (B) Activity of BRD1835 under high (50 
nM) and low (6.25 nM) PRC2 conditions. Data points represent the mean and standard error of triplicate 
measurements in each assay 
    
We next aimed to explore whether PRC2 inhibition by BRD1835 was specific to 
DELFIA, using an orthogonal readout for product formation. Reactions were carried out 
in the presence of DMSO or 25 uM BRD1835 in a radiometric time-course assay. Using 
biotinylated peptide and 
3H-SAM cofactor, reactions were quenched at 30 min intervals 
and product was detected with LSC (Figure 4.3A). Compared to DMSO, BRD1835 was 
able to reduce apparent reaction velocity, suggesting that its activity against PRC2 was   82 
not a DELFIA-dependent artifact.  Since this assay, like DELFIA, used a peptide 
substrate and was dependent on a streptavidin-biotin interaction for product purification, 
we performed a filter-binding assay (6-8) using histone H3.1 as a substrate. In this 
assay, product was captured by filtration of reaction mixtures through a high-protein-
binding membrane (HA or PVDF) and the levels of 
3H-incorporation were measured via 
LSC. Measuring BRD1835 activity in 8-point dose, we confirmed that its inhibition was 
unlikely an artifact of detection methods dependent on biotin pull-down or use of peptide 
substrate, as similar potency (~10 uM) was observed (Figure 4.3B). 
 
Figure 4.3  BRD1835 activity in orthogonal radiometric assays  
(A) PRC2 time course using peptide substrate in the presence of DMSO or 25 uM BRD1835. A ‘No PRC2’ control 
was added to measure background. (B) BRD1835 activity in a filter-binding assay using histone H3.1 as a substrate. 
Data points represent the mean and standard error of triplicate measurements in filter-binding assay and single 
measurements in the time course assay. 
 
As EZH2 activity is dependant on interactions between PRC2 partner proteins and only 
the monomeric catalytic domains of G9a and NSD2 were used in counterscreening, we 
speculated that PRC2 might be uniquely sensitive to compounds that could disrupt 
protein-protein interactions. To determine whether inhibition by BRD1835 was due to 
nonspecific complex disruption, we incubated PRC2 with varying concentrations of 
compound for 1 hr and assessed complex integrity by NativePAGE. At all   83 
concentrations tested (up to 100 uM BRD1835), neither dimeric nor monomeric forms of 
PRC2 were disrupted (Figure 4.4). 
 
Figure 4.4 NativePAGE of PRC2 in the presence of BRD1835 
PRC2 was incubated with 100 uM, 50 uM, 25 uM, and 12.5 uM BRD1835 or DMSO and separated by native PAGE.  
Bands corresponding to monomeric (~325 kDa) and dimeric (~650 kDa) forms of 5-component PRC2 could be 
detected. 
 
Encouraged by these results, we next aimed to confirm the cellular activity of 
BRD1835 and its stereoisomers by measuring their ability to lower H3K27me3 levels in 
HeLa cells. Since our H3K27me3 HCS assay initially suggested BRD0475 to be active 
in cells, we chose to verify this finding and explore BRD1835 cellular activity by way of 
histone extraction and western blot analysis. After 48 hr treatment, each stereoisomer 
appeared to lower levels of both di- and trimethylated H3K27 at 10 uM in a manner 
correlated to their in vitro potency (Figure 4.5).  Moreover, this activity appeared to be 
selective for H3K27 methylation, as no effect on H3K36me2 or H3K9me2 was detected. 
Using HEK293T, we repeated this experiment, measuring the levels of additional 
histone marks and treating cells for 96 hrs with varying concentrations of BRD1835. At 
high concentrations (20 and 40 uM), BRD1835 was able to selectively reduce 
H3K27me2 and H3K27me3 levels and increase the levels of H3K27me1 and H3K27ac 
(Figure 4.6A). This behavior is consistent with previous reports demonstrating that 
inhibition of EZH2 (7,11), given the processive nature of histone methyltransferases,   84 
leads to accumulation of monomethylation and rapid acetylation of unmodified H3K27 
residues.   
 
Figure 4.5 Effects of BRD0475 stereoisomers on global histone methylation levels in HeLa 
Western blot detection of global H3K27me2/3, H3K9me2, and H3K36me2 levels in HeLa cells following treatment 
with BRD0475 or given stereoisomer at 10 um,   
  
   
We next examined whether BRD1835 could induce other cellular phenotypes 
suggestive of PRC2 inhibition. Since PRC2 trimethylation of H3K27 results in the 
silencing of target genes, inhibition of PRC2 through siRNA-mediated knockdown or 
small-molecule treatment leads to concomitant derepression and activation of their 
expression. For example, EZH2 inhibition by GSK126 had been shown to markedly 
increase transcript levels of PRC2 target genes, TXNIP and TNFSR21, in DLBCL cell 
lines (7). To evaluate BRD1835’s ability to induce gene expression changes suggestive 
of EZH2 inhibition, we measured the levels of TXNIP and TNFSR21 expression in four 
DLBCL lines (Pfeiffer, WUS-DLCL2, HT, and OCI-LY-19) by RT-qPCR after 96 hr 
treatment with BRD1835 or GSK-2d1 (an active GSK126 analog synthesized in our lab). 
In a dose-responsive fashion, both BRD1835 and GSK-2d1 were able to activate TXNIP 
and TNFRS21 expression—further suggesting that BRD1835 may be inhibiting PRC2 in 
cells (Figure 4.6B). However, as always, caution must be taken when interpreting any 
cellular change occurring as a result of treatment with high concentrations of compound,   85 
as these changes could be results off-target effects generated through nonspecific 
interactions.   
 
Figure 4.6 Global histone methylation and PRC2- target gene expression changes induced by BRD1835 
(A) Western blot detection of global H3K27me2/3/1/ac, H3K9me2, H3K4me3, H3K79me2, and H3K36me2 levels in 
HEK293T cells following 96 hr treatment with BRD1835. (B and C) RT-qPCR analysis of TXNIP and TNFRS21 
expression in four DLBCL lines (Pfeiffer, WSU-DLCL2, HT, and OCI-LY-19) upon 96 hr treatment with BRD1835 or 
GSK126 analog (GSK-2d1), respectively. Fold-change data represent the mean and standard error of four 
normalized replicates.  
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4.2.2  Cofactor and peptide competition studies  
While the Ki (true potency) for competitive inhibitors should be invariant under 
differing substrate and cofactor conditions, the IC50 is known to change in a manner 
proportional to the ratio of substrate concentration to KM, a relationship described by the 
Cheng-Prusoff equation (see Equation 4-1) (9). With interest in assigning a specific 
mechanism of action to BRD1835, we speculated whether we could use PRC2 
DELFIA—an assay not amenable to kinetic studies—to quickly assess whether our 
compound was inhibiting through a competitive mechanism, varying concentrations of 
substrate or cofactor and measuring BRD1835 activity (IC50) under each of these 
conditions. Using an active GSK126 analog, GSK-2d1 (synthesized by a member of our 
lab), we explored whether we could confirm SAM-competitive inhibitors using this 
method, as the parent compound was reported to be cofactor-competitive (10).  As 
expected, varying concentrations of peptide (up to 7X KM) had no effect on GSK-2d1 
activity, while high levels of SAM (up to 70X KM) decrease potency in a linear fashion 
(Figure 4.7, top).  
We next performed a similar analysis on BRD1835, varying peptide and 
substrate across a wide range of concentrations and measuring its activity (IC50) against 
PRC2. Interestingly, BRD1835 demonstrated near opposite behavior to that of GSK-
2d1, with potency being unchanged at various SAM concentrations and highly 
attenuated in the presence of micromolar concentrations of peptide (Figure 4.7, bottom). 
These results suggested BRD1835 to be a peptide-competitive inhibitor, distinct from 
the many reported SAM-competitive inhibitors (10-13). Despite exhibiting modest   87 
potency, this novel MOA encouraged us to continue probe development efforts and 
further characterize BRD1835. 
Equation 4-1 Cheng-Prusoff equation for competitive inhibition (9) 
 
 
 
Figure 4.7  SAM and H3[21-44] competition experiments in PRC2 DELFIA 
(Top) GSK-2d1, an active GSK126 analog, inhibits PRC2 with similar IC50 across varying peptide concentrations; 
while IC50 is altered by increasing concentrations of SAM, consistent with the finding that GSK126 is cofactor-
competitive (7). (Bottom) BRD1835 retains the same potency at varying concentrations of SAM, but its IC50 is altered 
at increasing peptide concentrations, suggestive of a peptide-competitive mechanism. IC50 values were determined 
as described in Experimental methods. 
  
4.2.3  SPR studies on BRD1835 and PRC2  
Although previous data suggest that BRD1835 inhibits PRC2 in a manner 
independent of assay format and competitive for peptide, it was essential to confirm 1:1 
target engagement. Isothermal titration calorimetry (ITC) is a widely used approach for 
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determining stoichiometry and affinity (Ka) of ligand-protein interactions since these 
properties can be determined through the measurement of heat released upon ligand 
binding (14). Due to the low apparent affinity between BRD1835 and PRC2, as well as 
the difficulty in achieving high concentrations of soluble protein complex in solution, ITC 
was not pursued, as the concentrations for both compound and protein required to 
characterize binding proved to be a barrier. Surface plasmon resonance (SPR) is 
another technique used to determine kinetic constants, such as KD and associated on- 
and off-rates. SPR biosensors measure the change in mass of a surface functionalized 
with a ligand of interest or immobilized target (15,16). Since measured responses (RU) 
have a theoretical maximum (RUMAX) dependent on the molecular weight of surface 
bound (MWimmobilized) and unbound interactants (i.e. ligand; MWLigand), stoichiometry of 
binding (n) can be determined by measuring responses achieved upon surface 
saturation (16). Since this method can been used to confirm binding of low-affinity 
compounds and requires little protein (ng-ug scale), we chose to determine 
stoichiometry of BRD1835-PRC2 binding by SPR.  
Equation 4-2  Maximum RU equation  
 
 
Given that our recombinant PRC2 harbored FLAG-EZH2, we used a Biacore 
T200- compatible CM5 chip to covalently attach anti-FLAG M2 antibody to its surface, 
enabling immobilization of PRC2. Initial studies revealed that 5-component complex 
could be captured on the surface, but only to a maximal level of ~2000 RU. As the 
molecular weight of PRC2-antibody complex is quite large (~475 kDa) compared to that 
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of BRD1835 (~569 Da), the resulting theoretical maximum response  (~2.4 RU) was 
determined to be insufficient for accurate determination of binding stoichiometry given 
the baseline noise (>0.5 RU). In addition to these baseline fluctuations, a >3 RU/min 
drift was measured—likely the result of PRC2 or its components dissociating from the 
surface under chosen assay conditions (Figure S4.2). To address this issue, we 
considered purification of EZH2 (solo) and EZH2-EED complex; however, their lack of 
catalytic competency was thought to be a complicating factors in interpreting the 
relevance of any associated binding data. For these reasons, we pursued other means 
to confirm target engagement.  
4.2.4  Activity of BRD1835 in peptide-displacement assays 
  We next aimed to explore whether the apparent peptide-competitive behavior of 
BRD1835 was occurring through a truly competitive mechanism—involving direct 
binding of the inhibitor to the EZH2 substrate pocket. Towards this aim, we developed a 
fluorescence polarization (FP) assay using a HiLyte™ Fluor 488-conjugated derivative of 
the H3[21-44] peptide to determine whether BRD1835 could disrupt the interaction 
between PRC2 and substrate. In the presence of 31.25 nM tracer peptide, we titrated 
PRC2 from 1.6 to 100 nM to confirm PRC2-substrate binding and to determine an 
appropriate concentration for subsequent competition assays. As expected, we 
measured dose-dependent increases in FP signal with increasing concentrations of 
PRC2, confirming interaction with the tracer peptide. Furthermore, we identified a 
concentration of PRC2 that would achieve 80% tracer binding for competition 
experiments (Figure 4.8A).    90 
Under optimized FP conditions, we examined whether BRD1835 could lower FP 
signal, including unlabeled H3[21-44] as a positive control. While the positive control 
peptide was able to reduce FP signal to background levels, BRD1835 failed to lower 
signal at the highest concentration tested (25 uM), suggesting that it is unable to directly 
compete with substrate binding or displace bound substrate from PRC2 (Figure 4.8B). 
From these results, we concluded that BRD1835 is likely inhibiting PRC2 through either 
a nonspecific or allosteric mechanism influenced by peptide concentration.   
 
Figure 4.8  FP binding assay for PRC2 and peptide substrate interaction  
(A) Titration of PRC2 in the presence of 31.25 nM H3[21-44]-HiLyte™ Fluor 488 (B) FP signal resulting from addition 
of DMSO, 25 uM BRD1835, or 25 uM unlabeled H3[21-44]. . Data points represent the mean and standard error of 
four replicate measurements in each experiment. - 
 
4.2.5  BRD1835 is competitive with H3K27me3 peptide and destabilizes EED 
  As discussed in Chapter I, PRC2 can be allosterically activated through two 
known mechanisms: 1) SUZ12 binding histone H3 (residues 35-42) within nucleosomes 
(17) and 2) EED binding repressive histone marks, such as H3K27me3 or H3K9me3 
(18,19). Given the inability of BRD1835 to directly displace peptide in FP assays, we 
questioned whether PRC2 inhibition was occurring through interaction with other 
complex members, such as SUZ12 or EED. One could imagine that apparent peptide-  91 
competitive inhibition would be observed if BRD1835 bound the allosteric activation site 
of SUZ12, blocking its association with H3[21-44] (or histone H3) substrate, which 
happens to include the stimulating region of histone H3 (residues 35-44).  Alternatively, 
BRD1835 could potentially disrupt the association between EED and the product of 5C- 
PRC2, H3K27me1 and H3K27me2, as even these methylation states have been shown 
to stimulate PRC2 activity (18). Lastly, BRD1835 could inhibit through binding an 
uncharacterized allosteric site—one influenced (or bound) by substrate (histone H3 or 
peptide) –within any of the PRC2 components.  
  As we were previously unable to determine a possible mode of nonspecific 
inhibition (i.e. assay interference, aggregation, etc), we investigated whether BRD1835 
inhibits PRC2 through one of the aforementioned allosteric mechanisms. To narrow 
down the possible target components, we expressed, purified, and assayed the minimal 
catalytically active complex, EZH2-EED-SUZ12, in Sf9 cells (Figure 4.9A). After 
confirming activity of 3-component PRC2 (3C-PRC2) in DELFIA, we measured the IC50 
of BRD1835 against this complex. Albeit with lower potency (~20 uM IC50), BRD1835 
was able to inhibit 3C-PRC2, suggesting that AEBP2 and RBBP4 were unlikely targets 
(Figure 4.9). 
With the potential targets of BRD1835 limited to EZH2, EED, or SUZ12, we next 
explored whether its activity against PRC2 could be attenuated by H3K27me3 peptide. 
As H3K27me3 binds only the WD40 domain of EED (17-19), we suspected that if 
BRD1835 inhibits PRC2 through disruption of a feed-forward loop—involving EED-
based PRC2 stimulation by its product —or by inducing a conformational change within 
EED that inhibited EZH2, H3K27me3 binding may alter its activity. Using 5C-PRC2, we   92 
measured BRD1835 activity in the presence of increasing concentrations of an 
H3K27me3-modified peptide (H3[23-34], K27me3). In a dose-dependent fashion, 
addition of H3K27me3 peptide significantly lowered potency of BRD1835 against PRC2 
(Figure 4.10), suggesting a possible connection between EED and compound activity 
 
Figure 4.9  BRD1835 activity in 3-component PRC2 DELFIA 
(A) 4-12% SDS-PAGE of purified 1x-FLAG-EZH2/EED/6XHIS-SUZ12 complex (3C-PRC2). Molecular weight marker 
shown to the left (in kDa) (B) Activity of BRD1835 on 3C-PRC2 as measured by DELFIA. Data points represent the 
mean and standard error of triplicate measurements. 
   
 
Figure 4.10 H3K27me3 peptide-induced abrogation of BRD1835 activity in DELFIA 
BRD1835 activity was measured in 5C-PRC2 DELFIA in the presence of 3.125 uM and 50 uM H3K27me3-modified 
peptide (H3[23-34]). Data points represent the mean and standard error of triplicate measurements.  
 
  To further investigate a potential EED-BRD1835 interaction, we expressed and 
purified full-length 6XHIS-EED from Sf9 cells (Figure 4.11A) and evaluated direct 
BRD1835 binding through fluorescence-based thermal shift assays (TSA), measuring 
the denaturation midpoint (Tm) for EED in the presence of DMSO or 25 uM BRD1835.   93 
While a majority of ligands are known to thermally stabilize their target protein, 
increasing the measured Tm (20), BRD1835 was found to thermally destabilize EED by 
1.3°C (Figure 4.11B). This behavior could be suggestive of preferential binding to the 
unfolded state of the protein (20); however, from these results, we speculated that 
BRD1835 could be inducing a conformational change within EED that altered the overall 
enzymatic activity of EZH2 or, as mentioned earlier, disrupted a feed-forward 
mechanism established through EED during the course of reaction.  
 
Figure 4.11  Activity of BRD1835 in EED thermal shift assay. 
 (A) 4-12% SDS-PAGE of purified 6XHIS-EED. (B) Derivative (d/dT) transformation of thermal melt curves for 6XHIS-
EED in DMSO (red) and 25 uM BRD1835 (green) – 3 replicate wells per condition are shown. Relative to DMSO, 
EED is destabilized by an average of 1.3 °C in the presence of BRD1835.    
   
4.2.6  BRD1835 disrupts interaction between EED and H3K9me3 
Given that BRD1835 was found to destabilize purified EED and that its activity 
could be attenuated by the addition of H3K27me3 peptide, we next explored whether 
BRD1835 could disrupt the interaction between EED and a peptide harboring a 
repressive modification (e.g. H3K9me3). Since GST-EED[78-441] (WD40 domain) could 
be expressed in bacteria with high yields (compared to full-length EED expression in 
Sf9 cells) and binds peptides harboring repressive marks (18,19), we pursued   94 
development of an AlphaLISA assay, a bead-based proximity assay commonly 
employed to identify inhibitors of protein-protein interactions (21,22). Using a 
biotinylated H3K9me3-modified peptide (H3[1-21]) and GST-EED[78-441], we 
developed an assay capable of measuring disruption of an EED-H3K9me3 interaction, 
using H3K27me3-modified and unmodified H3 peptides for assay validation (Figure 
4.12A).  
Consistent with data supporting an EED-binding hypothesis, BRD1835 lowered 
AlphaLISA signal in a dose-responsive manner, suggesting that it competes with 
H3K9me3 binding (Figure 4.12B). Similar to potency measured in 3C-PRC2 DELFIA, 
BRD1835 inhibited EED-H3K27me3 binding with an IC50 around 20 uM. As many 
compound are known to nonspecifically disrupt singlet oxygen transfer in AlphaLISA 
assays, we next examined whether dose-responsive loss of signal was artifactual by 
testing BRD1835 activity in a control assay using biotinylated-GST under similar 
detection conditions. BRD1835 was unable to significantly reduce AlphaLISA signal at 
concentrations up to 200 uM in control assays (Figure 4.12C).  
 
Figure 4.12 Activity of BRD1835 in EED[78-441] -H3K9m3 AlphaLISA. 
(A) Activity of known competing peptide (H3[21-44], H3K27me3) versus negative control (H3[21-44]) and (B) 
BRD1835 activity in GST-EED[78-441]-H3K9me3 AlphaLISA and (C) biotin-GST control assay. Data points represent 
the mean and standard error of triplicate measurements in each assay. 
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4.2.7  SPR efforts to confirm binding of BRD1835 to EED   
While previous experiments suggested an interaction between EED and 
BRD1835, we wished to confirm direct binding by SPR. As the molecular mass of GST-
EED[78-441] is substantially less than that of PRC2 and its smaller size could allow 
immobilization at high density on an SPR surface, we expected a high probability of 
success in detecting a BRD1835-EED interaction (i.e. higher theoretical response 
levels, RUMAX). We immobilized anti-GST antibody on a CM5 surface to capture GST-
EED[78-441]  and validated the activity of the immobilized species through kinetically 
monitoring binding of an H3K27me3-modified peptide at various concentrations. As 
shown in Figure 4.13A, we were not only able to detect H3K27me3 binding, but 
measured KD values (in the 50 uM range) similar to those previously reported (18,19). 
We next measured SPR responses in the presence of various concentrations of 
BRD1835, attempting to verify direct EED binding and determine affinity (Figure 4.13B). 
These results suggested an interaction between EED and BRD1835 (i.e. dose-
dependent SPR response); however, we were unable to reach surface saturation at 
higher concentrations. Moreover, these responses appeared to increase in magnitude 
far beyond the expected theoretical maximum (RUMAX), implying super-stoichiometric 
binding characteristic of a nonspecific, aggregation-based interaction with the surface. T
  To eliminate baseline drift, we were forced to use buffer conditions that differed 
significantly from those used in all previous assays (PBS-EP+ pH 7.4 versus 50 mM Tris 
pH 8.5 with 5mM DTT and 0.01% Tween 20). With that said, we reasoned that 
BRD1835 solubility could have been compromised in these studies, leading to the 
formation of high molecular weight aggregates or precipitate and super-stoichiometric   96 
behavior at higher concentrations (50 and 25 uM). To explore this hypothesis, BRD1835 
aggregate formation was assessed by DLS in SPR buffer conditions (PBS and PBS-
EP+ at pH 7.4). While intensity autocorrelations for DMSO in PBS-EP+ buffer were 
slightly characteristic of aggregate presence (potentially due to the P20 Surfactant 
additive), BRD1835 appeared to clearly aggregate at concentrations >12.5 uM in both 
PBS and PBS+EP conditions (Figure S4.3), thus providing an explanation for its 
behavior in SPR. Interestingly, these aggregates appear to bind EED with some 
selectively, as all SPR responses were reference-subtracted (measuring BRD1835-GST 
interactions in parallel). While suggestive of BRD1835’s potential to form EED-binding 
aggregates in a manner dependent on buffer condition, these studies were unable to 
confirm a classical 1:1 interaction with EED. 
 
Figure 4.13 SPR studies on BRD1835 interaction with GST-EED[78-441]  
(A) H3K27me3-peptide titration and KD determination validating the activity of GST-EED[78-441] surface. (B) Titration 
of BRD1835 across GST-EED[78-441] surface. Super-stoichiometric binding could be detected at 25 and 50 uM 
BRD1835. All sensorgrams above are background-subtracted using a GST surface as a reference. 
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4.2.8  Photo-crosslinking as a strategy to confirm EED target engagement 
As our attempts to confirm BRD1835 target engagement through SPR were 
inconclusive, we next explored a photo-crosslinking strategy, aiming to determine the 
target PRC2 component using purified 5-component complex. We synthesize an analog 
of BRD1835 (HU172) harboring a photoreactive benzophenone in place of the 
cyclopentyl propyne moiety as well as an alkyne on the northeast hydroxyl group to 
enable biotin attachment using click chemistry (Figure 4.14A). Prior to photo-
crosslinking experiments, we characterized HU172 in PRC2 DELFIA and EED-
H3K9me3 AlphaLISA to verify that its biochemical activity was similar to that of 
BRD1835. HU172 exhibited activity in both DELFIA and AlphaLISA assays with similar 
potency (~10 uM IC50), although the dose-response curves appeared quite steep – a 
potential sign of aggregation-based inhibition (5).  However, given its structural similarity 
to BRD1835 and biochemical activity, we proceeded with crosslinking studies, using 
HU172 concentrations at its IC50 (10 uM).    
 
Figure 4.14  Biochemical activity of HU172 – a BRD1835 photocrosslinkable analog,  
(A) Structure of HU172 with alkyne and benzophenone moieties depicted in red. Activity of HU172 in (B) PRC2 
DELFIA and (C) GST-EED[78-441]-AlphaLISA. Data points represent the mean and standard error of four replicate 
measurements in each assay. 
 
To identify the potential target of BRD1835, purified PRC2 and HU172 were 
incubated in the presence or absence of competing BRD1835 (100 uM) and photo-  98 
crosslinking was initiated by 60 min UV exposure. After a copper-catalyzed click 
reaction with biotin azide, we initially identified labeled bands by western blot using 
streptavidin-HRP (chemiluminescence) for detection. After several attempts, no labeled 
bands within the molecular weight range of PRC2 components were identified and only 
a single band of ~25 kDa showed strong labeling and competition by BRD1835 (Figure 
S4.4A). When IR fluorescence detection was used in place of chemiluminescence 
(substituting IRDye® 800CW streptavidin for streptavidin-HRP), all PRC2 components 
appeared to be labeled by HU172; however, as seen previously only the 25 kDa band 
was competitive with BRD1835 (Figure S4.4B).  
While of initial interest, this band was not identified when other active 
preparations of PRC2 were used. In fact, photo-crosslinking experiments using 
alternative batches revealed BRD1835-competitive bands within the mass range of 
PRC2 components, corresponding most strikingly to presumed SUZ12/EZH2 bands at 
~100 kDa (Figure 4.15A). To determine whether HU172 labeling or BRD1835 
competition could be influenced by the addition of peptide substrate, photo-crosslinking 
was repeated in the presence of 62.5 and 500 nM H3[21-44], with and without 
competitor. Intriguingly, HU172 labeling appeared to increase in a manner dependent 
on peptide concentration, with very strong labeling occurring in the ~100 kDa range 
(Figure 4.15B). Moreover, 100 uM BRD1835 was able to significantly reduce the 
labeling intensity of these HU172-conjugated bands in the presence of peptide, 
suggesting interactions between EZH2 or SUZ12, and the inhibitor. Bands 
corresponding to AEBP2, RBBP4, and EED were only modestly labeled in a manner 
weakly competitive with BRD1835.   99 
 
Figure 4.15 HU172 photo-crosslinking of 5C-PRC2 components 
(A) Results of 5C-PRC2 photo-crosslinking studies using 10 uM HU172 in the presence of DMSO or 100 uM 
BRD1835. (B) HU172 photo-crosslinking and BRD1835 (100 uM) competition in the presence of 62.5 nM or 500 nM 
H3[21-44] peptide. 
 
 
Overall, these results put into question whether BRD1835 inhibits PRC2 through 
engagement of EED and raises the possibility of direct interaction with EZH2 or SUZ12. 
Furthermore, the increased intensity of HU172 labeling in the presence of H3[21-44] 
implicates substrate in the mechanism of inhibition—implying that, while its inhibitory 
activity is substrate-competitive, the interaction between BRD1835 and PRC2 is 
positively influenced by substrate binding. However, the labeling of the 25 kDa species 
in one PRC2 preparation, likely precluding the labeling of other PRC2 components, may 
suggest the ability of BRD1835 to bind promiscuously. Follow-up studies revealed that 
this band is nonspecifically detected by both EED and EZH2 antibodies and does not 
emerge as a result of photo-crosslinking (Figure S4.5). Given that this species could   100 
only be detected when mouse IgGs were used, we speculated that this band may be 
contaminating anti-FLAG M2 IgG light chain (mouse) that remained bound to FLAG-
EZH2 throughout purification.   
4.2.9  NMR studies suggest BRD1835 interaction with peptide and potential  
aggregation  
With contradictory evidence and inconclusive results surrounding BRD1835 
engagement with EED, we re-examined the possibility of aggregation. Since initial DLS 
and detergent-sensitivity assays were unable to convince us of significant aggregate 
formation, we looked for orthogonal approaches. It has been recently reported that 
proton NMR can provide a sensitive means to determine the critical aggregation 
concentrations (CACs) of organic molecules in aqueous solution (23).  This is based on 
the observation that proton NMR spectra are sharpest when a compound is completely 
soluble in solution and unusually broad as they begin to form soluble aggregates or 
precipitates (23). In collaboration with Professor Andy Phillips, we sought to determine 
the CAC of BRD1835 (and two inactive analogs) by collecting proton NMR spectra at 
varying concentrations of compound and identifying the concentration in which peak 
broadening became detectable.  
  In an attempt to improve potency, several analogs of BRD1835 were synthesized 
and assayed in both PRC2 DELFIA and EED-H3K9me3 AlphaLISA. While we were 
unable to generate compounds of significantly greater potency, we were able to identify 
several inactive analogs. The structures and associated biochemical activity of these 
compounds are shown in Figure 4.16. To determine if the ability to form aggregates was 
the basis for inhibition, we performed proton NMR aggregation studies, measuring the    101 
CACs for BRD1835, BRD5100, and BRD7301. As the results in Figure 4.17 indicate, 
peak broadening becomes strongly apparent for BRD1835 at concentrations of 50 uM 
and above, but seems to occur to some degree at 25 uM, suggesting a CAC between  
 
Figure 4.16  Structure and biochemical activity of Inactive BRD1835 analogs 
(A) Structures of inactive analogs (BRD7301 and BRD5100) and BRD1835. (B) Activity of BRD1835, BRD7301, and 
BRD5100 in PRC2 DELFIA. (C) Activity of BRD1835, BRD5100, and BRD7301 in EED-H3K9me3 AlphaLISA. Data 
points represent the mean and standard error of triplicate measurements in each assay 
 
25-50 uM. BRD7301, a methylester derivative of BRD1835, was completely insoluble in 
the sodium phosphate buffer used in these studies, while BRD5100, an analog lacking 
the cyclopentyl propyne moiety, exhibited no detectable aggregation up to 100 uM.  
As DLS was previously unable to detect particles in assay buffer (50 mM Tris pH 8.5, 5 
mM DTT, 0.01% Tween 20) containing upwards of 250 uM BRD1835, we repeated 
these measurements in the 50 mM sodium phosphate buffer (pH 7.4) used in the NMR 
studies. As shown in Figure 4.17, DLS estimations were in near perfect agreement with 
the CACs determined by NMR, revealing significant BRD1835 aggregation at 25 uM    102 
 
Figure 4.17 CAC determination of BRD1835 and analogs by 
1H NMR and DLS  
1H NMR spectra and DLS intensity autocorrelation curves for various concentrations of BRD1835 (A and B, resp.), 
BRD5100 (C and D, resp.), and BRD7301 (E and F, resp.) in 50 mM sodium phosphate, pH 7.4. Both methods 
confirm likely aggregation at >25 uM BRD1835 and at all concentrations of BRD7301 tested. BRD5100 showed no 
detectable aggregation at concentrations up to 100 uM. Each intensity autocorrelation curve represents the average 
of 10 single-well acquisitions for each condition. 
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and above, no aggregation of BRD5100 up to 100 uM, and significant aggregation 
formation at all BRD7301 concentrations tested (3.125 uM and above).    
Small-molecule aggregation is a buffer-dependent phenomenon, however, the 
extreme differences in BRD1835 CAC exhibited between NMR and activity assay 
buffers were seemingly suspicious. The phenomenal agreement between DLS and 
NMR-based aggregation assays inspired us to reexamine previous DLS results and 
procedures to verify the CAC of BRD1835 in the buffer used to measure biochemical 
activity. As several compounds were profiled during our initial round of DLS, compounds 
were added directly to assay plates by pin tool as opposed to being manually diluted in 
larger volumes and dispensed accordingly. As this was the only alteration in our 
protocol, we revisited DLS studies, estimating the CACs for BRD1835, both inactive 
analogs, and the photo-affinity probe, HU172, in PRC2 assay buffer (50 mM Tris pH 
8.5, 5 mM DTT, and 0.01% Tween 20). As shown in Figure 4.18, BRD1835 formed 
clear aggregates at 100 uM. While this CAC is still higher than those measured in NMR 
and SPR buffers, it does demonstrate that BRD1835 aggregates at a lower 
concentration than previously estimated. As expected, BRD5100 formed no detectable 
aggregates (up to 200 uM), while BRD7301, although soluble in PRC2 assay buffer, 
formed clear aggregates at 100 uM. Moreover, the photo-crosslinking analog, HU172, 
was found to aggregate at 25 uM, a concentration much lower than that of BRD1835.  
   From these studies, we determined that, while it may contribute, aggregation 
formation alone was unable to predict activity against PRC2, as the inactive analog, 
BRD7301, was found to aggregate at concentrations similar to that of BRD1835. 
However, it is noteworthy that HU172, an analog found to inhibit EED-H3K9me3   104 
interaction with potency greater than that of BRD1835, was the strongest aggregator in 
PRC2 assay buffer. Furthermore, though the measured biochemical activity (IC50) for 
both HU172 and BRD1835 in PRC2 DELFIA was 4-10X lower than their estimated 
CACs, PRC2 was potently inhibited in the presence of these aggregates. While 
inhibition through specific mechanisms can occur at concentrations below the CAC, 
these findings suggest that only specific compound aggregates can inhibit PRC2, 
potentially though a mechanism distinct from the enzyme sequestration or unfolding 
mechanisms that have been previously described (24).  
 
 
Figure 4.18 DLS analysis of BRD1835, HU172, BRD5100, and BRD7301 under activity assay buffer conditions 
DLS intensity autocorrelation curves for various concentrations of BRD1835, HU172, BRD5100, and BRD7301 in 
activity assay buffer (50 mM Tris pH 8.5, 5 mM DTT, 0.01% Tween 20). BRD1835 and BRD7301 show large 
aggregate formation at >100 uM, while HU172 forms large aggregates at >25 uM. BRD5100 shows no sign of 
aggregation at all concentrations tested (up to 100 uM). Each intensity autocorrelation curve represents the average 
of 10 single-well acquisitions for each condition.  
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4.2.10 Exploring BRD1835 peptide-binding activity 
With new knowledge regarding BRD1835 aggregation potential, we next 
explored whether BRD1835 aggregates could interact directly with peptide, as this 
might explain its peptide-competitive behavior. From our SAR studies, we learned that 
presence of the carboxylic acid was essential for activity and only when replaced with 
an isostere, such as a tetrazole, was the compound able to inhibit PRC2 activity. Given 
this dependence on a negatively charged group, we questioned whether this potentially 
promoted binding to the positively charged substrate and whether aggregates harboring 
a carboxylic acid were capable of binding in a manner that was inhibitory  
 To test this hypothesis, we conducted proton NMR experiments on BRD1835 
(200 uM) in the presence of peptide substrate (2 uM H3[21-44]), looking for signs of 
interaction through changes in the BRD1835 or peptide spectra. While there were no 
significant changes in chemical shifts for either molecule, H3[21-44] was found to 
significantly lower the apparent CAC of BRD1835, suggesting an interaction between 
compound and substrate (Figure 4.19A). Interestingly, there appeared to be selectivity 
in regard to this peptide-induce deaggregation phenomenon, where only H3[21-44] 
peptide was able to significantly lower BRD1835 CAC, while H3[1-21] and H3[69-89] 
was unable to do so. Ultimately, these results suggest that BRD1835 activity on PRC2 
could involve nonspecific, aggregation-based inhibition that’s reversed by addition of 
peptide substrate, giving it the appearance of peptide-competitive behavior. 
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Figure 4.19  
1H NMR and DLS studies on BRD1835 in the presence of histone H3-derived peptides 
(A) 
1H NMR spectra of 200 uM BRD1835 in the presence of 2 uM H3[1-21], H3[21-44], and H3[68-89] in 50 mM 
sodium phosphate buffer, pH 7.4 (B) DLS intensity autocorrelation curves of 100 uM BRD1835 in the presence of 
various H3[21-44] concentrations in activity assay buffer (50 mM Tris pH 8.5, 5 mM DTT, and 0.01% Tween 20). 
While NMR studies suggest potential deaggregation of 200 uM BRD1835 the presence of H3[21-44], DLS 
experiments reveal that large BRD1835 particles are not diminished by  H3[21-44] peptide under activity assay buffer 
conditions. Each intensity autocorrelation curve represents the average of 10 single-well acquisitions for each 
condition.  
 
To determine whether this deaggregation phenomenon occurred in PRC2 assay 
buffer, we examined BRD1835 aggregation by DLS in the presence or absence of 
H3[21-44] peptide. As seen previously, BRD1835 appeared to aggregate at 100 uM, 
however, these aggregates were not eliminated by the addition of 62.5 nM or 2 uM 
H3[21-44] (Figure 4.19B). While peptide-induced deaggregation may only occur under 
specific buffer conditions or represent a phenomenon specific to these NMR studies, the 
interaction between BRD1835 and peptide may still occur under our assay conditions.     
In earlier characterization efforts using EED-H3K9me3 AlphaLISA, we were able 
to demonstrate that BRD1835 disrupted the interaction between GST-EED[78-441] and 
H3K9me3 peptide, while H3[21-44] had no effect up to 200 uM. Considering this likely 
involved BRD1835 aggregation and that H3[21-44] could potentially bind and sequester 
these aggregates, we tested BRD1835 activity in the GST-EED[78-441]-H3K9me3 
AlphaLISA in the presence or absence of 2 uM H3[21-44]. Indicative of an interaction, 
BRD1835 activity was abrogated by the addition of H3[21-44], implying a reduction of   107 
activity due to peptide binding (Figure 4.19B). To explore this behavior further, we 
revisited our fluorescent polarization assay using HiLyte™ Fluor 488-H3[21-44]. While 
25 uM BRD1835 exhibited no activity in this assay, we questioned whether aggregating 
concentrations of active compounds were able to increase FP signal in the presence of 
tracer peptide alone. At 100 uM, both HU172 and BRD1835 markedly increased FP 
signal, while inactive analogs (BRD7301 and BRD5100) yielded FP levels equivalent to 
those generated by DMSO (Figure 4.21). These results confirm that, at least at 
aggregating concentrations, peptide-binding behavior tracks with compound activity in 
both EED-H3K9me3 AlphaLISA and PRC2 DELFIA. 
 
 
 
Figure 4.20  BRD1835-peptide interactions revealed by EED-H3K9me3 AlphaLISA and HiLyte™ Fluor 488-
H3[21-44] FP assay.  
(A) BRD1835 activity in EED-H3K9me3 AlphaLISA in the presence or absence of 2 uM H3[21-44]. (B) FP 
measurements of 31.25 nM HiLyte™ Fluor 488-H3[21-44] in the presence various BRD1835 concentrations. Data 
points represent the mean and standard error of four replicate measurements in each assay 
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Figure 4.21 HiLyte™ Fluor 488-H3[21-44] FP assay on active and inactive BRD1835 analogs.  
FP measurements of 31.25 nM HiLyte™ Fluor 488-H3[21-44] in the presence 100 uM BRD1835, HU172, and inactive 
analogs (BRD5100 and BRD7301). Compared to DMSO, FP signal increased in the presence of aggregating 
concentrations of active analogs only. Data points represent the mean and standard error of four replicate 
measurements in each assay. 
 
4.2.11 Discussion and outlook 
The widespread presence of aggregators in screening collections is an issue that 
has only quite recently been appreciated (25). As most organic molecules aggregate at 
some critical concentration in aqueous solution depending on the conditions, their 
identification and removal from screening decks has proven challenging. This challenge 
is underscored by the fact that many compounds can be well behaved and maintain 
biologically meaningful activity at concentrations below their CAC, as can be seen by 
the large number of drugs that can inhibit promiscuously by aggregation-based 
mechanisms (4). Furthermore, unlike promiscuous reactive compounds, aggregation is 
difficult to predict on the basis of structure alone, requiring one to empirically determine 
aggregation potential under their specific assay conditions. As previously mentioned, 
there are certain hallmarks that can be considered when determining whether a 
compound’s activity in a biochemical assay is due to specific target engagement or 
promiscuous inhibition via aggregate formation. These include sensitivity to detergent,   109 
formation of large particles detectable by DLS, sensitivity to enzyme concentration, and 
noncompetitive behavior (26).  
In the case of BRD1835, we found this compound to be active in the presence of 
detergent, insensitive to enzyme concentration, and competitive for peptide substrate in 
PRC2 DELFIA. Along with its apparent cellular activity, no particle formation could be 
detected by DLS within the IC50 range, suggesting a mechanism that was potentially 
specific and on-target.  While BRD1835 was unable to directly compete with labeled 
peptide substrate in FP experiments, the ability of H3K27me3 to attenuate activity was 
suggestive of an EED-based allosteric mechanism influenced by peptide concentration. 
EED TSA and H3K9me3-competition assays further suggested an interaction between 
BRD1835 and EED, prompting SPR studies that revealed an interaction, but with clear 
super-stoichiometric behavior at high concentrations.  
As SPR results were inconclusive, we pursued PRC2 photo-crosslinking studies 
using a biochemically active, photoreactive analog of BRD1835, HU172. These 
experiments suggested EZH2 or SUZ12 (and not EED) to be the possible target and 
revealed, in addition to its ability to bind with some promiscuity, a positive influence of 
substrate on HU172 photolabeling. Consistent with this later finding, 
1H NMR studies 
uncovered a potential interaction between BRD1835 and H3[21-44]. Furthermore, NMR 
and follow-up DLS experiments exposed the potential of BRD1835, BRD7301, and 
HU172 to aggregate under different buffer conditions, with FP and EED-H3K9me3 
interaction assays demonstrating the ability of only biochemically active aggregates to 
bind peptide substrate.    110 
While the measured CAC of BRD1835 in our activity assay buffer exceeds its 
IC50 in PRC2 DELFIA, these results are suggestive of a novel aggregation-based 
mechanism of inhibition implicating the peptide substrate. Although it is an intriguing 
possibility, peptide sequestration by compound alone is an unlikely mechanism, as 
BRD1835 exhibits no activity in NSD2 DELFIA—an assay utilizing the same peptide 
substrate in biochemical, albeit at slightly higher concentration. Furthermore, this 
compound fails to displace the peptide from PRC2 in FP experiments. Lastly, photo-
crosslinking experiments demonstrate a peptide-dependent increase in HU172 labeling 
and clear competition with a PRC2 component by BRD1835.  
Taken together, it is likely that BRD1835 forms aggregates that engage substrate 
and PRC2 components nonspecifically under lower substrate conditions, with apparent 
peptide-competitive behavior arising from substrate-dependent sequestration of 
compound at higher substrate concentrations (Figure 4.22). Activity below the CAC can 
likely be explained by the formation of small aggregates that evade DLS detection, as 
differing ionic strength has been shown to impact particle size (27), but increase their 
number. Although it was initially assumed that differing aggregation behavior exhibited 
in SPR, NMR, and activity assay buffers were primarily the result of pH (given that 
BRD1835 harbors an ionizable tertiary amine), its possible that differences in salt 
concentration may have only impacted the size of aggregates and not their presence.  
While these investigations were unsuccessful in delivering a novel small-
molecule probe for PRC2, they do clearly illustrate the potential of small-molecules to 
behave in artifactual ways that have not previously been appreciated. BRD1835 is likely   111 
a novel example of an aggregator, violating many of the currently established hallmarks 
through displaying substrate-competitive inhibition and insensitivity to protein 
 
Figure 4.22 Proposed MOA for BRD1835 and active analogs 
Under conditions of low substrate concentration, small negatively-charged aggregates of BRD1835 engage the 
substrate-bound complex in the vicinity of SUZ12, EED, and SUZ12, blocking activity (left). With increased 
concentrations of substrate, BRD1835 is effectively sequestered by excess peptide enabling PRC2 to freely 
methylate available substrate.    
 
 
concentration. Moreover, the aggregates formed are potentially of a nature that evades 
detection by DLS under low ionic conditions. Although these small aggregates appear to 
inhibit through a nonspecific mechanism (i.e. lacking classical 1:1 target engagement), 
they are not entirely promiscuous, given that no activity was measured in G9a and 
NSD2 assays. Moreover, it is yet undetermined whether the apparent cellular activity 
exhibited by BRD1835 is a result of direct PRC2 engagement or nonspecific interactions 
with the H3K27 region of histone H3 or other proteins. Confirmation of the later 
possibility would underline the issue of confirming intracellular target engagement using   112 
broad target-connected phenotypes. With that said, the use of mass spectrometry-
based target ID methods (28) or mutagenesis and resistance studies to identify 
dominant drug-resistant alleles (29) should always be considered, as these methods 
provide the most substantial proof for intracellular activity.   
Lastly, it should be noted that other molecules likely share the novel inhibitory 
mechanism exhibited by BRD1835. As discussed in the previous chapter, three 
additional, distinct structural classes of putative PRC2 inhibitors were found to be 
strongly peptide-competitive, selective for PRC2, and able to bind peptide at high 
concentrations (as inferred by FP). Furthermore, all were active in the presence of 
detergent and lacked the ability to form large aggregates detectable by DLS. Taken 
together, these familiar properties are highly suggestive of nonspecific activity against 
PRC2 and may perhaps be predictive of artifactual behavior occurring in other HMT 
assays. Whether this phenomenon is specific to assays using highly charged peptides 
or those derived from histones remains to be determined. In any case, upfront 
assessment of peptide-binding activity may provide a means to rapidly and cost-
effectively identify undesirable molecules in large screening collections or to avoid their 
pursuit if identified in future HTS campaigns.  
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4.3  Experimental methods  
PRC2 DELFIA.  PRC2 activity was measured using DELFIA performed on 384-well, 
white, streptavidin-coated plates (PerkinElmer). In short, PRC2 was diluted in 20 uL 2X 
Enzyme Buffer (50mM Tris HCl pH 8.5, 10 mM DTT, 0.02% Tween 20), 100 nL 
compound was pinned, reactions were initiated with 20 uL of a SAM (NEB) solution 
containing H3[21-44]-GK-biotin (Anaspec). Plates were incubated at room temperature 
for 1 hr and then washed three times with 100 uL of wash buffer (50mM Tris pH 7.4, 
150 mM NaCl, 0.05% Tween 20, 0.2% BSA). Fluoroimmunoassay (FI) Buffer (50 mM 
Tris HCl pH 7.8, 150 mM NaCl, 0.05% Tween 40, 25 µM DTPA, 0.2% BSA, 0.05% 
BGG) containing a anti-H3K27me2 rabbit IgG (Cell Signaling, #9728) with 691 ng/mL 
Eu-N1-anti-rabbit IgG (PerkinElmer) was added at 50 uL per well. Following 1 hr 
incubation at room temperature, the plates were washed three times with wash buffer 
and 50 uL of Enhancement Solution (PerkinElmer) was added to each well. Plates were 
incubated for 30 min at room temperature and time-resolved fluorescence (TRF) was 
measured on Wallac Envision 2104 Multilabel Reader (400 us window, 400 us delay, 
320 excitation, 615 emission). 
PRC2 radiometric assays.  PRC2 was diluted to final concentration in 2X enzyme 
buffer (50mM Tris HCl pH 8.5, 10 mM DTT, 0.01% Tween 20). Reactions were initiated 
with an equal volume of an SAM solution (NEB) containing 
3H-SAM (at 25% total SAM 
concentration; NET155001MC; PerkinElmer) and H3[21-44]-GK-biotin (AnaSpec) or 
histone H3.1 (NEB) and incubated at room temperature. For kinetic analysis, 100 uL 
aliquots were quenched in an equal volume of 3.2 mM SAM at various time points in a 
96-well plate. After all time points were collected, quenched reactions were transferred   114 
to a streptavidin-coated 96-well DELFIA plates (PerkinElmer) and incubated at RT for 1 
hr. Unreacted 
3H-SAM was removed by washing plates three times with 200 uL of wash 
buffer (50mM Tris pH 7.4, 150 mM NaCl, 0.05% Tween 20, 0.2% BSA) per well. 
Modified peptide was then eluted by a 1 hr RT incubation with 100 uL/ well elution buffer 
(70% ACN, 5% formic acid, 1 mM biotin) and 
3H incorporation was measured by LSC 
(TriCarb 2910; PerkinElmer). For histone H3 assays, 50 mM histone H3.1 was 
substituted for peptide and reactions were filtered through an Immobilon (Bio-Rad) 
membrane using the 96-well Miniblot I Spot-Blot System (Sigma). Membranes were 
subsequently washed 3X with PBS and incubated in Ponceau S for protein 
visualization. Individual spots were excised and transferred to scintillation fluid for ON 
incubation before LSC.  
DLBCL cell culture and RT-qPCR.  DLBCL lines (Pfeiffer, WSU-DLCL2, HT, and OCI-
LY-19) were cultured using conditions described in (10).  Primer sequences for TXNIP, 
TNFRS21, and GAPDH used in RT-qPCR were identical to those described in (10) and 
obtained through Integrated DNA Technologies. DLBCL cells were seeded in 6-well 
plates at a density of 4E5 cells per well and treated with compound or DMSO. After 96 
hours, cells were collected by centrifugation, washed with PBS, and RNA was extracted 
using RNeasy Mini Kit columns and QIAshredder homogenization (Qiagen). RNA was 
quantified by NanoDrop 2000 spectrophotometer and cDNA was synthesized from 5 ug 
RNA on a 100 uL scale using the High-Capacity cDNA Reverse Transcription Kit (Life 
Technologies) and random primers.   RT-qPCR was conducted in 384-well ABI- plates 
with the Applied Biosystems 7900HT default protocol using 1 uL cDNA per well in 10 uL 
reactions containing 2X Power SYBR® Green Master Mix (Life Technologies) and 1 uM   115 
concentrations of each primer. Ct values for each primer set, treatment condition, and 
cell line were measured in quadruplicate and fold-change over DMSO was calculated 
using GAPDH normalization of mean Ct values.  
Surface plasmon resonance. SPR was performed using a Biacore T200 instrument 
using CM5 chips (GE Healthcare) to immobilize anti-FLAG M2 antibody (Sigma) in 50 
mM acetate, pH 4.5. or anti-GST antibody provided by GST Capture Kit (GE) using the 
Amine Coupling Kit (GE). For 5C-PRC2 capture, 6 nM PRC2 was injected at a flow rate 
of 2 uL/min over anti-FLAG surface until saturation. For GST-EED[78-441], 30 ng/uL 
protein solution was injected at 10 uL/min over anti-GST surface to saturation. 
BRD1835 DMSO stock was diluted in PBS+EP Buffer (GE) to a final DMSO 
concentration of 5% in PBS+EP Buffer (GE) and injected for 60s at a flow rate of 60 
uL/min.   
Thermal shift assay.  6XHIS-EED (500 ng/uL in Assay Buffer) was mixed with 
SYPRO® Orange 5000X DMSO stock (Sigma) diluted 100X. To each well of a 384-well 
LightCycler® 480 multiwell plate Compounds were pinned at 100 nL per well and 
fluorescence was measured over a 25 °C – 95 °C temperature ramp using a Roche 480 
LightCycler. 
GST-EED[78-441] AlphaLISA. GST-EED[78-441] and biotinylated H3K9me3 peptide 
(H3[1-21]-GK-biotin) were diluted to 140 ng/uL and 2 uM in assay buffer (50 mM Tris, 
pH 8.5, 150 mM NaCl, 5 mM DTT, 0.01% Tween 20), respectively, and added to 384-
well AlphaPlates (PerkinElmer) at 10 uL per well. Compounds and competing peptides 
were diluted in assay buffer to 2X final concentration and 10 uL stocks were mixed with 
GST-EED and H3K9me3 peptide. After 1 hr incubation, AlphaLISA Streptavidin Donor   116 
Beads (PerkinElmer) and AlphaLISA anti-GST Acceptor Beads (PerkinElmer) were 
diluted in 1X Epigenetics Buffer (PerkinElmer) to 20 ug/mL each and added to plates at 
20 uL per well. Alpha signal was detected using the Wallac Envision 2104 Multilabel 
Reader after 1 hr incubation.  
Detergent and DELFIA-interference assays DELFIA assays were conducted as 
above with the following modifications. Detergent screening was performed using assay 
buffer with and without 0.01% Tween 20. For DELFIA-disruption assays, compounds 
were either pinned 1 hr post-reaction initiation and washed after 10 min or pinned into 
2X Enzyme Buffer without enzyme, substituting H3K27me2-modified H3[21-44]-GK-
biotin (AnaSpec) for unmodified H3[21-44]-GK-biotin. 
1H-NMR CAC determination 
1H NMR spectra were recorded on a 600 MHz Agilent 
spectrometer equipped with an automatic sample changer and a C{H} cold probe. 1680 
scans with a relaxation plus acquisition time of 2 seconds were used for each spectrum. 
The residual solvent peak (H2O) was referenced to 4.79 ppm and a Bernstein 
polynomial fit (order =3) baseline correction was applied along f1. Dilution series was 
carried out in 50 mM sodium phosphate, pH 7.4 formulated in D2O following procedures 
outlined in (23). Data were collected by Michal Hallside, a graduate student in the 
laboratory of Professor Andy Phillips at Yale University. 
HU172 photo-crosslinking.  0.5 uL of DMSO or BRD1835 was added to 24 uL of 5C-
PRC2 diluted to 300 ng/uL in storage buffer (50 mM Tris, pH 8, 150 mM NaCl, 10% 
glycerol) and incubated for 15 minutes on ice. HU172 was diluted in DMSO to 500 uM 
and 0.5 uL was then added for a final concentration of 10 uM. After 15 min incubation 
on ice, mixture was transferred to a 96-well PP plate and irradiated by UV lamp (ENF-  117 
260C) or 60 min at 365 nM. After crosslinking, 19.5 uL of sample was transferred to an 
eppendorf tube and 2.5 uL of 10% SDS, 0.5 uL of 5 mM biotin-PEG-azide (Life 
Technologies), and click catalyst (4 mM TBTA, 40 mM TCEP, and 40 mM CuSO4) were 
added. After 60 min incubation at 50 °C, 1X LDS Sample Buffer (Life Technologies) was 
added and samples were immediately separated by SDS-PAGE; Precision Plus Protein 
Kaleidoscope standards (Bio-Rad) were used for downstream molecular weight 
estimation. Proteins were transferred to Immobilon PVDF membrane (Bio-Rad) at 30V 
for 1 hr and membranes were blocked with 5% BSA in TBST. Biotin was detected by 
ON incubation with 1:1000 dilution of streptavidin-HRP (Thermo) or IRDye® 800CW 
Streptavidin (LI-COR) followed by TBST washes and development using SuperSignal 
West Pico Chemiluminescent Substrate (Thermo) or high-sensitivity imaging (84 um 
resolution; 700/800 nm dual scan) on Odyssey
® CLx Infrared Imaging System. 
Histone Extraction and Western Blotting 293T cells (ATCC) were cultured in DMEM 
supplemented 10%(v/v) FBS and 100 U mL
-1 penicillin-streptomycin. Cells were plated 
at 2e5 cells/well in 6-well dishes and treated with compound or DMSO vehicle on the 
following day. After 48 hr incubation, cells were rinsed with PBS, scraped into ice-cold 
PBS, and collected via centrifugation at 200 x g for 10 minutes. Pellets were 
resuspended in 0.2 volumes of 0.4 N HCl and incubated for at least 30 minutes on ice to 
extract histones. Cellular debris was then cleared by centrifugation at 10,000 x g for 10 
minutes. Supernatant containing extracted histones was then neutralized with 0.4 
volumes of 1 M sodium phosphate (pH 12.5) and concentration was determined via 
Bradford assay. 1 ug of acid-extracted histones from each treatment was separated on 
a precast 12% NuPAGE Bis-Tris SDS-PAGE gel (Life Technologies) and transferred to   118 
a PVDF membrane. After blocking in 5% (w/v) non-fat dry milk dissolved in TBST for 
1hr at RT, membranes were incubated overnight in blocking buffer containing primary 
antibody at 4°C. Membranes were then washed with TBST, incubated in blocking buffer 
containing a 1:2500 dilution of HRP-linked anti-rabbit IgG (GE Healthcare), and 
developed using chemiluminescence detection (SuperSignal, Thermo Fisher Scientific; 
Image Station 4000MM Pro, Kodak). For loading normalization, membranes were 
stripped using Restore Plus (Thermo) and re-probed with total H3 antibody (#9715, Cell 
Signaling). 
Dynamic light scattering. DLS experiments as described in (7) with modifications. 
DMSO stock solutions were pinned at 250 nL in black 384-well clear bottom plates 
(Corning) containing 40 uL of assay buffer (50 mM Tris, pH 8.5, 5 mM DTT, 
0.01%Tween 20). Alternatively, compounds were diluted manually into 100 uL of assay 
buffer, 50mM Sodium Phosphate (pH 7.4), PBS (pH 7.4), or 1X PBS-EP+ (pH 7.4; GE 
Healthcare). Autocorrelation functions were collected using DynaPro Plate Reader II 
using default settings.  
Fluorescence polarization. Compound, DMSO, or competitor peptide was diluted to 
2X final concentration in 1X Enzyme Buffer and added at 20 uL per well in black 384-
well plates. H3[21-44] -HiLyte488 peptide (62.5 nM) and PRC2 (12.5 nM) were diluted 
in 1X Enzyme Buffer and added at 20 uL per well. Following 10 min incubation, 
fluorescence polarization (mP) was measured using Wallac Envision 2104 Multilabel 
Reader (FP FITC dual optical module; Excitation: 480 nm, Emission: 535 nm for both S- 
and P-channels).   119 
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5  Characterization of putative PRC2 activators, BRD8284 and 
BRD3934 
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Collaborator Contributions 
•  Dr. Fumika Hirobe Yakushiji and Mengfei Zhang resynthesized BRD8284 and 
BRD3934. 
•   Dr. Fumika Hirobe Yakushiji performed H3.1 assays (radiometric and western 
blot) for biochemical evaluation of BRD8284 and BRD3934 activity on PRC2.  
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5.1  Introduction  
In contrast to the overwhelming number of identified chemical probes and drugs 
that inhibit their protein targets, very few synthetic, small-molecule activators of enzyme 
function have been identified to date (1). Some examples include activators of 
glucokinase (RO281675; ref. 2), PDK1 (PS48; refs. 3,4), RNase L (C1; ref. 5) , AMPK 
(A769662; refs. 6,7), and most famously, SIRT1 (resveratrol and SRT1720; refs. 8,9)—
although the ability of SIRT1 probes to directly activate enzyme activity has generated 
debate (10,11).  Biochemical activation of a given target can occur through a small 
molecule binding an allosteric site within the catalytic domain (RO281675; ref. 12) or 
regulatory subunit (A769662; ref.13) to stabilize the active enzyme conformation or 
induce activating multimerization (C1; ref 5). The therapeutic utility of small-molecule 
activators varies from target to target. However, regardless of therapeutic impact, 
elucidating the MOA of small-molecule activators often can lead to advances in 
biological understanding by illuminating previously unknown and/or underappreciated 
mechanisms of allosteric regulation (1). 
In Chapter III, we described the use of DELFIA to assay, over two rounds of 
screening, >120,000 diverse small molecules for their ability to modulate PRC2 activity. 
In the second round, among a set of 58,917 DOS compounds screen, we discovered a 
large number of high signal outliers that were potential PRC2 activators. In total, we 
identified 274 compounds that increased DELFIA signal by >50% relative to DMSO. 
Among these initial hits, 23 compounds increased apparent PRC2 activity in a dose-
responsive manner (Figure 5.1A). These putative activators clustered into five major 
structural categories (with AC50s in the 3-25 uM range); however, two chemotypes,   125 
azocane and bridged bicyclic, were overrepresented (Figure 5.1B). Since the most 
potent activators were bridged bicyclic compounds, we chose members of this structural 
class for further study. This chapter describes the identification and characterization of 
two such bridged bicyclic activators, BRD8284 and BRD3934.   
 
Figure 5.1 Activity and structures of identified PRC2 activator candidates 
(A) Dose-response curves for 23 activator hits identified. (B) Major structural classes of clustered activator 
candidates. A majority of activator candidates were of the bridged bicyclic DOS series (13/24). 
 
5.2  Results and discussion 
5.2.1  Initial SAR studies and the identification of BRD8284 and BRD3934 
The Broad Institute’s unique DOS compound libraries, which contain a large 
number of stereoisomers and analogs for any given DOS molecule, are designed to 
facilitate rapid identification of both structure-activity relationships (SAR) and 
stereochemical structure-activity relationships (SSAR) (14). As the bridge bicyclic PRC2 
activator candidates were derived from DOS, we were able to establish preliminary SAR 
and identify analogs of improved potency by obtaining compounds of interest directly 
from internal compound management services at the Broad Institute. For subsequent 
SAR studies, we selected the most potent activator identified by hit retest in PRC2 
DELFIA, BRD-K51079083 (Figure 5.2A).   126 
 
Figure 5.2 Structure and activity of BRD-K51079083 
(A) Structure of BRD-K51079083 and (B) its activity in PRC2 DELFIA. Data points represent mean and standard error 
of triplicate measurements.  
 
In DELFIA format, BRD-K51079083 increased apparent PRC2 activity by ~10-
fold in a dose-responsive manner, exhibiting an AC50 in the ~2 uM range (Figure 5.2B). 
For initial SAR studies, we obtained nine analogs harboring different phenyl substituents 
(meta-, ortho-, and para-fluoro phenyl, meta-methyl phenyl, etc.) and varying in their 
stereochemical configurations (Figure 5.3A). Upon evaluating these analogs in PRC2 
DELFIA, we discovered, while BRD-K51079083 increased PRC2 DELFIA signal by only 
2-fold over DMSO, BRD-K31198284 (BRD8284) was able to increase signal to a 
greater degree (a 3-fold increase over DMSO). In contrast to BRD-K51079083, 
BRD8284 contains a phenyl substituent in place of the para-fluoro phenyl group and 
differed in configuration at all stereocenters (Figure 5.3B). Interestingly, BRD-
K68443934 (BRD3934), differing from BRD8284 in configuration at the C7 
(pseudo)stereocenter, appeared to activate PRC2 to a lesser degree (~1.5 fold 
activation over DMSO) with lower potency (Figure 5.3B,C).  
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Figure 5.3 SAR summary of BRD-K51079083 analogs and identification of BRD8284 and BRD3934 
(A) SAR summary of BRD-K51079083 analogs and their maximum activity relative to DMSO in PRC2 DELFIA, 
representing the mean of triplicate measurements (B) Structures of BRD-K31198284 (BRD8284) and BRD-
K68553934 (BRD3934). (C) Activity of BRD-K31198284 (BRD8284) and BRD-K68553934 (BRD3934) in PRC2 
DELFIA. Data points represent the mean and standard error of triplicate measurements, 
 
While no striking SAR could be established within the series tested, we were able 
to identify an analog with activity superior to that of our initial activator candidate. We 
selected both BRD8284 and BRD3934 for resynthesis and further study, given that their 
differing stereochemistry appeared to influence their ability to activate in PRC2 
DELFIA—a potentially useful feature that could be exploited to gauge the validity and 
specificity of their activity in downstream characterization efforts (e.g. orthogonal   128 
biochemical and cellular assays). Since probe discovery efforts have yielded few 
examples of small-molecule activators of enzyme activity (1) and no synthetic molecules 
capable of activating PRC2 are known, we were attracted by the possibility of 
developing first-in-class PRC2 activators. 
5.2.2  Investigating the substrate dependency of BRD8284 and BRD3934 
After resynthesis of BRD8284 and BRD3934, we retested their activity in PRC2 
DELFIA. Unexpectedly, resynthesized BRD8284 was unable to significantly increase 
signal, while BRD3934, a stereoisomer previously shown to exhibit weaker activity, was 
able to increase apparent PRC2 activity by >2-fold at the highest concentration tested 
(100 uM; Figure 5.4A). Moreover, the potency (AC50) of these resynthesized analogs 
appeared comparatively weaker (no dose-response curve convergence up to 100 uM) 
than those obtained through internal compound management services (2-10 uM AC50). 
While the exact reasons for this difference in activity were never uncovered, BRD3934 
displayed reproducible activation in PRC2 DELFIA, thus we pursued further study. 
To determine whether activation by BRD3934 and BRD8284 were artifacts of 
DELFIA or, similar to SIRT1 activators (10,11), dependent on use of peptide substrate, 
we tested the activity of these candidates in an orthogonal radiometric assay using full-
length histone H3.1 and 
3H-SAM, measuring 
3H incorporation over time by LSC. To 
ensure that reaction conditions were such that activation of PRC2 could be measured, 
we included, as a positive control, an H3K27me3-modified peptide (H3[23-34], K27me3; 
25 uM) previously shown to allosterically increase PRC2 activity (VMAX) (15). Compared 
to DMSO, BRD3934 (at 50 uM) was able to effectively increase PRC2 reaction velocity 
in this orthogonal assay, while BRD8284 displayed little activity, consistent with PRC2   129 
DELFIA (Figure 5.4B). These results suggest that the apparent activation of PRC2 
measured in DELFIA can occur independently of peptide substrate and is not an artifact 
of assay readout.  
 
Figure 5.4 Activity of resynthesized activators in DELFIA and histone H3.1 assays 
(A) Activity of resynthesized BRD8284 and BRD3934 in PRC2 DELFIA. Data points represent the mean and 
standard error of triplicate measurements. (B) Activity of 50 uM BRD8284, 50 uM BRD3934, and 25 uM 
H3[23-34]-K27me3 peptide in a PRC2 radiometric time-course assay using histone H3.1 substrate. Data 
points represent the mean and standard deviation of triplicate measurements. (C) Western blot detection of 
H3K27me2-and H3K27me3-modified H3.1 substrate, at various reaction time points, generated in the 
presence of BRD8284 and BRD3934 at 50 uM. Samples from each PRC2 reaction were quenched with LDS 
loading buffer at the times indicated and separated by SDS-PAGE (12% BT gel). BRD1835 and GSK126 
were used as inhibitor controls.  
 
We next aimed to explore whether BRD3934 or BRD8284 influenced the degree 
of methylation (i.e. H3K27me2 or H3K27me3) achieved by PRC2. In vitro, 5-component 
PRC2  (EED, SUZ12, AEBP2, and RBBP4) is able to catalyze H3K27 mono- and   130 
dimethylation, yet it is unable to achieve efficient H3K27 trimethylation (16,17). By way 
of EZH2 mutation (e.g. Y641 and A677 alterations) or PHF1/PCL1 binding, PRC2 can 
adopt conformations that enable trimethylation of its substrate (17-20). As most known 
small-molecule activators stabilize a specific enzyme states (1), we questioned whether 
PRC2 activators could endow trimethylation activity in vitro by way of stabilizing PRC2 
conformations resulting typically from PCL1 binding or activating mutation.   
Using histone H3.1 as a substrate, we conducted a PRC2 time course assay in 
the presence of BRD8284 or BRD3934 (both at 50 uM) and measured specific changes 
in H3K27me2 and H3K37me3 levels by western blot to assess the degree of 
methylation achieved under each condition. Compared with DMSO and BRD8284, 
BRD3934 increase H3K27me2 levels by >2-fold at 50 uM, while neither activator 
candidate induced substantial differences in H3K27me3 (Figure 5.4C). Interestingly, an 
apparent increase in H3K27me3 could be detected under DMSO conditions. While the 
use of full-length histone H3.1 (rather than peptide fragment) may endow greater 
H3K27me3 activity in vitro, these findings were likely the result of nonspecific antibody 
binding. 
5.2.3  Exploring BRD8284 and BRD3934 mechanism-of-action (MOA) 
Endogenous and biochemical PRC2 activation has been previously shown to 
occur through several mechanisms. In addition to PCL1 regulation discussed in the 
previous section (19), PRC2 can be allosterically activated by SUZ12 binding histone 
H3 (residues 35-42) within nucleosomes (21) and EED binding repressive histone 
marks, such as H3K27me3 or H3K9me3 (15,22). As these mechanisms could provide a   131 
basis for small-molecule activation, we questioned whether BRD3934 activated PRC2 
through engagement of SUZ12, EED, or a previously uncharacterized allosteric site.  
As we were unable to obtain sufficient quantities of pure SUZ12 protein to 
support assay development, we were limited to studies on EED. As GST-EED[78-441] 
(WD40 domain) could be expressed in bacteria with high yields and binds H3K9me3 
with reasonable affinity (~10 uM KD) (15,22), we developed an AlphaLISA assay (23,24) 
using a biotinylated H3K9me3-modified peptide (H3[1-21]) and GST-EED[78-441] to 
measure potential disruption of EED-H3K9me3 interaction. We speculated that if 
BRD3934 were modulating PRC2 activity through an interaction with EED, it might bind 
the same allosteric site as its known ligands and thus compete with H3K9me3 peptide 
binding. With this in mind, we evaluated the activity of BRD8284 and BRD3934 in an 
EED-H3K9me3 AlphaLISA, expecting potential reductions in signal corresponding to 
displacement of H3K9me3 from EED (Figure 5.5A). Interestingly, BRD8284 showed 
modest dose-responsive activity, while BRD3934 was essentially inactive. Given that 
resynthesized BRD8284 failed to exhibit significant activation of PRC2 in previous 
assays, we suspected that its apparent activity on EED was likely the result of 
nonspecific inhibition. 
While BRD8284 and BRD3934 were unlikely binding the known allosteric site on 
EED, interaction with EED at another site remained a possibility. To investigate any 
potential interaction between EED and our activator candidates, we obtained full-length 
6XHIS-EED (purified from Sf9 cells) and evaluated direct binding through fluorescence-
based thermal shift assays (TSA) by measuring the denaturation midpoint (Tm) for EED 
in the presence of DMSO or high concentrations of BRD8284 and BRD3934 (125 uM).   132 
As ligand binding is often exemplified by thermal stabilization of target proteins (25), we 
expected BRD3934 (and to a lesser degree, BRD8284), if the compound bound EED, to 
increase the Tm of EED. However, neither BRD8284 nor BRD3934 was able to alter the 
thermal stability of EED relative to DMSO (Figure 5.5B), suggesting their activation of 
PRC2 does not involve EED binding. 
 
Figure 5.5 Activity of BRD8284 in EED-H3K9me3 AlphaLISA and EED TSA 
(A) Activity of BRD8284 and BRD3934 in GST-EED[78-441]-H3K9me3 AlphaLISA. Data points represent 
the mean and standard error of four replicate measurements. (B) 6X-EED thermal shift assay (TSA) with 
125 uM BRD8284 and 125 uM BRD3934. The curve minima are representative of Tm. Each curve 
represents a single sample.   
 
While aggregation-based inhibition is excepted as a widespread phenomenon, 
aggregation-induced activation has only recently been demonstrated and its mechanism 
remains poorly understood (26). Regardless, as we had identified a large number of 
aggregator hits from our PRC2 HTS campaign, we sought to rule out such an 
aggregation-based activation mechanism. As dynamic light scattering (DLS) 
successfully enabled identification of large aggregates in past studies, we used this 
method to estimate the critical aggregation concentrations (CACs) of BRD8284 and 
BRD3934. By measuring intensity autocorrelation functions to detect the presence of 
particles, we found that BRD3934 exhibited no sign of large aggregate formation (up to   133 
200 uM), while BRD8284 clearly aggregated at 25 uM (and above) in activity assay 
buffer (50 mM Tris pH 8.5, 5 mM DTT, 0.01% Tween 20; Figure 5.6).  
Although BRD8284 does not inhibit PRC2 activity at concentrations above its 
CAC, the ability of BRD8284 to form large aggregates may explain its activity in EED-
H3K9me3 AlphaLISA, as apparent disruption could occur through an aggregation-based 
mechanism. Furthermore, since BRD3934 formed no detectable aggregates in activity 
assay buffer (up to 200 uM), differing aggregation behavior might underlie the ability to 
activate PRC2 and relate to activity discrepancies between compound preparations. In 
other words, varying purity could influence aggregation, while the formation of large 
particles impedes activation. Future studies will aim to explore this hypothesis through 
synthesis and biochemical evaluation of analogs with improved solubility.  
 
 
Figure 5.6 DLS evaluation of BRD8284 and BRD3934 in activity assay buffer 
DLS intensity autocorrelation functions for BRD8284(A)  and BRD3934(B)  in activity assay buffer. While no 
aggregation could be detected for BRD3934 (up to 200 uM), BRD8284 exhibited clear aggregation at 25 uM 
and above. Data represent the average of 10 acquisitions of single samples.  
 
5.2.4  Evaluating cellular activity of putative activators 
To determine whether BRD8284 or BRD3934 were able to activate PRC2 in 
cells, we evaluated their activity in an H3K27me3 HCA, treating HeLa cells with DMSO   134 
or compound in 10-point dose. Following 72 hr incubation, cells were stained for 
H3K27me3 and imaged by automated microscope (IX Micro), using an optimized 
immunofluorescence protocol described in Chapter II.  Average nuclear fluorescence 
(presumed H3K27me3 levels) and total cell number were determined by image analysis  
 
Figure 5.7  Cellular activity of BRD8284 and BRD3934 in H3K27me3 HCA following 72 treatment 
DMSO-normalized average nuclear fluorescence (top panels) and average nuclei counts (bottom panels) 
per well following 72 hr treatment with (A) BRD8284 and (B) BRD3934. Data points represent mean and 
standard error of six replicates across two assay plates. 
 
for each treatment condition. As seen in Figure 5.7, BRD3934 (at concentrations above 
50 uM) decreased average nuclear fluorescent signal, while similar concentrations of 
BRD8284 lead to an apparent increase. However, both BRD8284 and BRD3934 
significantly decreased cell number at these concentrations, suggesting that apparent 
changes in global H3K27me3 levels were likely artifacts of immunostaining, as dead or   135 
dying cells typically display autofluorescence and can effectively skew estimates of 
average nuclear fluorescence (often though erroneous detection of nuclei).  
Given their apparent toxicity at biochemically active concentrations, we were 
unable to determine the cellular activity of BRD8284 or BRD3934. Moreover, both 
BRD8284 and BRD3934 impacted cell number with steep dose-response curves at 
concentrations above 10 uM, suggesting that solubility (or aggregation) may underlie 
cellular toxicity. Whether this finding can be extrapolated to biochemical assays, 
suggesting potential formation of small BRD3934 aggregates that were less readily 
detected than BRD8284 aggregates but that may still underlie apparent PRC2 
activation, is yet to be determined. In any case, these results reveal future challenges in 
developing BRD3934 into a cell-active probe, as significant improvements in potency 
and/or solubility will be required to avoid nonspecific toxicity. However, before such 
medicinal chemistry efforts are undertaken, additional work toward establishing SAR 
and verifying target engagement should be conducted.    
5.2.5  Discussion and future studies 
In contrast to the development of PRC2 inhibitors (27-31), efforts to discover 
small-molecule activators of PRC2 have not been described—undoubtedly a 
consequence of their perceived lack of therapeutic utility. The motivation to develop 
potent EZH2 inhibitors is clear, stemming from the assumed oncogenic role of PRC2 
(20,32-34) and the strong evidence of EZH2 dependencies in several human cancers, 
including DLBCL (35) and aggressive rhabdoid sarcomas (36). While EZH2 does 
appear to function as a tumor suppressor in different cancer contexts (e.g. MDS/MPN 
and T-ALL; refs. 37,38), the presumed scenario in which PRC2 activation would provide   136 
therapeutic benefit, small-molecules that stimulate PRC2 activity in an in vitro setting 
may also, while seemingly contradictory, provide benefit in EZH2-dependent cancers.  
For instance, small molecules binding SUZ12 or EED in cells could potentially block 
effective H3K27me3 propagation necessary to establish repressive chromatin domains, 
leading to a global loss of H327me3 and derepression of PRC2 target genes, 
functioning as an effective inhibitor.  PRC2 activators may also prove useful in H3.3-
K27M-driven pediatric glioblastoma, as H3.3-K27M-sequestered PRC2 may be freed 
upon small-molecule binding (40,41) 
Regardless of therapeutic utility, small-molecule PRC2 activators may reveal 
previously unknown mechanisms through which the complex is allosterically regulated, 
contributing to our understanding of PRC2 biology. Further study of BRD3934 may 
provide a route to the development of such activators, as these candidates were able to 
activate PRC2 in a substrate-independent manner and through a mechanism distinct 
from those involving EED. While mechanism-of-action studies will be required to confirm 
target engagement and rule out an aggregation-based mechanism, continued 
exploration of BRD3934 may demonstrate the feasibility of small-molecule PRC2 
activator development, uncover novel PRC2 regulatory mechanisms, or, at the very 
least, contribute to our understanding of nonspecific activation mechanisms.   
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5.3  Experimental methods 
PRC2 DELFIA.  PRC2 activity was measured using DELFIA performed on 384-well, 
white, streptavidin-coated plates (PerkinElmer). In short, PRC2 was diluted in 20 uL 2X 
Enzyme Buffer (50mM Tris HCl pH 8.5, 10 mM DTT, 0.02% Tween 20), 100 nL 
compound was pinned, reactions were initiated with 20 uL of a SAM (NEB) solution 
containing H3[21-44]-GK-biotin (Anaspec). Plates were incubated at room temperature 
for 1 hr and then washed three times with 100 uL of wash buffer (50mM Tris pH 7.4, 
150 mM NaCl, 0.05% Tween 20, 0.2% BSA). Fluoroimmunoassay (FI) Buffer (50 mM 
Tris HCl pH 7.8, 150 mM NaCl, 0.05% Tween 40, 25 µM DTPA, 0.2% BSA, 0.05% 
BGG) containing a anti-H3K27me2 rabbit IgG (Cell Signaling, #9728) with 691 ng/mL 
Eu-N1-anti-rabbit IgG (PerkinElmer) was added at 50 uL per well. Following 1 hr 
incubation at room temperature, the plates were washed three times with wash buffer 
and 50 uL of Enhancement Solution (PerkinElmer) was added to each well. Plates were 
incubated for 30 min at room temperature and time-resolved fluorescence (TRF) was 
measured on Wallac Envision 2104 Multilabel Reader (400 us window, 400 us delay, 
320 excitation, 615 emission). 
PRC2 radiometric assays  PRC2 was diluted to final concentration in 2X enzyme 
buffer (50mM Tris HCl pH 8.5, 10 mM DTT, 0.01% Tween 20). Reactions were initiated 
with an equal volume of an SAM solution (NEB) containing 
3H-SAM (at 25% total SAM 
concentration; NET155001MC; PerkinElmer) and H3[21-44]-GK-biotin (AnaSpec) or 
histone H3.1 (NEB) and incubated at room temperature. For kinetic analysis, 100 uL 
aliquots were quenched in an equal volume of 3.2 mM SAM at various time points in a 
96-well plate. After all time points were collected, quenched reactions were transferred   138 
to a streptavidin-coated 96-well DELFIA plates (PerkinElmer) and incubated at RT for 1 
hr. Unreacted 
3H-SAM was removed by washing plates three times with 200 uL of wash 
buffer (50mM Tris pH 7.4, 150 mM NaCl, 0.05% Tween 20, 0.2% BSA) per well. 
Modified peptide was then eluted by a 1 hr RT incubation with 100 uL/ well elution buffer 
(70% ACN, 5% formic acid, 1 mM biotin) and 
3H incorporation was measured by LSC 
(TriCarb 2910; PerkinElmer). For H3.1 filter binding assay, reaction volume was scaled 
to 100 uL per well and 50 nM histone H3.1 (NEB) was substituted for peptide.  
Reactions were quenched with equal volumes of cold SAM (3.2 mM) and filtered 
through 96-well HA filter plates (Millipore) after 1 hr incubation. Wells were washed 3X 
with PBS pH 7.4 and membranes were dried. 50 uL MicroScint (PerkinElmer) was 
added per well before reading on TopCount NTX.  
Thermal shift assay.  6XHIS-EED (500 ng/uL in Assay Buffer) was mixed with 
SYPRO® Orange 5000X DMSO stock (Sigma) diluted 100X. To each well of a 384-well 
LightCycler® 480 multiwell plate Compounds were pinned at 100 nL per well and 
fluorescence was measured over a 25 °C – 95 °C temperature ramp using a Roche 480 
LightCycler. 
GST-EED[78-441] AlphaLISA. GST-EED[78-441] and biotinylated H3K9me3 peptide 
(H3[1-21]-GK-biotin) were diluted to 140 ng/uL and 2 uM in assay buffer (50 mM Tris, 
pH 8.5, 150 mM NaCl, 5 mM DTT, 0.01% Tween 20), respectively, and added to 384-
well AlphaPlates (PerkinElmer) at 10 uL per well. Compounds and competing peptides 
were diluted in assay buffer to 2X final concentration and 10 uL stocks were mixed with 
GST-EED and H3K9me3 peptide. After 1 hr incubation, AlphaLISA Streptavidin Donor 
Beads (PerkinElmer) and AlphaLISA anti-GST Acceptor Beads (PerkinElmer) were   139 
diluted in 1X Epigenetics Buffer (PerkinElmer) to 20 ug/mL each and added to plates at 
20 uL per well. Alpha signal was detected using the Wallac Envision 2104 Multilabel 
Reader after 1 hr incubation.  
Fluorescence polarization. Compound or DMSO was diluted to 2X final concentration 
in 1X Enzyme Buffer and added at 20 uL per well in black 384-well plates. H3[21-44] -
HiLyte488 peptide was then diluted to 62.5 nM in 1X Enyzme Buffer and added at 20 uL 
per well. Following 10 min incubation, fluorescence polarization (mP) was measured 
using Wallac Envision 2104 Multilabel Reader (FP FITC dual optical module; Excitation: 
480 nm, Emission: 535 nm for both S- and P-channels).  
Immunofluorescence.  HeLa cells (ATCC) were cultured in DMEM supplemented 
10%(v/v) FBS, 1 mM sodium pyruvate, and 100 U mL-1 penicillin-streptomycin. Cells 
were diluted in culture medium at 5e4 cells/mL and plated in black clear-bottom 96-well 
plates (Corning, 3904) at 100 uL/well. After 24 hr incubation at 37°C/5% CO2, 100 nL of 
compound or DMSO vehicle was pinned into each well and cells were incubated for an 
additional 48 hrs. Treated cells were fixed with 4% paraformaldhyde for 10 min, 
permeabilized with 0.3% Triton X-100 in PBS for 20 min, and blocked with 3% BSA in 
PBST for 1 hr at room temperature. Cells were then incubated with primary antibody 
(anti-H3K27me3; Cell Signaling, #9733) diluted in blocking buffer overnight at 4°C. A 
mixture of 1 nM Hoechst 33342 (Life Technologies) and 2 ug/mL Alexa Fluor 488 goat 
anti-rabbit IgG (Life Technologies, A11008) in blocking buffer was then added. 
Following a 1 hr incubation at RT, cells were then imaged on an ImageXpress Micro 
automated microscope (Molecular Devices) using a 10X objective with laser-based 
focusing. Image analysis was performed using the Cell Scoring module in the   140 
MetaXpress software (Molecular Devices) to determine average nuclear fluorescence 
and nuclei counts per well. Mean and standard deviation (STDEV) were calculated for 
all DMSO wells within each assay plate.  
Data analysis and curve fitting (AC50).  For AC50 determination, DMSO-normalized, 
background-subtracted activity values (see equation below) for each compound at 
varying concentration were fit using Condoseo GeneData Screener (Smart Fit Strategy 
using default settings with no restrictions and no requirement for convergence).  
€ 
%Activity =100 ×
SignalCompound − MEAN(SignalPosCon wells)
MEAN(SignalDMSO wells) − MEAN(SignalPosCon wells)
 
Dynamic light scattering. DLS experiments as described in (7) with modifications. 
DMSO stock solutions were pinned at 250 nL in black 384-well clear bottom plates 
(Corning) containing 40 uL of assay buffer (50 mM Tris, pH 8.5, 5 mM DTT, 
0.01%Tween 20). Alternatively, compounds were diluted manually into 100 uL of assay 
buffer, 50mM Sodium Phosphate (pH 7.4), PBS (pH 7.4), or 1X PBS-EP+ (pH 7.4; GE 
Healthcare). Autocorrelation functions were collected using DynaPro Plate Reader II 
using default settings.  
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6.1  Introduction 
Dysregulation of H3K27me3 is a common occurrence in many cancers, often 
driven by the altered expression or mutation of cellular factors governing H3K27 
methylation—most frequently, the components of PRC2 and H3K27me3 demethylases 
(1,2). While much attention has been given to the development and evaluation of direct 
EZH2 inhibitors (3-8), efforts towards the identification and therapeutic investigation of 
compounds that target upstream regulators of PRC2 or those that engage EZH2 co-
regulatory components (e.g. SUZ12, EED) have not been described. Inhibitors of UTX 
and JMJD3 have been recently disclosed (9), but their potential therapeutic utility is only 
beginning to be explored (10).  
Phenotypic screening of compound libraries offers several key advantages over 
biochemical target-based approaches, enabling the direct discovery of cell-active small 
molecules that modulate a desired phenotype (11-13). In addition, subsequent target 
identification can yield insights into the regulatory mechanisms underlying the chosen 
phenotype and uncover novel therapeutic targets (14,15). With that said, phenotypic 
screening efforts to identify small molecules altering global H3K27me3 levels may be of 
great value for discovering small-molecule probes and also for revealing novel 
mechanisms underlying the regulation and dysregulation of H3K27 levels.   
   In a recent study, a method coined CROSS (Chromatin Regulation Ontology 
SiRNA Screening) was used to identify known histone regulators that influence levels of 
H3K27me3 by measuring the mark upon siRNA-mediated knockdown of >500 distinct 
chromatin factors (16). While they identified few novel regulators, PRC2 regulatory 
factors undoubtedly extend beyond those explored in this study, as many new   148 
regulatory mechanisms have recently surfaced. For example, EZH2 activity is regulated 
by CDK1- and AKT1-mediated phosphorylation (17-20) and glycosylation by OGT (21). 
As further discussed in Chapter VII, PRC2 activity is also regulated through substrate 
level ‘crosstalk; for example, H3S28 phosphorylation by MSK1(22) and H3K36 (or 
H3K4) methylation by their associated HMTs (23,24) render PRC2 unable to methylate 
H3K27, thus implicating these CMEs in PRC2 regulation. A small-molecule phenotypic 
screen may uncover targets and mechanisms undetected by the siRNA screen, as they 
could inhibit PRC2-regulatory factors beyond those associated with chromatin.  
  This chapter describes the use of an HCS assay to identify known bioactive 
compounds that alter global H3K27me3 levels, aiming to identify compounds that target 
novel H3K27me3-connected regulatory nodes or target PRC2 (or opposing 
demethylases) directly. This screen ultimately led to the discovery of an antifungal 
agent, miconazole, capable of activating PRC2 activity in vitro, as well as a mucolytic 
agent, bromhexine, that selectively ablates cellular H3K27me3 levels through targeting 
an activity distinct from PRC2.  
 
6.2  Results and discussion 
6.2.1  Screening 2,230 bioactives identifies bromhexine as a potential, selective 
H3K27me3 modulator. 
  To identify compounds that modulate cellular nodes influencing H3K27 
methylation, we initially screened 2,230 bioactive compounds in a cell-based high-
content assay (HCA) measuring H3K27me3 levels by immunofluorescence (IF) staining. 
Here, we implemented, with minor modifications, an HCA protocol developed by Bayer   149 
HealthCare and used to screen the BHC internal compound library and the Broad’s 
DOS library in collaboration with the Broad Institute’s Center for the Science of 
Therapeutics. While similar to our previously described H3K27me3 HCS assay 
(Chapter II), notable differences included the substitution of MDA-MB-231 (breast 
adenocarcinoma) cells for HeLa and the use of higher concentrations of both primary 
and secondary antibodies (6- and 10-fold increase, respectively).  As before, cells were 
treated with compound for 72 hrs in 384-well plates and global H3K27me3 levels were 
inferred by measuring average nuclear fluorescence after staining and imaging. A 
reported EZH2 inhibitor, GSK343 (7), was used at 1 uM as a positive control. For each 
assay plate, average nuclear fluorescence signals from DMSO- and GSK343-treated 
wells were used for normalization in Genedata Assay Analyzer, setting their respective 
value distribution medians to 0% and -100%. Compounds that reduced normalized 
average nuclear fluorescence to -40% or less were considered potential hits.  However, 
those that lowered cell number by >25% (compared with DMSO) were rejected, as toxic 
compounds can nonspecifically influence staining intensity.  
  Out of the 2,230 bioactives screened (Figure 6.1), 91 unique compounds met our 
selection criteria (4.1% hit rate), 50 of which were immediately available from internal 
compound management services and obtained for single-dose retest. Referencing the 
signal distribution of DMSO wells, compounds reducing average nuclear fluorescence 
by >2 standard deviations (Z-score <-2) in both replicates were considered for further 
study. As shown in Figure 6.2, only five bioactive compounds were able to reduce 
presumed H3K27me3 levels by these standards—bromhexine (a mucolytic agent; ref. 
25), papaverine (an antispasmodic; ref. 26), pentamidine (an antimicrobial; ref.27),   150 
ketoconazole (an antifungal; ref. 28)), and chlorpromazine (a typical anti-psychotic; ref. 
29). Of these compounds, bromhexine exhibited an apparent reduction in H3K27me3 
closest to that of EPZ005687, an inhibitor of EZH2 (4) and positive control used in retest 
assays.  
While activities of the remaining compounds were not explored further, the most 
potent compound, bromhexine, was assayed by HCA in dose, revealing apparent dose-
responsive reduction of global H3K27me3 in MDA-MB-231 cells with an IC50 of 10 uM 
(Figure 6.3B). Given these findings, we next tested bromhexine activity in HEK293T 
cells, treating for 96 hrs and extracting histones for western blot analysis of global levels 
of various histone marks. While bromhexine exhibited little effect on H3K4me3, 
H3K9me3, and H3K36me2 at the concentrations tested, the compound potently 
reduced global levels of H3K27me3 (<2.5 uM EC50; Figure 6.2C). The increased 
potency exhibited by bromhexine in this assay may reflect differences between cell lines 
or the extended treatment period (30). Interestingly, no reduction of H3K27me2 levels 
was observed suggesting that this compound does not directly target EZH2 (which 
results in similar levels of reduction of H3K27 di and tri methylation; ref. 30,31)  and may 
instead target (through direct or indirect means) a specific regulator of H3K27 
trimethylation—for example, PHF1 (32). Furthermore, bromhexine (up to 50 uM) 
exhibited no activity in a PRC2 biochemical assay, suggesting that its cellular effects 
occurred through a mechanism distinct from direct PRC2 inhibition (Figure S6.1).  
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Figure 6.1 Summary 2,230 bioactive compounds screened in H3K27me3 HCA 
Scatter plot of total nuclei count versus normalized H3K27me3 signal for all assay wells. Of the 2,230 
bioactives screened, those with < -40% normalized H3K27me3 signal and <25 % reduction in cell number 
(relative to DMSO; >1200 cells per well) were considered ‘active’ hits (shown in green). Data for positive 
control (1 uM GSK343; Blue) and DMSO (Yellow) wells are included above. ‘Inactive’ compounds are shown 
in red.  
 
 
Figure 6.2 Retest of 50 bioactive hit compounds in H3K27me3 HCA. 
(A) Z-score scatter plot (replicate 1 versus replicate 2) for 50 bioactive hits. Those with a z-score below -2 in 
both replicates were considered for further study (shown in red). Data for positive control, EPZ005687, is 
shown in blue. (B) Selected bioactive compounds and their associated activity in H3K27me3 HCA. (C) 
Structures of selected bioactive hit compounds. Z-scores were calculate as described in Experimental 
methods 
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Currently, bromhexine (also known as ambroxol) is administered as an 
expectorant and mucoactive agent, increasing cough effectiveness through stimulation 
of sufactant secretion within the lung (25). The exact mechanism by which this is 
accomplished is unknown, providing little insight into the potential cellular targets of 
bromhexine in cells. Further study will be required to understand the exact mechanism 
by which bromhexine alters H3K27me3 levels; however, success in identifying its target 
may reveal novel mechanisms of H3K27me3 regulation or provide a useful starting 
point for the development of a new cell-active chemical probe. However, before such 
undertaking, these findings should be confirmed by orthogonal approaches, such as 
mass spectrometry-based global chromatin profiling (33). 
 
 
Figure 6.3 Activity of bromhexine in cellular assays measuring global H3K27me3 levels 
(A) Structure of bromhexine. (B) Activity of bromhexine in H3K27me3 HCA after 72 hr treatment of MDA-MB-231 
cells. Data points represent the mean of duplicate measurements. (C) Global levels of histone marks measured by 
western blot of histones extracted from HEK293T cells following 96 hr treatment with various concentrations of 
bromhexine or DMSO. Total histone H3 was used as a loading control.  
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6.2.2  Miconazole as an activator of PRC2 activity  
In parallel to retesting in a cellular assay, all 50 bioactive hit compounds 
identified in our H3K27me3 HCA screen were assayed for their ability to inhibit PRC2 
biochemical activity, as their observed cellular effects could result from direct PRC2 
engagement. For this purpose, we measured PRC2 activity on a peptide substrate 
(H3[21-44]) by scintillation proximity assay (SPA)— a radiometric approach using 
streptavidin-coated, scintillant-containing beads which luminesce upon capture of 
biotinylated 
3H-labeled product (34). While no compounds exhibited PRC2 inhibition, 
one compound, miconazole, increased apparent PRC2 biochemical activity in a dose-
responsive manner (Figure 6.4A,C). To confirm that activation was not dependent on 
peptide or an artifact of SPA, we tested miconazole activity in an orthogonal filter-
binding assay that uses histone H3.1 as a substrate and measures 
3H-incorporation 
over time. At 25 uM, miconazole increased PRC2 reaction velocity by >40% compared 
with DMSO control, suggesting that apparent activation was unlikely to be an artifact of 
assay format (Figure 6.4D).  
As the PRC2 SPA enabled well-controlled enzyme kinetic studies in high-
throughput, we next performed mechanistic kinetic analysis of PRC2 activation by 
miconazole, determining VMAX and KM for both SAM and peptide under varying 
concentrations of compound (Figure 6.5). From these results, we determined that, while 
KM values for SAM and peptide were not significantly altered, miconazole induced a 
clear dose-responsive increase in VMAX (by up to ~50% compared with DMSO; Figure 
6.5C,D), suggesting an allosteric activation mechanism.    154 
 
Figure 6.4 Biochemical and cellular activity of miconazole 
(A) Structure of miconazole. (B) Cellular activity of miconazole determined by H3K27me3 HCA. Data 
represent mean of duplicate wells. (C) Biochemical activity of miconazole in PRC2 SPA and (D) PRC2 filter-
binding assay using histone H3.1. Data points represent the mean and standard error of duplicate 
measurements in each assay.  
 
While it might at first appear contradictory that a compound that inhibits H3K27 
methylation levels in cells could be a PRC2 activator in vitro, PRC2 is a multi-protein 
complex that is highly regulated in cells and a compound that binds PRC2 to potentiate 
activity in an in vitro context may, depending on the mechanism of in vitro activation, 
have a net impact of reducing global cellular H3K27me3. For instance, as there are 
known allosteric activation sites within two PRC2 components, EED or SUZ12 (35,36), it 
is possible that miconazole activates the complex through binding these components or 
a yet uncharacterized site (within any of the five). In cells, small molecules that bind 
EED (or other regulatory domains) and disrupt PRC2 histone localization could 
potentially block effective H3K27me3 propagation necessary to establish repressive   155 
chromatin domains, leading to a global loss of H327me3 and derepression of PRC2 
target genes, regardless of their ability to stimulate PRC2 biochemical activity in vitro.  
6.2.3  Investigating the MOA for PRC2 activation by miconazole 
Intrigued by this possibility, we pursued further mechanistic characterization of 
miconazole. To further investigate the basis of miconazole-induced alterations of VMAX 
measured by PRC2 SPA, we first aimed to rule out potential nonspecific mechanisms of 
activation. As VMAX is dependent on the total enzyme concentration (37,38), miconazole 
may activate in an artifactual manner involving nonspecific PRC2 stabilization or effects 
on adsorption to the assay plate, as each scenario could influence total active enzyme 
concentration. Unfortunately, the prevalence of these effects are unknown and 
additional mechanisms for nonspecific activation have not been described (39). 
As miconazole is a known bioactive (an antifungal agent) included in many 
screening collections, we explored whether there were any previous reports describing 
its nonspecific activation of enzyme activity or its aggregation. While we were unable to 
find precedence of in vitro activation, one study, reported by Shoichet and colleagues, 
describes miconazole as a strong aggregator (>25 uM CAC) in 50 mM sodium 
phosphate buffer (pH 7.4) and capable of inhibiting several enzymes by nonspecific 
mechanisms (40). To corroborate these findings, we assessed aggregation potential by 
DLS at various concentrations of miconazole under buffer conditions identical to those 
used in the study. As Figure 6.6A indicates, miconazole exhibited clear aggregation 
under the reported conditions (at concentrations above 12.5 uM), suggesting that an 
aggregation-based mechanism could potentially underlie its activity. To explore this 
possibility, we repeated these experiments under our activity assay buffer conditions    156 
 
Figure 6.5 Miconazole activity in mechanistic PRC2 kinetic studies 
Kinetic studies were performed using H3[21-44] peptide as a substrate in radiometric PRC2 SPA. Initial 
velocities were estimated by measuring activity (CPM) at a single time point (t=120 min) within the linear 
range of reaction. (A) Estimated initial velocities versus H3[21-44] or (B) SAM concentration in the presence 
of DMSO or 100 uM miconazole. Data points represent the mean and standard error of four replicate 
measurements. Miconazole exhibited clear effects on VMAX, increasing its apparent values by ~1.4X under at 
the highest concentration tested (100 uM). (C,D) VMAX and (E, F) KM values for H3[21-44] and SAM, 
respectively, versus miconazole concentration Nonlinear regression fits were performed using the Michaelis-
Menten model in PRISM 6.0 to obtain and plot best-fit VMAX and KM values and their associated standard 
errors.      157 
(50 mM Tris pH 8.5, 5 mM DTT, and 0.01% Tween 20), detecting no large aggregates 
at all concentrations tested (up to 200 uM; Figure 6.6B). Still, this may be the result of 
the low ionic strength of our activity assay buffer and suggest the potential of 
miconazole to form small, undetectable aggregates under these conditions as 
previously described (Chapter IV).  However, unlike other nonspecific PRC2 
modulators found in earlier studies, we were unable to detect miconazole-substrate 
binding or its influence on PRC2-peptide interaction by a FP assay (Figure 6.6C). 
Moreover, given that nonspecific activation is likely promiscuous (39), we measured 
miconazole activity in a G9a SPA, but detected no apparent activation at concentrations 
up to 100 uM (Figure 6.6D).  
  Absence of miconazole aggregation under PRC2 assay conditions and its 
nonpromiscuous behavior might alternatively suggest a mechanism involving specific 
engagement of PRC2. Given this possibility, we next sought to determine which PRC2 
component might be the target of miconazole. To investigate whether AEBP2 or RBBP4 
were required for activation, we evaluated miconazole activity on 5-component and 3-
component PRC2 (EZH2/EED/SUZ12) in the histone H3.1 filter binding assay. As 
shown in Figure 6.7A, miconazole exhibited dose-responsive activation (~2-fold 
compared with DMSO) of 3-component PRC2 with an apparent AC50 of ~10 uM, 
suggesting AEBP2 and RBBP4 to be unlikely targets.  
As these data suggested engagement with EZH2, SUZ12, or EED, we chose to 
first explore the possibility of miconazole binding EED, as this factor harbors a known 
allosteric site that, upon ligand binding, can influence VMAX (kcat) in PRC2 kinetic assays 
We previously described (Chapter IV) development of an AlphaLISA assay (41,42),   158 
 
Figure 6.6 Exploring potential nonspecific mechanisms of miconazole through aggregation (DLS), peptide-
binding (FP), and G9a activation studies. 
(A) DLS intensity autocorrelation curves for various concentrations of miconazole in 50 mM sodium phosphate pH 
7.4 and (B) activity assay buffer (50 mM Tris pH 8.5, 5 mM DTT, 0.01% Tween 20). Each intensity autocorrelation 
curve represents the average of 10 single-well acquisitions for each condition. (C) Activity of 100 uM miconazole in 
of H3[21-44]-HiLyte™ Fluor 488  FP assay in the presence (left pair of columns) or absence (right pair of columns) 
of 10 nM PRC2. Data represent mean and standard error of four replicate measurements. As indicated by resulting 
FP signal, miconazole is unable to disrupt PRC2-tracer interaction nor able to bind tracer alone. (D) Activity of G9a 
in radiometric SPA at various concentrations of miconazole. 
 
 using a biotinylated H3K9me3-modified peptide (H3[1-21]) and GST-EED[78-441] 
capable of measuring EED-H3K9me3 interaction.  We speculated that if miconazole 
were modulating PRC2 activity through an interaction with EED, it might bind the same 
allosteric site as its known ligands and compete in their binding. With this in mind, we 
evaluated the activity of miconazole in an EED-H3K9me3 AlphaLISA, expecting 
potential reductions in signal corresponding to displacement of H3K9me3 from EED 
(Figure 6.7B). Interestingly, miconazole was able to exhibit modest dose-responsive   159 
activity in this assay, suggesting that miconazole may activate PRC2 through bind a 
known allosteric site on EED.  
  Crystallographic studies have revealed that the interaction between EED and 
repressive trimethyllysine marks, H3K9me3 and H3K27me3, requires an ‘aromatic 
cage’ consisting of F97, Y148, and Y365 residues within the EED WD40 domain 
(35,43). Substitution of these residues by alanine renders EED incapable of binding 
trimethyllysine and PRC2 harboring EED(Y365A) cannot be allosterically activated by 
either H3K27me3 or H3K9me3 (35). To investigate further whether miconazole 
stimulates PRC2 through binding EED at its allosteric site, we expressed and purified 
PRC2-EED(Y365A) (Figure S6.2A), assuming that mechanistic insights might be gained 
if miconazole activity differed between mutant and wild-type EED complexes.  
After confirming the inability PRC2-EED(Y365A) to be allosterically activated by 
an H3K27me3-modified peptide (Figure S6.2B), we evaluated miconazole activity on 
mutant complex in a radiometric assay using histone H3.1. Interestingly, miconazole 
was unable to stimulate PRC2-EED(Y365A) activity at the concentrations tested (up to 
50 uM), demonstrating miconazole-induced PRC2 activation be EED-dependent. 
Furthermore, these results suggest potential engagement with EED through its 
trimethyllyine-binding pocket. It should be noted, however, that PRC2-EED(Y365A) has 
demonstrated reduced binding affinity for chromatin (35), raising the possibility that  
miconazole activity may instead be influenced by conformational changes related to this 
phenomenon.  
While additional effort will be required to confirm target engagement and rule out 
aggregation-based mechanisms, the continued exploration of miconazole may provide a    160 
 
Figure 6.7 Biochemical studies on the mechanism of PRC2 activation by miconazole. 
 (A) Activity of 5C-PRC2 and (B) 3C-PRC2 in a radiometric histone H3.1 filter-binding assay at various 
concentrations of miconazole. (C) Activity of miconazole in GST-EED[78-441]-H3K9me3 AlphaLISA. (D) Activity of 
5C-PRC2-EED(Y365A) compared with 5C-PRC2 activity in histone H3.1 filter-binding assay at various 
concentrations of miconazole. Filter-binding assay data points represent the mean of duplicate measurements, 
while AlphaLISA data points represent the mean and standard error of four replicate measurements.   
 
useful starting point in the development of EED chemical probes. While the therapeutic 
utility of EZH2 activation seems unclear in principle, given its oncogenic role in several 
cancers (2,44-46), the impact of biochemical PRC2 activators in a cellular context may 
prove to yield novel strategies for its inhibition. Although miconazole exhibited only 
weak apparent activity on H3K27me3 levels upon retest, it is intriguing that such an 
activator emerged from a screen for compounds reducing H3K27me3 levels. Whether   161 
this is exemplary of target inhibition through engagement of EED will have to be 
confirmed in future studies.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   162 
6.3  Experimental methods 
Histone extraction and western blotting.  Cells were rinsed with PBS, scraped into 
ice-cold PBS, and collected via centrifugation at 200 x g for 10 minutes. Pellets were 
resuspended in 0.2 volumes of 0.4 N HCl and incubated for at least 30 minutes on ice to 
extract histones. Cellular debris was then cleared by centrifugation at 10,000 x g for 10 
minutes. Supernatant containing extracted histones was then neutralized with 0.4 
volumes of 1 M sodium phosphate (pH 12.5) and concentration was determined via 
Bradford assay. After normalization, extracts were diluted in 1X LDS Sample Buffer 
containing 1X Reducing Agent (Life Technologies) and separated on 12% Bis-Tris 
NuPAGE gels (Life Technologies) prior to 1 hr transfer (30V at RT) onto Immobilon 
PVDF membranes (Bio-Rad). Primary antibodies were diluted in 5% non-fat milk or 5% 
BSA in TBST to manufacturer’s specification for overnight primary antibody incubations. 
Anti-mouse IgG or anti-rabbit IgG HRP conjugates (GE) diluted 1:2500 in primary 
antibody diluent (incubated at RT for 1hr) was used for chemiluminescence detection 
with SuperSignal West Pico Chemiluminescent Substrate (Pierce) following TBST 
washes 
Immunofluorescence – H3K27me3 HCA.  MDA-MB-231 cells (ATCC) were cultured in 
F12K media supplemented 10%(v/v) FBS and 100 U mL-1 penicillin-streptomycin. Cells 
were diluted in culture medium at 3E3 cells/well and plated in black clear-bottom 384-
well plates (Aurora) at 40 uL/well. After 24 hr incubation at 37°C/5% CO2, 100 nL of 
compound or DMSO vehicle was pinned into each well and cells were incubated for an 
additional 72 hrs. Treated cells were fixed with 4% paraformaldhyde for 10 min, 
permeabilized with 0.3% Triton X-100 in PBS for 20 min, and blocked with 3% BSA in   163 
PBST for 1 hr at room temperature. Cells were then incubated with primary antibody 
(anti-H3K27me3; Cell Signaling, #9733 ) diluted in blocking buffer overnight at 4°C. A 
mixture of 1 nM Hoechst 33342 (Life Technologies) and 2 ug/mL Alexa Fluor 488 goat 
anti-rabbit IgG (Life Technologies, A11008) in blocking buffer was then added. 
Following 1 hr incubation at RT, cells were then imaged on an ImageXpress Micro 
automated microscope (Molecular Devices) using a 10X objective with laser-based 
focusing. Image analysis was performed using the Multi Wavelength Cell Scoring 
module in MetaXpress (Molecular Devices) to determine average nuclear fluorescence 
and nuclei counts per well. Z-scores were calculated as indicated below. Mean and 
standard deviation (STDEV) were calculated for all DMSO wells within each assay 
plate. 
 
 PRC2 and G9a radiometric assays.  PRC2 and G9a were diluted to their final 
concentration in 2X enzyme buffer (50mM Tris HCl pH 8.5, 10 mM DTT, 0.01% Tween 
20). 20 uL reactions were initiated with an equal volume of an SAM solution (NEB) 
containing 3H-SAM (at 25% total SAM concentration; NET155001MC; PerkinElmer) and 
H3[21-44]-GK-biotin (Anaspec; PRC2) or biotin-H3[1-21] (G9a) and incubated at room 
temperature for 2 hrs. Methylation levels were detected by SPA as previously described 
(34) on a TopCount NTX (PerkinElmer). For H3.1 filter binding assay, reaction volume 
was scaled to 100 uL per well and 50 nM histone H3.1 (NEB) was substituted for 
peptide.  Reactions were quenched with equal volumes of cold SAM (3.2 mM) and 
filtered through 96-well HA filter plates (Millipore) after 1 hr incubation. Wells were 
PBST for 1 hr at room temperature. Cells were then incubated with primary antibody 
(anti-H3K27me3; Cell Signaling, #9733) diluted in blocking buffer overnight at 4°C. A 
mixture of 1 nM Hoechst 33342 (Life Technologies) and  2 ug/mL Alexa Fluor 488 goat 
anti-rabbit IgG (Life Technologies, A11008) in blocking buffer was then added. 
Following a 1 hr incubation at RT, cells were then imaged on an ImageXpress Micro 
automated microscope (Molecular Devices) using a 10X objective with laser-based 
focusing. Image analysis was performed using the Multi Wavelength Cell Scoring 
module in MetaXpress (Molecular Devices) to determine average nuclear fluorescence 
and nuclei counts per well. Z-scores were calculated as indicated below. Mean and 
standard deviation (STDEV) were calculated for all DMSO wells within each assay 
plate.   
€ 
Z − score =
Average Nuclear FluorescenceCompound − MEAN(Average Nuclear FluorescenceDMSO Wells)
STDEV(Average Nuclear FluorescenceDMSO Wells)
 
 
Data analysis and curve fitting (IC50, AC50).  For IC50 and AC50 determination, DMSO-
normalized, background-subtracted activity values (see equation below) for each 
compound at varying concentration were fit using Condoseo GeneData Screener 
(Smart Fit Strategy using default settings with no restrictions and no requirement for 
convergence).  
€ 
%Activity =100 ×
SignalCompound − MEAN(SignalPosCon wells)
MEAN(SignalDMSO wells) − MEAN(SignalPosCon wells)
 
 
Compound clustering. All compound clustering was performed using ChemMine- 
Binning Clustering (0.6 Tanimoto Coefficient) online tool (22)   164 
washed 3X with PBS pH 7.4 and membranes were dried. 50 uL MicroScint 
(PerkinElmer) was added per well before reading on TopCount NTX.  
GST-EED[78-441] AlphaLISA. GST-EED[78-441] and biotinylated H3K9me3 peptide 
(H3[1-21]-GK-biotin) were diluted to 140 ng/uL and 2 uM in assay buffer (50 mM Tris, 
pH 8.5, 150 mM NaCl, 5 mM DTT, 0.01% Tween 20), respectively, and added to 384- 
well AlphaPlates (PerkinElmer) at 10 uL per well. Compounds and competing peptides 
were diluted in assay buffer to 2X final concentration and 10 uL stocks were mixed with 
GST-EED and H3K9me3 peptide. After 1 hr incubation, AlphaLISA Streptavidin Donor 
Beads (PerkinElmer) and AlphaLISA anti-GST Acceptor Beads (PerkinElmer) were 
diluted in 1X Epigenetics Buffer (PerkinElmer) to 20 ug/mL each and added to plates at 
20 uL per well. Alpha signal was detected using the Wallac Envision 2104 Multilabel 
Reader after 1 hr incubation. 
Dynamic light scattering. DLS experiments as described in (7) with modifications. 
DMSO stock solutions were pinned at 250 nL in black 384-well clear bottom plates 
(Corning) containing 40 uL of assay buffer (50 mM Tris, pH 8.5, 5 mM DTT, 
0.01%Tween 20). Alternatively, compounds were diluted manually into 100 uL of assay 
buffer, 50mM Sodium Phosphate (pH 7.4), PBS (pH 7.4), or 1X PBS-EP+ (pH 7.4; GE 
Healthcare). Autocorrelation functions were collected using DynaPro Plate Reader II 
using default settings.  
 
 
 
   165 
6.4  References 
1.  Lim S, Metzger E, Schuele R, Kirfel J, Buettner R. Epigenetic regulation of 
cancer growth by histone demethylases. International Journal of Cancer. Wiley 
Subscription Services, Inc., A Wiley Company; 2010;127(9):1991–8.  
 
2.  Chase A, Cross NCP. Aberrations of EZH2 in cancer. Clin Cancer Res. 
American Association for Cancer Research; 2011 May 1;17(9):2613–8.  
 
3.  McCabe MT, Ott HM, Ganji G, Korenchuk S. EZH2 inhibition as a therapeutic 
strategy for lymphoma with EZH2-activating mutations. Nature. 2012.  
 
4.  Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, et al. 
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant 
lymphoma cells. Nat Chem Biol. 2012 Nov;8(11):890–6.  
 
5.  Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, et al. Selective inhibition of Ezh2 
by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci 
USA. 2012 Dec 26;109(52):21360–5.  
 
6.  Garapaty-Rao S, Nasveschuk C, Gagnon A, Chan EY, Sandy P, Busby J, et al. 
Identification of EZH2 and EZH1 small molecule inhibitors with selective impact 
on diffuse large B cell lymphoma cell growth. Chem Biol. 2013 Nov 
21;20(11):1329–39.  
 
7.  Verma SK, Tian X, LaFrance LV, Duquenne C, Suarez DP, Newlander KA, et al. 
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine 
Methyltransferase EZH2. ACS Med Chem Lett. 2012 Dec 13;3(12):1091–6.  
 
8.  Konze KD, Ma A, Li F, Barsyte-Lovejoy D, Parton T, Macnevin CJ, et al. An 
orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and 
EZH1. ACS Chem Biol. 2013 Jun 21;8(6):1324–34.  
 
9.  Kruidenier L, Chung C-W, Cheng Z, Liddle J, Che K, Joberty G, et al. A selective 
jumonji H3K27 demethylase inhibitor modulates the proinflammatory 
macrophage response. Nature. 2012 Aug 16;488(7411):404–8.  
 
10.  Ntziachristos P, Tsirigos A, Welstead GG, Trimarchi T, Bakogianni S, Xu L, et al. 
Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic 
leukaemia. Nature. 2014 Aug 17.  
 
11.  Mayr LM, Bojanic D. Novel trends in high-throughput screening. Curr Opin 
Pharmacol. 2009 Oct;9(5):580–8.  
 
12.  Moffat JG, Rudolph J, Bailey D. Phenotypic screening in cancer drug discovery - 
past, present and future. Nat Rev Drug Discov. 2014 Aug;13(8):588–602.    166 
 
13.  Prior M, Chiruta C, Currais A, Goldberg J, Ramsey J, Dargusch R, et al. Back to 
the future with phenotypic screening. ACS Chem Neurosci. 2014 Jul 
16;5(7):503–13.  
 
14.  Schenone M, Dančík V, Wagner BK, Clemons PA. Target identification and 
mechanism of action in chemical biology and drug discovery. Nat Chem Biol. 
2013 Apr;9(4):232–40.  
 
15.  Cong F, Cheung AK, Huang S-MA. Chemical genetics-based target 
identification in drug discovery. Annu Rev Pharmacol Toxicol. 2012;52(1):57–78.  
 
16.  Baas R, Lelieveld D, van Teeffelen H, Lijnzaad P, Castelijns B, van Schaik FM, 
et al. A novel microscopy-based high-throughput screening method to identify 
proteins that regulate global histone modification levels. J Biomol Screen. SAGE 
Publications; 2014 Feb;19(2):287–96.  
 
17.  Kaneko S, Li G, Son J, Xu CF, Margueron R, Neubert TA, et al. Phosphorylation 
of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding 
to ncRNA. Genes & Development. 2010 Dec 1;24(23):2615–20.  
 
18.  Chen S, Bohrer LR, Rai AN, Pan Y, Gan L, Zhou X, et al. Cyclin-dependent 
kinases regulate epigenetic gene silencing through phosphorylation of EZH2. 
Nature Publishing Group. Nature Publishing Group; 2010 Oct 10;12(11):1108–
14.  
 
19.  Wei Y, Chen Y-H, Li L-Y, Lang J, Yeh S-P, Bin Shi, et al. CDK1-dependent 
phosphorylation of EZH2 suppresses methylation of H3K27 and promotes 
osteogenic differentiation of human mesenchymal stem cells. Nature Publishing 
Group. Nature Publishing Group; 2010 Dec 5;13(1):87–94.  
 
20.  Kim E, Kim M, Woo D-H, Shin Y, Shin J, Chang N, et al. Phosphorylation of 
EZH2 activates STAT3 signaling via STAT3 methylation and promotes 
tumorigenicity of glioblastoma stem-like cells. Cancer Cell. 2013 Jun 
10;23(6):839–52.  
 
21.  Chu C-S, Lo P-W, Yeh Y-H, Hsu P-H, Peng S-H, Teng Y-C, et al. O-
GlcNAcylation regulates EZH2 protein stability and function. Proc Natl Acad Sci 
USA. 2014 Jan 28;111(4):1355–60.  
 
22.  Lau PNI, Cheung P. Histone code pathway involving H3 S28 phosphorylation 
and K27 acetylation activates transcription and antagonizes polycomb silencing. 
Proc Natl Acad Sci USA. 2011 Feb 15;108(7):2801–6.  
 
 
   167 
 
23.  Yuan W, Xu M, Huang C, Liu N, Chen S, Zhu B. H3K36 methylation antagonizes 
PRC2-mediated H3K27 methylation. Journal of Biological Chemistry. 2011 Mar 
11;286(10):7983–9.  
 
24.  Schmitges FW, Prusty AB, Faty M, Stützer A, Lingaraju GM, Aiwazian J, et al. 
Histone methylation by PRC2 is inhibited by active chromatin marks. Molecular 
Cell. 2011 May 6;42(3):330–41.  
 
25.  Rogers DF. Mucoactive agents for airway mucus hypersecretory diseases. 
Respir Care. 2007 Sep;52(9):1176–93–discussion1193–7.  
 
26.  Labrid C, Dureng G, Bert H, Duchene-Marullaz P. Different membrane 
mechanisms of action for tiemonium; a comparison with atropine and 
papaverine. Arch Int Pharmacodyn Ther. 1976 Oct;223(2):231–45.  
 
27.  Barrett MP, Gemmell CG, Suckling CJ. Minor groove binders as anti-infective 
agents. Pharmacol Ther. 2013 Jul;139(1):12–23.  
 
28.  Rojas FD, Sosa M de LA, Fernández MS, Cattana ME, Córdoba SB, Giusiano 
GE. Antifungal susceptibility of Malassezia furfur, Malassezia sympodialis, and 
Malassezia globosa to azole drugs and amphotericin B evaluated using a broth 
microdilution method. Med Mycol. Oxford University Press; 2014 Aug;52(6):641–
6.  
 
29.  Hettige NC, Zai C, Hazra M, Borlido C, Kennedy JL, Strauss J, et al. Use of 
candidate gene markers to guide antipsychotic dosage adjustment. Prog 
Neuropsychopharmacol Biol Psychiatry. 2014 Oct 3;54:315–20.  
 
30.  McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. 
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating 
mutations. Nature. 2012 Dec 6;492(7427):108–12.  
 
31.  Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang K-C, Xiao Y, et al. 
Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in 
EZH2 Mutant Non-Hodgkin Lymphoma. Mol Cancer Ther. 2014 Feb 21.  
 
32.  Sarma K, Margueron R, Ivanov A, Pirrotta V, Reinberg D. Ezh2 requires PHF1 
to efficiently catalyze H3 lysine 27 trimethylation in vivo. Molecular and Cellular 
Biology. 2008 Apr;28(8):2718–31.  
 
33.  Jaffe JD, Wang Y, Chan HM, Zhang J, Huether R, Kryukov GV, et al. Global 
chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic 
leukemia. Nat Genet. 2013 Nov;45(11):1386–91.  
 
   168 
 
34.  Horiuchi KY, Eason MM, Ferry JJ, Planck JL, Walsh CP, Smith RF, et al. Assay 
development for histone methyltransferases. Assay Drug Dev Technol. 2013 
May;11(4):227–36.  
 
35.  Margueron R, Justin N, Ohno K, Sharpe ML, Son J, DruryIII WJ, et al. Role of 
the polycomb protein EED in the propagation of repressive histone marks. 
Nature. Nature Publishing Group; 2009 Aug 10;461(7265):762–7.  
 
36.  Yuan W, Wu T, Fu H, Dai C, Wu H, Liu N, et al. Dense chromatin activates 
Polycomb repressive complex 2 to regulate H3 lysine 27 methylation. Science. 
American Association for the Advancement of Science; 2012 Aug 
24;337(6097):971–5.  
 
37.  Yang J, Copeland RA, Lai Z. Defining balanced conditions for inhibitor screening 
assays that target bisubstrate enzymes. J Biomol Screen. SAGE Publications; 
2009 Feb;14(2):111–20.  
 
38.  Michaelis L, Menten ML, Johnson KA, Goody RS. The original Michaelis 
constant: translation of the 1913 Michaelis-Menten paper. Biochemistry. 2011. 6 
p.  
 
39.  Goode DR, Totten RK, Heeres JT, Hergenrother PJ. Identification of 
promiscuous small molecule activators in high-throughput enzyme activation 
screens. J Med Chem. 2008 Apr 24;51(8):2346–9.  
 
40.  Seidler J, McGovern SL, Doman TN, Shoichet BK. Identification and prediction 
of promiscuous aggregating inhibitors among known drugs. J Med Chem. 2003 
Oct 9;46(21):4477–86.  
 
41.  Ullman EF, Kirakossian H, Switchenko AC, Ishkanian J, Ericson M, Wartchow 
CA, et al. Luminescent oxygen channeling assay (LOCI): sensitive, broadly 
applicable homogeneous immunoassay method. Clin Chem. 1996 
Sep;42(9):1518–26.  
 
42.  Wigle TJ, Herold JM, Senisterra GA, Vedadi M, Kireev DB, Arrowsmith CH, et 
al. Screening for inhibitors of low-affinity epigenetic peptide-protein interactions: 
an AlphaScreen-based assay for antagonists of methyl-lysine binding proteins. J 
Biomol Screen. 2010 Jan;15(1):62–71.  
 
43.  Xu C, Bian C, Yang W, Galka M, Ouyang H, Chen C, et al. Binding of different 
histone marks differentially regulates the activity and specificity of polycomb 
repressive complex 2 (PRC2). Proc Natl Acad Sci USA. National Acad 
Sciences; 2010 Nov 9;107(45):19266–71.  
 
   169 
 
44.  Lund K, Adams PD, Copland M. EZH2 in normal and malignant hematopoiesis. 
Leukemia. 2014 Jan;28(1):44–9.  
 
45.  Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, et al. EZH2 oncogenic activity 
in castration-resistant prostate cancer cells is Polycomb-independent. Science. 
2012 Dec 14;338(6113):1465–9.  
 
46.  Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM, et al. 
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated 
hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell 
lymphomas. Proc Natl Acad Sci USA. 2010 Dec 7;107(49):20980–5.  
 
 
 
  
 
 
 
 
 
 
Chapter VII 
 
7  Identification of novel crosstalk mechanisms regulating PRC2 
biochemical activity  
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7.1  Introduction 
Crosstalk between chromatin-modifying enzymes (CMEs) and their modifications 
comprises an important facet of regulation occurring on the level of chromatin (1-3). 
Some chromatin marks (in cis or trans) may facilitate CME recruitment to its substrate 
or allosterically stimulate its activity, while others may block substrate recognition or 
directly inhibit CME activity (4-6). Several of these crosstalk mechanisms have been 
implicated in the regulation of PRC2—for example, binding H3K4me3 or H3K27me3 
allosterically inhibits (7) or stimulates its activity (8,9), respectively.  Beyond these 
allosteric mechanisms, PRC2 substrate recognition is disrupted by the presence of 
H3S28 phosphorylation (10), H3K36 methylation (7,11), or H327ac (10).    
As dysregulation of H3K27me3 is a common occurrence in many cancers (12), 
identification and elucidation of PRC2-regulatory crosstalk mechanisms may implicate 
additional CMEs in supporting tumorigenesis and reveal new drug targets within these 
cancer contexts. This chapter discusses our efforts to identify novel PRC2-connected 
crosstalk mechanisms. Through screening libraries of uniquely modified histone 
peptides for their ability to bind to PRC2 or act as substrates for PRC2 H3K27 
methylation, we uncovered a role for H3R26 methylation in suppressing PRC2 activity, 
implicating CARM1 in PRC2 regulation. Furthermore, we find further evidence to 
support a role for H3K23me1, a mark only recently reported in humans (13,14), in 
repressing PRC2 activity.   172 
7.2  Results and discussion 
7.2.1  Identification of histone modifications regulating PRC2 binding and 
activity.  
As we were able to express and purify active 5-component PRC2, we sought to 
use this and other biochemical assays to further explore the biochemical regulation of 
this key HMT. The commercial availability of histones and histone-derived peptides 
harboring known modifications found in chromatin provides opportunities to study the 
impact of these modifications on the binding and enzymatic activity of chromatin-
associated factors, including readers, writers and erasers (15-17). Using an array 
containing 384 uniquely modified histone peptides (Celluspots peptide array), we aimed 
to identify histone modifications that modulated PRC2 binding. We incubated the 
peptide arrays with PRC2 containing 1XFLAG-EZH2 and, after several washes, 
detected PRC2 binding by subsequent incubations with anti-FLAG M2 antibody and 
HRP-conjugated secondary antibody.. 
Figure 7.1A shows the raw data obtained following chemiluminescence detection 
of an array incubated with recombinant PRC2. To quantify the levels of PRC2 bound to 
each peptide, we measured chemiluminescence intensity of corresponding peptide 
‘spots’ by densitometry. With these data, we could then examine the relative degrees to 
which PRC2 binding occurred on unmodified peptides derived from different histones 
and different histone regions (Figure 7.1B). We found that, out of the 8 unique 
unmodified peptides, PRC2 bound most strongly to H3[16-35], a peptide containing 
H3K27 and the ARKS motif (8), while other H3 peptides, H3[7-26] and H3[26-45],    173 
 
Figure 7.1 5C-PRC2 peptide-binding explored using MODified Histone Peptide Array 
(A) Raw chemiluminescence signal from PRC2 bound to spotted peptides on MODified Histone Peptide 
Array. Map indicates locations of modified-peptides of the same histone and regions from which they were 
derived. (B) Relative chemiluminescence signal from each unmodified histone peptide spot. Data are 
normalized to H3[16-35] and represent ratios derived from mean signal from duplicate arrays. (C) Relative 
chemiluminescence signal from various H3[16-35]-derived modified peptides spots. Data are normalized to 
H3[16-35] signal, with ratios <1 transformed [=1-1/(mod/unmod)] and represent ratios derived from the mean 
signal from duplicate arrays. 
 
lacking the full motif bound to a lesser degree. Interestingly, H3[7-26] exhibited much 
higher PRC2 binding than H3[26-45], suggesting necessary engagement with residues   174 
upstream of H3K27. Of note, PRC2 bound H2B[1-19] with near equal affinity to the top 
H3-derived peptide; a finding potentially consistent with recent evidence suggesting 
H2B (H2BK120) methylation by PRC2 (18). 
Given that PRC2 bound most strongly to H3[16-35], we examined the extent of 
PRC2 binding to singly-modified H3[16-35] peptides present on the array. All 
modifications, with the exception of H3R26Cit, reduced PRC2 binding compared with 
H3[16-35] (Figure 7.1C). As expected, H3S28 phosphorylation completely ablated 
PRC2 binding, consistent with previous findings (10). Interestingly, H3R26 methylation 
was among the peptide modifications that reduced binding – an observation that we 
explored further in PRC2 activity assays (see below). The effects of single modifications 
on PRC2 interaction with additional histone-derived peptides (e.g. H2B[1-19] and H3[7-
26]) are included in Figure S7.1.  
  Following these studies, large sets of modified histone peptides in ‘unbound’ 
formats  (i.e. free in solution) became available from a number companies (Alta 
Biosciences, JPT peptide, etc), enabling additional efforts to profile the influence of 
specific histone modifications on PRC2 activity, to complement our binding studies 
described above. As these sets often comprise biotinylated peptides, PRC2 biochemical 
assays developed over the course of our earlier HTS and hit characterization efforts 
were implemented to measure activity on various modified substrates —the Histone H3 
(Set 1), Histone H3/N-terminal H4 (Set 3), and Histone phosphorylation and Arginine 
methylation (Set 5) collections available from Alta Biosciences. Each of these sets 
contained 94 distinct histone peptides harboring various modifications, including 
acetylation, phosphorylation, and methylation in multiple combinations.  To measure   175 
PRC2 activity on each peptide, we arrayed peptide sets in 384-well source plates and, 
after pin transfer into PRC2-containing assay wells, we initiated reactions with 
3H-SAM 
and measured 
3H incorporation by scintillation proximity assay (SPA)— a radiometric 
approach using streptavidin-coated, scintillant-containing beads which luminesce upon 
capture of biotinylated 
3H-labeled product (19).  
PRC2 activity (CPM) on each unmodified histone peptide is shown in Figure 
7.2A. As expected, PRC2 methylated H3[14-34] (and other H3K27-containing peptides) 
to the most significant degree; however, activity was also detected on H3[1-21], a likely 
result of low H3K9 methyltransferase activity that has previously been suggested (20). 
No significant methylation was detected on histone H2A, H2B, or H4-derived peptides. 
As PRC2 exhibited the highest activity on H3[14-34], which is consistent with our prior 
observation that PRC2 bound H3[16-35] most strongly, we next compared methylation 
levels exhibited between singly-modified H3[14-34] peptides present in the collection. 
We observed weaker activity on peptides harboring previously described inhibitory 
modification, such as H3S28 phosphorylation (10); PRC2 exhibited no activity on 
H3K27me3, little activity on H3K27me2, and reasonable activity on H3K27me1 as 
expected from wild-type EZH2 complexes (21).  
In addition to these expected results, novel findings did emerge. Notably, H3K23 
methylation appeared to increase PRC2 activity, while peptides methylated at R26, 
were not viable substrates for PRC2 (Figure 7.1). As the impact of these modifications 
on PRC2 activity had not previously reported, we further evaluated their biochemical 
and cellular impact in preliminary follow-up studies.    176 
 
Figure 7.2 PRC2 activity screen on 282 modified histone peptides from Alta Biosciences 
(A) Raw PRC2 activity (CPM) on unmodied peptides (5 uM) from Alta Biosciences. SPA data represent the 
mean of four replicate measurements. (B) Relative PRC2 activity on various H3[14-34]-derived modified 
peptides. Data are normalized to H3[14-34] and represent ratios derived from the means of four replicate 
measurements 
 
7.2.2  Characterizing H3K23me1 modulation of PRC2 biochemical activity 
As substrate profiling suggested increased PRC2 activity on H3K23 methylated 
peptides, we next kinetically characterized the activity of PRC2 on an H3K23me1-
modified peptide (H3[21-44], K23me1) in SPA, measuring VMAX  and KM. We focused 
specifically on the monomethylated H3K23 peptide, as the presence of H3K23me2/3 in 
humans is unclear (14,22). As shown in Figure 7.3A, PRC2 exhibits both an increase in 
VMAX (~1.6 fold) and a decrease in KM (~2-fold) when H3K23me1 is present on its 
substrate. These findings suggest that H3K23me1 stimulates PRC2 activity (in cis or in 
trans) and that PRC2 also has higher binding affinity for H3K23me1. To explore the 
latter, we used a fluorescence polarization (FP) assay to compare the ability of 
H3K23me1-modified (H3[21-44]-H3K23me1) and unmodified (H3[21-44]) peptides to 
disrupt the interaction between PRC2 and fluorescently-labeled H3[21-44] tracer. 
Consistent with the suggestion of higher binding affinity, H3[21-44]-H3K23me1 exhibited   177 
greater potency (0.3 uM vs. 1.7 uM) in disrupting PRC2-H3[21-44] tracer compared with 
H3[21-44] unmethylated at H3K23 (Figure 7.3B).  
How H3K23me1 modification impacts PRC2 VMAX remains to be determined. 
While this enhanced affinity could result from H3K23me1-induced stabilization of the 
enzyme-substrate complex (regulation in cis), it also is possible that conformational 
changes in the EZH2 substrate-binding pocket, related to trans H323me1 stimulation, 
can alter PRC2 affinity for the peptide substrate. If this is the case, one might expect to 
see synergistic behavior between H3[21-44]-H3K23me1 and H3[21-44] in the previously 
described competitive FP assay. Furthermore, if H3K23me1 stimulation does occurs in 
trans, it raises the question as to which PRC2 component harbors the allosteric site. 
Additional studies will be required to decipher the exact mechanism of H3K23me1 
stimulation and could uncover previously unknown allosteric regulatory sites within 
PRC2, expanding our understanding of the scope of its regulation. 
The role of H3K23 methylation in chromatin regulation remains poorly 
understood and the CMEs involved in its deposition and removal have not been 
identified. Recent studies, however, are beginning to reveal connections between 
H3K23me1 and heterochromatin, including biochemical and cellular evidence of an 
association between H3K23me1 and HP1ß, a heterochromatin-associated factor (13). 
Most interestingly, focused H3K23me1 ChIP studies have revealed evidence of 
enrichment of the mark on genes within heterochromatin, as well as known Polycomb 
targets (23). Future studies characterizing the genome-wide localization of H3K23me1 
(ChIP-seq) may reveal stronger connections between H3K23 methylation and   178 
heterochromatin, as well as its potential involvement in PRC2 localization and 
regulation. 
 
Figure 7.3 PRC2 kinetic and FP studies on H3[21-44]-K23me1 peptide  
Kinetic studies were performed using indicated peptides as a substrates in radiometric PRC2 SPA. Initial velocities 
were estimated by measuring activity (CPM) at a single time point (t=120 min) within the linear range of reaction. (A) 
Estimated initial velocities versus H3[21-44] or H3[21-44]-K23me1. Data points represent the mean and standard 
error of four replicate measurements. Nonlinear regression fits were performed using the Michaelis-Menten model in 
PRISM 6.0 to obtain and plot best-fit VMAX and KM values and their associated standard errors. (B) FP 
measurements of 31.25 nM HiLyteTM Fluor 488-H3[21-44] in the presence various concentrations of peptide. 
H3K23me1 and unmodified peptides exhibited apparent IC50 values of 0.3 and 1.7 uM, respectively. Data points 
represent the mean and standard error of four replicate measurements in each assay. Nonlinear regression fits were 
performed using the ‘log(inhibitor) vs response—variable slope (four parameter)’ module in PRISM 6.0 to obtain IC50 
values.    
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7.2.3   Investigating the impact of H3R26 methylation on PRC2 biochemical and 
cellular activity  
In addition to H3K23me1, our substrate profiling also revealed a role for H3R26 
methylation in regulating PRC2 activity, as both monomethylation (H3R26me) and 
asymmetric dimethylation (H3R26me2a) rendered PRC2 unable to methylate H3K27 
within the same peptide substrate. In parallel to H3K23me1 studies, we examined 
PRC2 kinetic behavior on peptide substrates harboring H3R26me and H3R26me2a 
modifications, as well as peptides asymmetrically methylated and citrullinated 
(H3R26me2s and H3R26Cit) at the same position. In contrast to unmodified substrates 
(H3[21-44] and H3[15-36]), all R26-methylated peptides supported no significant PRC2 
activity relative to background at all concentrations tested (Figure 7.4). These data 
suggest that H3R26me and H3R26Cit strongly antagonize H3K27 in vitro, potentially 
implicating their associated CMEs in PRC2 regulation. Whether this effect is the result 
of cis or trans interactions remains to be determined. 
 
Figure 7.4 PRC2 kinetic studies on various H3R26-modified peptides 
Kinetic studies were performed using indicated peptides as a substrates in radiometric PRC2 SPA. Initial 
velocities were estimated by measuring activity (CPM) at a single time point (t=120 min) within the linear 
range of reaction. (A) Estimated initial velocities versus H3[15-36] and R26me-, R26me2s-, and R26me2a-
modified H3[15-36]. (B) Estimated initial velocities versus H3[21-44] and H3[21-44]-R26Cit. Data points 
represent the mean and standard error of four replicate measurements. Nonlinear regression fits were 
performed using the Michaelis-Menten model in PRISM 6.0 to obtain and plot best-fit VMAX and KM values 
and their associated standard errors 
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CARM1/PRMT4 and PAD2 mediate H3R26 methylation(24) and citrullination(25), 
respectively. Given the ability of both of these modifications to block subsequent H3K27 
methylation in vitro, we questioned whether alterations in CARM1 or PAD2 expression 
in cells could influence the expression of PRC2 target genes. To investigate this 
possibility, we searched publically available data through Gene Expression Omnibus 
(GEO) in an effort to find gene expression profiles associated with PAD2 or CARM1 
perturbation.  While we were unable to find any data associated with PAD2, we located 
a record for a study that investigated the impact of CARM1 knockdown and 
overexpression on estrogen receptor α (ERα) target gene expression(26) in MCF7 
cells. In this study, DOX-inducible CARM1 expression or shRNA-mediated knockdown 
proceeded for five days prior to gene expression profiling by microarray – a length of 
time that should be sufficient for any expected alterations in H3K27me3 to occur 
(27,28).  
As we hypothesized based on our in vitro data that increasing CARM1 activity 
would effectively block PRC2 activity at a given loci, we focused on gene expression 
profiles obtained for MCF7 cells overexpressing CARM1. We analyzed data from these 
samples using the GEO2R web tool (29), comparing the replicate gene expression 
profiles from CARM1-overexpressing cells (DOX-induced) to those obtained from DOX-
untreated controls (three biological replicates per conditions). From this analysis, we 
selected the most significantly upregulated (96 total; p-value <0.01) and downregulated 
(91 total; p-value <0.02) genes resulting from CARM1 overexpression. 
Each of these lists were investigated using the ‘Compute Overlaps’ function on 
the Molecular Signatures Database (MSigDB) website to explore whether the identified    181 
Table 7-1 Summary of the top overlapping gene sets (FDR q-value <0.05)  for most significant 96 
upregulated genes (black) and 91 downregulated genes (red) after 5-day CARM1 overexpression in 
MCF7 (GEO accession: GSE26454). PRC2-connected gene sets are emphasized in bold.  
 
 
genes shared statistically significant overlap with any curated gene sets (C2 category) 
(30,31). As shown in Table 7-1, of the top gene sets overlapping with genes 
upregulated by CARM1 overexpression (FDR q-value <0.05), nearly half (7/15) appear 
to be PRC2 connected. In fact, three of the gene sets comprise genes bound by 
individual PRC2 components (EZH2, EED, and SUZ12) and the remaining four 
comprise those enriched in H3K27me3 (32-34). No PRC2-connected gene sets were 
found to overlap significantly with genes downregulated by CARM1 overexpression. 
While preliminary, these results suggest that CARM1 might oppose PRC2 activity in a 
cellular context, lowering H3K27me3 levels through increased H3R26 methylation.  
  Taken together, the preliminary results presented here and in Chapter VI, 
suggest that more remains to be uncovered regarding how PRC2 activity is regulated in 
a cellular context and whether this regulation is altered in disease. If so, efforts toward   182 
the identification of novel PRC2-regulatory nodes and mechanisms may reveal new 
drug targets with different impact compared with direct EZH2 inhibition. While it remains 
to be determined whether CARM1, PAD2, or the yet-to-be-identified H3K23 
methyltransferase represent such nodes, their further study in the context of PRC2 
regulation may yield novel insights leading to discovery of impactful therapeutics.  
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7.3  Experimental methods 
 PRC2 radiometric assays.  PRC2 was diluted to final concentration in 2X enzyme 
buffer (50mM Tris HCl pH 8.5, 10 mM DTT, 0.01% Tween 20). 20 uL reactions were 
initiated with an equal volume of an SAM solution (NEB) containing 
3H-SAM (at 25% 
total SAM concentration; NET155001MC; PerkinElmer) and indicated peptide 
(AnaSpec/Alta) and incubated at room temperature for 2 hrs. Methylation levels were 
detected by SPA as previously described (19) on a TopCount NTX (PerkinElmer)  
MODified™ Histone Peptide Array.  Histone peptide arrays (ActiveMotif) were blocked 
with %5 non-fat milk in TBST for 1 hr at RT prior to antibody incubation. Was diluted in 
activity assay buffer (50 mM Tris pH 8.5, 5 mM DTT, 0.01% Tween 20) and incubated 
on individual arrays for 1 hr at RT. Arrays were washed with TBST and incubated with 
anti-FLAG M2 antibody diluted 1:1000 in blocking buffer for 1 hr. After TBST washes, 
anti-rabbit IgG-HRP (GE) diluted 1:2500 in blocking buffer for 1 hr at RT and washed in 
TBST prior to chemiluminescence detection with SuperSignal West Pico 
Chemiluminescent Substrate (Pierce). Arrays were imaged on an Image Station 
4000MM Pro (Kodak) and densitometry was performed using included Carestream 
software.  
Fluorescence polarization. Competing peptide or DMSO was diluted to 2X final 
concentration in 1X Enzyme Buffer and added at 20 uL per well in black 384-well plates. 
H3[21-44] - HiLyte488 peptide was then diluted to 62.5 nM in 1X Enzyme Buffer and 
added at 20 uL per well. Following 10 min incubation, fluorescence polarization (mP) 
was measured using Wallac Envision 2104 Multilabel Reader (FP FITC dual optical 
module; Excitation: 480 nm, Emission: 535 nm for both S- and P-channels).   184 
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Chapter 3 Supplementary information: 
  
Table S3 1 Potency (IC50) and selectivity of PRC2 hits exhibiting activity on G9a 
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Table S3 2 Potency (IC50) and selectivity of PRC2 hits exhibiting activity on NSD2 
 
 
   191 
 Table S3 3 Results of detergent screening to eliminate aggregators  
 
 
 
 
 
Figure S3 1 Activity of BRD-K66064682 and its enantiomer in PRC2 DELFIA 
Activity (PRC2 DELFIA) and structure of (A) the top Pyridone PRC2 inhibitor candidate, BRD-K660664682,  
and (B) its enantiomer, BRD-K57393707. All data points for triplicate measurements are shown. IC50 values 
were calculated as described in Experimental methods (3.3) and are indicated above.  
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Figure S3 2 Activity of BRD-K41008034 and its enantiomer in PRC2 DELFIA 
Structural, activity (PRC2 DELFIA), and HPLC data for (B) the top Povarov PRC2 inhibitor candidate, BRD-
K41008034, and (A) its enantiomer, BRD-K34245999. BRD-K41008034 exhibited no activity in this assay 
due to its remarkably low purity. All data points for triplicate measurements are shown. IC50 values were 
calculated as described in Experimental methods (3.3) and are indicated above. HPLC traces were 
generated by the Broad Institute’s Therapeutics Platform analytical chemistry team and obtained through 
compound management services.  
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Figure S3 3 Potency (IC50) of BRD-K5506668 stereoisomers in PRC2 DELFIA 
(A) Structure of the top RCM PRC2 inhibitor candidate, BRD-K55066668, with labeled stereocenters (B) 
SSAR summary table with potency (IC50) data for all BRD-K55066668 stereoisomers tested in PRC2 
DELFIA. IC50 values were calculated as described in Experimental methods (3.3)  
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Chapter 4 Supplementary information: 
 
 
 
 
Figure S4.1 Initial DLS studies on BRD1835 in activity assay buffer 
DLS intensity autocorrelation curves for (A) various concentrations of BRD1835 (overlay of 2-fold dilution 
series from 2- 250 uM), DMSO replicates (15 samples shown), and 10 uM Nile Red (3 samples shown) in 
activity assay buffer (50 mM Tris pH 8.5, 5 mM DTT, 0.01% Tween 20. Compounds were pinned at 250 nL 
per well (into 40 uL of buffer). Each intensity autocorrelation curve represents the average of 10 single-well 
acquisitions. 
 
 
 
 
 
 
 
Figure S4.2 Anti-FLAG capture of 5-component PRC2 on Biacore CM5 chip. 
5C-PRC2 (6 nM) was injected (2 uL/min) over an anti-FLAG antibody-coated CM5 surface on a Biacore 
T200. After 5000s, injection was stopped and wash continued over the course of 3.5 hours to estimate drift.    
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Figure S4.3 DLS intensity autocorrelation functions of BRD1835 in SPR buffer conditions  
DLS intensity autocorrelation curves for various concentrations of BRD1835 in (A) 1X PBS-EP+ (GE) and 
(B) PBS (both at pH 7.4). Each intensity autocorrelation curve represents the average of 10 single-well 
acquisitions. 
 
 
 
Figure S4.4 Initial HU172 photo-crosslinking studies on PRC2 showing BRD1835-competitive band at 
25 kDa.  
(A) Initial HU172 photo-crosslinking studies revealing a BRD1835-competitive band at 25kDa and no 
apparent labeling of bands in the molecular weight range of PRC2 components. Streptavidin-HRP was used 
to detect biotin-linked HU172 by chemiluminescence (B) Using IRDye-streptavidin and infrared fluorescence 
detection, HU172 was found to label bands in the molecular weight range of PRC2 components; however, 
unlike the previously identified 25 kDa band, labeling was not competitive with BRD1835. Detection of this 
band was unique to a single PRC2 prep. 
 
 
 
   196 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4.5 EZH2 and EED western blot revealing non-specific detection with mouse IgG antibodies  
SDS-PAGE separation and western blot analysis of HU172-crosslinked and mock-treated 5C-PRC2 reveal 
the presence of a 25 KD detected by both anti-EZH2 and anti-EED antibodies. Interestingly, anti-EED 
antibodies derived from rabbit were unable to detect this band.  (L = M.W. standards) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   197 
Chapter 5 Supplementary information: 
 
Investigating potential BRD8284 and BRD3934 peptide-binding activity 
A described earlier in this chapter, DLS detected significant aggregation of 
BRD8284 in activity assay buffer (Figure 5.6A) and cellular studies revealed 
potential BRD3934 solubility issues in cell culture media (Figure 5.7B).  We 
explored whether aggregation-induced substrate binding could be detected, 
providing some clue to potential nonspecific mechanisms of activation, as several 
supposed PRC2 modulators identified by HTS had exhibited this phenomenon 
(Chapter III and Chapter IV).  
Using a HiLyte-Fluor 488-H3[21-44]  FP assay, we were unable to detect 
binding of BRD8284 or BRD3934 to the peptide tracer, suggesting no interaction 
between compound aggregates and substrate. However, an interaction between 
peptide and small aggregates or monomeric compound is still possible, as the 
mass of this compound-peptide complex may be too small to significantly alter 
the FP signal.  
 
Figure S5.1 Activity of BRD8284 and BRD3934 in HiLyte-Fluor 488-H3[21-44] FP assay.  
HiLyte-Fluor 488-H3[21-44] (31.23 nM) FP signal was measured in the presence of 100 uM BRD8284, 100 
uM BRD3934, 100 uM BRD1835, and DMSO. Data represent mean and standard error for four replicate 
measurement.   
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Chapter 6 Supplementary information:  
 
 
 
 
 
 
 
Figure S6.1 Biochemical activity of bromhexine in PRC2 SPA 
Bromhexine activity in a radiometric biochemical PRC2 assay (SPA) using peptide H3[21-44] as a substrate. 
Data points represent the mean and standard error of duplicate measurements. 
 
 
 
 
 
 
 
Figure S6.2 Expression, purification, and validation of 5C-PRC2-EED(Y365A) in SPA  
(A) 4-12% SDS-PAGE separation of purified 5C-PRC2-EED(Y365A). (B) Activity of 5C-PRC2 and 5C-
PRC2-EED(Y365A) in radiometric SPA assay at various concentrations of stimulating peptide (H3[23-34], 
K27me3). Unlike PRC2-EED(Y365A), PRC2-WT exhibits dose-responsive activation by stimulating peptide, 
corroborating previous findings. 
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Figure S6.3 Biochemical activity of R-miconazole, S-miconazole, and its racemate   
(A) PRC2 activity in histone H3.1 filter-binding assay time course in the presence of 50 uM R-miconazole, S-
miconazole, and miconazole racemate. (B) Dose-response of R-miconazole, S-miconazole, and miconazole 
racemate in histone H3.1 filter-binding PRC2 assay. Both stereoisomers appear to exhibit similar activity--a 
lack of stereochemical preference which may signify nonspecific activity.  
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Chapter 7 Supplementary information: 
 
 
Figure S7.1 PRC2 binding data for H2B[1-19] and H3[7-26] peptides harboring various modifications  
Relative chemiluminescence signal from various (A) H2B[1-19]-derived and (B) H3[7-26]-derived modified 
peptides spots. Data are normalized to H3[16-35] signal, with ratios <1 transformed [=1-1/(mod./unmod.)] 
and represent ratios derived from the mean signal from duplicate arrays. 
 
 
 
Figure S7.2 PRC2 activity data for peptides harboring various modifications  
Relative PRC2 activity on various (A) H3[13-32]-, (B) H3[22-41]-, (C) H3[20-40]-, and (D) H3[13-32]-derived 
modified peptides. Data are normalized to respective unmodified peptides and represent ratios derived from 
the means of four replicate measurements 
 
 